var title_f7_11_7344="Approach to inguinal adenopathy in children";
var content_f7_11_7344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Suggested approach to inguinal adenopathy in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 709px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; ESR: erythrocyte sedimentation rate; PPD: purified protein derivative test for tuberculosis.",
"     <br>",
"      * Empiric antibiotic therapy should include coverage for common pathogens such as group A streptococcus and",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      . Examples include clindamycin in areas with a high prevalence of community-associated methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (CA-MRSA),&nbsp;or a first-generation cephalosporin (eg, cephalexin) or amoxicillin-clavulanate in areas with a low prevalence of CA-MRSA.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Based on information from:",
"     <br>",
"      <ol>",
"       <li>",
"        Soldes OS, Younger JG, Hirschl RB. Predictors of malignancy in childhood peripheral lymphadenopathy. J Pediatr Surg 1999; 34:1447.",
"       </li>",
"       <li>",
"        Slap GB, Brooks JS, Schwartz JS. When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA 1984; 252:1321.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7344=[""].join("\n");
var outline_f7_11_7344=null;
var title_f7_11_7345="Loprazolam: International drug information";
var content_f7_11_7345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loprazolam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dormonoct (AR, BE, GB, IE, NL, PT, ZA);",
"     </li>",
"     <li>",
"      Havlane (FR);",
"     </li>",
"     <li>",
"      Somnovit (ES);",
"     </li>",
"     <li>",
"      Sonin (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Loprazolam Mesylate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 1-2 mg at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as mesylate: 2 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10407 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7345=[""].join("\n");
var outline_f7_11_7345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303338\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979357\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979359\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979362\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979358\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821114\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979361\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10407|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_11_7346="Parallel retention sutures";
var content_f7_11_7346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parallel retention sutures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7346=[""].join("\n");
var outline_f7_11_7346=null;
var title_f7_11_7347="Patient information: Hand pain (The Basics)";
var content_f7_11_7347=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16620\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/41/12944\">",
"         Osteoarthritis of the hand",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31828\">",
"          Rheumatoid arthritis in the hands",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/10/19631\">",
"           Trigger finger",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/56/29583\">",
"            Cyst on the finger",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/19/37170\">",
"             Dupuytren's contracture",
"            </a>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/49/18194\">",
"         Patient information: Carpal tunnel syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/17/2323\">",
"         Patient information: Common finger injuries (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/41/31377\">",
"         Patient information: Dupuytren&rsquo;s contracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/3/43058\">",
"         Patient information: Osteoarthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/15/10482\">",
"         Patient information: Tenosynovitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/46/16098\">",
"         Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/61/21463\">",
"         Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hand pain (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hand-pain-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6762492\">",
"      <span class=\"h1\">",
"       What can cause hand pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different conditions can cause hand pain, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Osteoarthritis &ndash; Arthritis is a general term that means inflammation of the joints. There are different types of arthritis. The most common type, called osteoarthritis, often comes with age. It can cause pain, stiffness, and swelling in the finger joints (",
"        <a class=\"graphic graphic_figure graphicRef81403 \" href=\"UTD.htm?12/41/12944\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Rheumatoid arthritis &ndash; Rheumatoid arthritis is another type of arthritis. It can also cause pain, stiffness, and swelling in the finger joints (",
"        <a class=\"graphic graphic_picture graphicRef70434 \" href=\"UTD.htm?31/5/31828\">",
"         picture 1",
"        </a>",
"        ). The stiffness is usually worst in the morning.",
"       </li>",
"       <li>",
"        Trigger finger &ndash; This condition keeps a finger from straightening normally. When people try to straighten their trigger finger, the finger &ldquo;locks&rdquo; or &ldquo;catches&rdquo; in a bent position (",
"        <a class=\"graphic graphic_picture graphicRef80186 \" href=\"UTD.htm?19/10/19631\">",
"         picture 2",
"        </a>",
"        ). Trigger finger can also cause pain in the finger or palm. Trigger finger is caused by a problem with a tendon. Tendons are strong bands of tissue that connect muscles to bones.",
"       </li>",
"       <li>",
"        Cysts &ndash; A cyst is an abnormal fluid-filled sac. If a cyst forms on or next to a tendon, it can cause a painful lump in the palm of the hand. Cysts can also form on joints (",
"        <a class=\"graphic graphic_picture graphicRef61957 \" href=\"UTD.htm?28/56/29583\">",
"         picture 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Dupuytren&rsquo;s contracture &ndash; This condition causes the tissue under the skin on the palm to get thick. Over time, this makes the fingers (usually the ring and little fingers) stiff and keeps them from straightening all the way (",
"        <a class=\"graphic graphic_picture graphicRef60082 \" href=\"UTD.htm?36/19/37170\">",
"         picture 4",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Mallet finger &ndash; Mallet finger can happen when the finger joint nearest the fingernail gets hurt. People usually have pain and swelling on top of that joint. They can also have trouble straightening that joint all the way.",
"       </li>",
"       <li>",
"        Carpal tunnel syndrome &ndash; This condition affects a nerve that passes through the wrist to the hand. It usually causes pain, numbness, and tingling in the thumb, index finger, middle finger, and side of the ring finger. People can also have pain in their arm.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6762507\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To ease your symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest your hand &ndash; Don&rsquo;t grip things too tightly or too often.",
"       </li>",
"       <li>",
"        Put heat on the area to reduce pain and stiffness &ndash; Don&rsquo;t use heat for more than 20 minutes at a time. Don&rsquo;t use anything too hot that could burn your skin.",
"       </li>",
"       <li>",
"        Do gentle exercises &ndash; Close your fingers to make a fist. Then straighten your fingers all the way.",
"       </li>",
"       <li>",
"        Take medicine to reduce pain and swelling &ndash; To treat pain, you can take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (brand name: Tylenol&reg;). To treat pain and swelling, you can take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You can also protect your hands from getting hurt by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wearing thick leather gloves when you do work that could hurt your hands",
"       </li>",
"       <li>",
"        Not letting your hands get too cold for too long",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6762522\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should see a doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your symptoms don&rsquo;t get better or get worse after you treat them on your own for a few days.",
"       </li>",
"       <li>",
"        Your hand is weak.",
"       </li>",
"       <li>",
"        You can&rsquo;t make a fist or straighten your fingers all the way.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6762537\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will ask about your symptoms and do an exam. He or she will examine your hand and fingers carefully and see how they move and work.",
"     </p>",
"     <p>",
"      Your doctor or nurse might do 1 or more of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An X-ray of your hand",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A procedure to make sure the diagnosis is correct &ndash; For example, if the doctor thinks that you have a cyst, he or she might drain the fluid with a needle.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6762552\">",
"      <span class=\"h1\">",
"       How is hand pain treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the cause of the hand pain. After your doctor knows what condition is causing your hand pain, he or she will discuss your treatment options.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6762566\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       Patient information: Osteoarthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/41/31377?source=see_link\">",
"       Patient information: Dupuytren&rsquo;s contracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/49/18194?source=see_link\">",
"       Patient information: Carpal tunnel syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/17/2323?source=see_link\">",
"       Patient information: Common finger injuries (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=see_link\">",
"       Patient information: Tenosynovitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"       Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/11/7347?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16620 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7347=[""].join("\n");
var outline_f7_11_7347=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6762492\">",
"      What can cause hand pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6762507\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6762522\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6762537\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6762552\">",
"      How is hand pain treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6762566\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/41/12944\">",
"      Osteoarthritis of the hand",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31828\">",
"       Rheumatoid arthritis in the hands",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/10/19631\">",
"        Trigger finger",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/56/29583\">",
"         Cyst on the finger",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/19/37170\">",
"          Dupuytren's contracture",
"         </a>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/49/18194?source=related_link\">",
"      Patient information: Carpal tunnel syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/17/2323?source=related_link\">",
"      Patient information: Common finger injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/41/31377?source=related_link\">",
"      Patient information: Dupuytren&rsquo;s contracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=related_link\">",
"      Patient information: Tenosynovitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_11_7348="Open mouth view of C1 and C2 dislocation";
var content_f7_11_7348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Open mouth (odontoid) view of C1/C2 dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 430px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGuAj4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6i5OO9J/FgYOaOT0/OgkY5AOBmgBsrhTg9/akZvlz0x6UOuRk/hTcgcP1oAjSZSDnntnFT5BPTHpiq8kbK3yg4NSoNi+v1oAmHPWgHI6gUi5A5HBpc8A5z9eKADJHGKUCjuM4/CgD24FAATRjpzSDk/U0H09KAFzk+lHHP1xRR7etAAMHPFGSGxRnpS56HvQAnp3pcY6nnNHt0oPQUAKelNAyKVuFOOpoB570AHfrQOmc80Y5NA+tAC9cfzpO1HBoHTnrQAL0NKfXFIvIOKM8CgAB69KXvR1GaKAA9s0lKeKackZBxQAvUjikbrSnpzSE8j6UAIeuKCMvx0PenAZ5pOoGKAAjGM9uKCcgGk/hGfWj0FADumPagc5H5Uho6ZxQAY60dKBR2NAB/EacePpSc5/CkxyO9AACOtGeeKO3sKUnrQAHA5HWjJAHoRR3zQOR7UAJ9MUfSgDpzS9Oo5oAXHQntSnmmnnFKOpBoAB9PxpCOe9L0po60AKeD9aMDjqKd3poGCcmgAJIIFL3OKD70nAegBR0pOB1oJoJoAFwQDRt70L6UEigBD1o9evNB+tDd+tAAfY0mRRkc4Pb0pqgt9T70AOHTrg+lBXOMmkbA+91B4pjSqMgHn0oAkzj+gpFICg9uahaTYBkjOKbBcq642kdqALQGcMKD059aanT6dKeemBnmgBuSO/X0pdpb0470f09KB144NADRnJ9P5UyYnaSBx6U/oOh5psyF1IoAIW3Jkgc9qHUNkADJpy42jaOlKQAefXtQA1BjBbpSnB69TTuOnY0hxwecUAKOccUh5HsaON3pxR3JoAU5PpxSdCMdMUp6jrikHQE5x7UAAHTihjgk0vcc1Hn5gM5P1oAfjPHA+lKBgH09aQdPSl4yemaAAdcY7UDt1o9/alBxigAIwQQKT6nPtSjPUcZ6UnagBQTyO2KXAOM0nXuKUctQA3r7GlWjj8aVelACZxgA0AkcHpQMDHIoXkk0AAPtjtRjn2pfxpMigAPApT7UZ4pD0oATrS/pQOmMdTSfSgBc+vekpR+VIBnpQAA4PtR/wAB4zSMyqMkVFLcrEm9s47UATf0FFRxSBkRicE9qduXuwB9zQA7rR3NQvcxL1bGOcCs+61Ux8KNoJ4NAGt078etFc0dSfJXdz14brUi3p4LS4PpigDekkRSNx6+lODLjIOcVzz3DhA+N2ODVmO5yF2Fhnk+9AGxnAAFKcY6mqMdwTjdzg44FWVlATJOR0PtQBL+OfrSY9O9AIbkEYpfrQAoHPNBPNIARjPrQDhunXpQAdKd0AJpo6UuKAD0o78daUelH86ADueaTvjtQB1pfqaAEP3eKM8/hSN2AzTqAEIJFGPY0H3pKAFxzxQR83TignoM0HjHNACcHApGOM0HsSaaxwCPXpQBHO5CADANLbtkccmopBhckc0kDsBkqQvrQA+Z1RvnYD6npWe9xtkLBue2KmvyWiz+fGKzI+vXOec5oA0oi5AL4C57mmySiInAVj256VAJyhypLknntTjG0zrIgBDUAalkxa2VmGCan6Z9M8VHbjEIGMEDBxUn+fpQAgznHtSN096cDnGO9Z2o6itu4jjbLd6ANDjAyaRsAEk49Oad2/xNRyY25BGaAH9+tHqM8Zz1psedoxkU49ufrQAo6DPA60nU+lBzjrQR7+9AB15ozxx1oOeCRwfek5B6c9vegBeo6c5o4z1zz+VAOT1wQaCRkZ4NAA2e3rUSgnBxg1Ljn3xSgewoAQcjpj2pRkn8OtJj8D2pRwOe1AARnOKUe/Wk68dqO4oAU/0oAGKDyc0DgUAKOnPWjt9KQ+47UozQA3PXFKvAoORSg8AnFACCjocDpQB3oP3qAFOaTt70p6ZpOM5NABx3xijOM85oPShvvdaAEHfHWg5wM0O6xj52Ue5OKoT6hGN4jcMy9cHigC3JMsXXk+lUri8bHGVA65rLu79URm80KO+TgiueuvEduiFTKXKnqBQB0lxfkygBto96yNS1WNIXBLAg9Qetcvea+kqh0k+UHnBrm7vVXmmZQ7cnpQB6pbawHsw0bthSOSeacmqo7jksRnO6vMrXW2hj8sq2B1z0p418yKSY9pU8kGgD1IXgYEFeDycVXlnWRMOQSpyBnrXn8fip5cKFBwOOcVYHiUyoei89etAHXzgOxdvk464qBJZA/DDG05JHWuWHiGZQc4Y5470ybW5GJwx9SR2oA657mSGLb5gw6/iKSxuH3Ahhz3Y4rkYNSeQfeZiOgJq5FqLsw3EZ/uigDtTPJkEkDvlauW93uzG5Ow8kAVy1vqCxlSznpjrmt21uVlQMshLHjOO1AHR20kewBSxAHcVYyNvA96yrScFBjk461eglBUjuOT/9agCcvgZJ5qqj7pC2TkdKfO4MZHoeahQnHzYXtQBcBp3rioYmDLnHSpCMg+h9DQA7J6d6Wm9QQenTmnDGM9qADHFHSkz+NHp6mgAbt7U4U3PPSgdf1oAG6+1A9O1LxmkBoATt0xS87enJpemB6UjZznpQA0n14qMu27BHH0qRuQ2OaqytjbyRg8+9AEzYPrjsRUUqhVJPf1NMkmAU4ByemajZ92Bjt9KAKV5KXGzOVHaq9uhZRuAHpgVNKjO5kjAA6GpLdSCdwwTx14oAhmU/IFI9+Kv6TGwBBJIxmnxx+bHhV4FXIIxEmxAOBzQA8DAwB+NL3PNKc+tJ9PyoAZNIIYXkY/KozXn17fu97IyqDnk5Ndj4guBFZeX3k9682v5PIk5J3E8g9qAPW8fp2pD37j0pcYHHX3o45xwPagBFIxjilJ55xScEdePpTl9ulABxikHTNKTzgDmk4I6UAIePc01TjPyjJ6ZpXbDDHXFV2mZDgqMUATAkdeBn8aVGyPUZxzURcNnbnB5pdwwOORQBYHIoB/PtUac4xwP51IOv+TQADFAP60nQkentTgMnNABxkUdhijnbQOcfSgA57/hQcjrR6A0hoAd25Jpo9ulGetKDg5oAXqKB1GKQ/dIoWgBfypD14ox1xR/F9KAFOcCjtR3pCfagBDnHPrVbUrr7Jb7gAZGOFFWcZ6Vy/i27EVwvzHcg45oAzNWvpcM7sSx461zOq+IGtVUITu28mqmu6jI0JkY4yxwK4a6uJDIZGfIHagDc1LW5ruVfNlc8Z61nG/ViRKzAEdjWTLMSeetR7mdASMFOQB3oA0DdqjEISA1MWYmbepIz2NUJ3cbQyfMOpzSrc7uvYYoA1BOVJG4DrzmmTStlRDIChGT/AIVnefmPJ4oE+UxkYoA0oGGx9x69KljmjQMVfFZ0UpKbMUELI+1iVGOtAGlHO/VDnJx1o3yR7ipY88mqVtIFRwwOc9ae1x8xDZbPoaANNLuTaob5VPQgVft7vCDkBgeua5+OUBtqgheuCc1Orh5AFyeKAOni1A45bIHXNaWka4Y3zksB261xX2hRujw2fQ0+1cpMD0XqMGgD2DT7/wC0vlQdpH3V710Vm0hTOMKMA+9eVaNqaxyoEkdUxmu60zVN21j82egz/SgDpCOSWBAIJqsyiJwSmSe+elOhvUc5kYD1AFW0dH4bqRgAjk0AMgbbyVwMc1ZRwRkdKryw5TbEDnHJz0qMySI2GKsPXpQBe6HpTvbFV4bhXPIxnpg5qfPNACnGOlIBS4znHWjoRzzQAh4IoHUmgDI68GlFAAKQjmlPejpQAEU0DnqcU7tR0oAYw4OOSaqStgj+VXG9O2KrvkfKR05oAqsxDqF7DODUUMZ2nPXJIB71ZkUFjnGPXvSKI1YMSWXoMigDKctFIwXODzV6CRJclwd2M+wqK4iLMSBjJ61YsrcswDdByaANCFQsYHrzT+v19aTsOKXg9PwoAUdME+1J2pc/MBxSLwc9B1oA5jxHIZbsxF9ioK4DxJLH9qIAXPtXeanA888zEHIGT9K8b8X6strqTorA/N1oA+jR0x7Uufvf0FMyP4h17inDv0P40AL9DTR0OO5xS8EjsaU85x1zQAD+maBjikOOOv40o7Yx0oAhl659elVw2PvL2yDVqbOzj6niq+392ct26igBXO9dxYAjjikRc99x/nUEQ2hlJ43ZqdmWMKQeD6UASqWB+YDFTIcrwcVWJbjIBXPOBzUqH07mgCUEY9TR24pAeM9+xoHXoc0AO74HHtQB0oHr/SjPtQADHOCc0oHvSDn2NKTg4xQAh96VhzkUEcdqOgoARRyc0Y9qX+Kg0AApP4s0L2NITkkjtQApOTSdj6VFdTrbW7zSHhBn6n0riNR8QyoHLykqxyB2FAHW6nqcdlEW+Vm9c15Rr+uGS7llL/L3G6oNd15pw5aR8DtmvP8AXNVyxw4oA1NV1f7Q2FPy+1ZUci/MHJIbv6Vh3N+u0EEdKjXU1ER/iNAGnevGiZ3jIPaqqXSA8tkmsl5zMr7R0Oc5qAShWU5JINAGvNcsccgketLbTHk8f0rCubnEnGefepbefK43c9+aAN55V8vjNRJIVJJ5rO+17sJnA96Sa46Ln8qANyO4L4KHacVMXG35jk1gQXG0kKAAatrcggc9qALwuXEgPOf0phusZ2nnNUZJW2kDp61BHKscjZOQPegDaS4OQWPNXY5SAXVgQTjFcq+oAy5B+Udqt294WZQp5HpQBv8Anhuh5B/OrVnM4lKnJ9hWHbzE5JUitK1fa27+I45zQB1FpcbSEGCTxW3p9+YbhRnaAPWuQSYgLjhz1arlvMQ4DqQT37mgD1XTtSEwUBlAYZyT1rcsbgO/zAn3BrzvTZirQruG0DODXcaO6vEql8MenPWgDpIifLQhc8nNVZFcK21VJJ6saqHUobdsTtn2FLY6nbyg7ZNx3cA8CgBwgI+eM7XzyM1rQOZIlbA3dDVViN5Khd2eoOasWw2qRkc89elAE39aO9IOv4UYxg+lACngDHWlJy1NPXmlxigBcjuKCeM0DtSHjgc0ACjig80DpwaAf1oAa3AzjNVp5Dt4PJHIFWieMZ61AYtq5OD9e9AESOuBkDPPamhfMbCYXnPFSrGqkdemamRVBzxQBD5RPUAmrEarGOBg0q8gUjH5TQAvAPPWj6VDEZAx3HjNTenJFACngZFRXEgSPnoe1SD0ziq2of6rggZ5yaAKGqoy27MiZOD09a+bvHFncS6tI2GHzHPHevpaGQtauHXKLya8z8W2tssyuyqu49+tAHr2PlxRjg59aB3waUc9RxQAnUDPFH8vagcZA6+9BOP8KAAdKX1GD9aO4oA5GcHmgBHGVx61D5OUwTxnmpwePofyppOBwMGgCIRBQRnjsPSlVAFAx1/lSSchsE7u3vUYLLtB78UAS7VXodvOaI5FJ4bk1HNkRnluOwFVlkaRUOeR6daAL6zKTtJyakHrz71XjQLtDZ+pqfOfpQA7PHvR1PBoNFAAM5HSjg0h7il/xoAMc+1B+9SngcdKB1oATuaX9aTGD1o6GgBB0qC7u4LSPzJ3CknAHc0+5nS3iMkhGAOnc1w3iDUGuZGl+VSPuKTkigCr4n8Rm6fyxlYweF9Pc1xWoXqncpkyKs6pIrklnyevPrXGaldlpmQq3HOAaAGaneyTMVU/ID1z1rm9WRyN5ztrVJdhgnGTnFUryBpUA5K5zQBzVxKSpC8nGKqCSSPKnjNdFDYqGBKhsHoRVS/sAQXwF5ztoAzHudsfXGPeqTXQVSSeTU95shYDhhWXJJvYqq7RnvQA+a9y/XNS2t274CcDqTVEwbpRhTk962LK18vAAyT1HrQA7zGcjc/QUyW4dM8c1orprOSdpUYzzVptPTyVDAFiaAOeF/IGIGfzq/aXhZBhsN15NMurAIfu4Oao+WY2z0wKAOhjlLxjB+ppjruBx8p61mWt/wCS20jKnqa04rqO4BYMM46GgDOn+Ryc5+lW7Gcqyg8ilnt9ykr3qtGrRsRjPpQB0NvdjgA8elbtuwEYckNjGAK5CyO5wMEfWumsUIQFDkHrigDSZy3lndkg9DWlbysWQFsEfxHtWXGgJyeGU96v2h80YVSRnkL1oA6vSd0zxRoA2OrGu1uLgWUCugJRVx07/Wuf8OQZhSTawG3g55ra1NmFp9mm3NFgsMetAFCS8ab96pDKD82e1NsLowk4AZi35VUtYykZHJRzwCe9XVRo3kRiu8rjcOhoA2rPUpo34f5W5xXQ2N7DMivuAJ6nOcmuLtVCDL4Axwat292sbKiAhQfzoA9BRg6kqcg+lKcjB7VyFhqjwuNjBl5yrHiul0+9ivoN8J5HBU9qALWeuOvrSDt9KDyelV728gsbczXLhFA4B70AWBk0pB5IGa4LUPE81xIht/kj7Y4qOx164FygeQlu/PFAHoPPfrnFH69ao22owzRhidjDkhu5qd51VAc5B6YoAdNKEAH8WKrrcb8gqc445qBmZmLD5/WkActuUHce47CgCZnkOM8j0FSwFs/MOtIkT7AccHt6U+U+XgoBnvmgBbi4EKZ25PQUlnO09vvdQDnpWbcKZpwoc4HIzV+2Ro17EenpQBaFHoaaz4GSMg9OaEJZcnGaAHLyetc/q+qKLtoFUYUYJ9627mTybaeTGNik5rzG9uTPMWB3bjyTQBv3OrpFCSzgj0xXj/i/VZpL0kMdmflGeldH4mujHb/LuGOh+leea/dLcbJBxzg/WgD6yzkfTinDr68elIpDDKnK+oPWgkdTzigAGDjPcelHTr1oONo/nSnPU9fSgBB94Up9+nrR+fIoPp/KgA6DGeetQyKfN3DmpjnPX6UHBHPbnmgCFlBAPf1pjBuc96skZ/OkYA9aAIGjY/e5+pqBIMMwOee9XPLGW/OnEDjg7aAGBSp+9xjFPXr0o9M80vfGOKADHI65pe1IfXpR06UABzjjijuT2NA70Y96ADnml4pDwW5OKTIwcnGKAFPGen+FZN5rKRSmOFN5zyx6Veu2O0IhALDn1rnZwNzhsg5PI6igCvf3kl0WaaYKgHTFc1eMpkEu8FQcAHqfetq8YFGCY4GCSK56+V5iWBIVRQBzV85aZzIwKg9K5K8fdcyMgOa6nUWzPynBH3jWROmyX5ANh6nFAGTIrbQSu0471OsMZg3swz2x3qK+SWa7wp+U9vWlvLhbSzWEr84bJoApXk8cL/dBOe1Y2oXwlUgfLx0xTNXnLMGTkHtWa75JLkD0FAFK6Us2eMelV2h2orbcZ65q+QGkJ6UwxO7hDyM0AW9Msw8YYrwD3Fbdtpy7w6jjsOlTWUCJZJk8helXbIDgE5zzQBA9iYtrF/vD8qRIAy4YZJNaTRKcZJIx0qWGEjHligDnr60D7go+YVzd/ARnK4I6iu4ukAZmXJYHmud1NXZSxUDvnFAHLyx7EBHGe1V0eSEllbHtWheTJtwR+dZkkn3qAN7TdRE67ZMA/lWlJEjFSgAOOcVx0cwDLtXBNdDpeoIx8tyM9OTQBqWkJLqMdOPXNb1oPLI4O7jpVSGMRiORPrla0o/mJJ5zzQBciwzssiEkjhga3NCsmN7Eo3cnHy1nWsKtDuD4cdK7vwNZqxEjxlm+9zQB1MFiLRVjVg2FznFPuYkkgRlbLHhgBWhJGETzGgLbuepHFRwtGBgrtAz65oAw3tyihFRTk7s96lA2gsyAkEDNavkBtrRk5PXdUNzCCCqEbe4xzmgDDvZYgEHzggdO1Ms9zTBpVISr8tk8jMFjZgOp9KsLYhIlLDPuDnFADGVQgVTyRUumStBMGUsj55FMaEGXAPHYle9aENvygkAYgcFe9AE03iO4jfasaOxzgYrmte1K4vRm5YKxONqjgCtyW2jjkIb5T346VnGyie4aRJ4hJnOTyCPpQByytIjKN2PrVmCcrcbnUE561tXGiLKTLHIm4HDfU96Wz0CRHVpiJEJ7d6ANK3ZmjXbtDcHk9q27VXdFZgPoKdp2mwR7TIjbvQ9K1VjUchQuOlAFOGJucAD3q2sKp0Bp/boMUZHOScUAIOFJ6e9Ubi6jX5gwOODzTb24CA4k49K4rxFr0dorANg44HrQB0x1S0gk33LBFP3eeppW15S4EIJHX61wGmW9zfr9slPyE8A9q2ouOc4IxxQBrXOrSMwjGVUfMTWnpN3cSqgOMHqT0rib67w7RKTnODmuq0x/KSGPA6Dn0NAFzxXc+TpEhDbd/wAp+lecx88kfKTwRXT+P7rZYIhLYBOfeuStXygYYK7c80AYXjG4bBA5QDgV5Br2pNFPsOTznrXpXiuf52I6gdK8V8SzeZeHnGD60AfY/hDxIsjLDMcA8EE/rXdg9GHIOK8H0iR4rndkgjp716FpOtzQOiSyBkYA4bmgDthzkZ/AUvrzWJ/b8IkAK8nkYNWItbsWwGmCNjo3SgDT7deKOAB6VDBcQTg+TKj/AE61N068UAB6Gg53e1Hrz+Ao7DIoAMYFHXP5UHAAzx+NGMLz9aAAjt3pRyMUnfGOtL07UAIOnSgnIoAxilIANACcZJoA6Ype5xSE9MUAHt6UE8mjuaMkA8UAAz3x0pBxknilbpnAJpPbFAEF3sX588+oFc/qEoCM5QBuxPeuhlg8zBORj0rF16FAPMdiRggfWgDmmuxKVD/NjO4Dis+7EAD+UTgHFWLt0QHLgMc4IFYGo3YSJSgwere9AFbV4I5G3k7RjgAVz1yvlOSTgZ6Y6VHfa2WucHIXOQKz9R1kSzIFGCBycUAW7kKhLnlh0OMYNchrt5/pTFpMk0a5qsu990rEmuR1K8ZmDEk56k0AaN3cs6Als46e1Z/nxluWzWVNdthuT1qET/OCWO00Abjzr0HT1NbGkqrwhmGCehrjfPZyTnj0zXTaFejyBHjJoA6qF40Uq7ADgVoQvESp6beA1cxPdIsYOMMTk5rPbU3E2d/AP3fWgDtnuQ6houCBg1oQ3SyRBgQrAY4rh7K+LKMng9RmtO1vkTO1/bFAHTGGORfvLk9AD1rF1qyPkmPZtbrRaaku75xnHIOKNV1ITFto2rj1oA831NWguGWQkLnFUzg+5NaWuSRyTE8fWqEaoTye/FAEJTk4p8LtG4I65q2kCkMAe3HvUlraKZBuXNAHRaLfzMEQ5we9dna2000QKpg9c+tY+iwQ7I8IN+K9H0RGmiigONo6AigCppOnPJ5YMRLHg+9eveFdM8i2QNGRgDJGKzNE0dUKMfrwOhrvIIhDGFGD07UAZ08LLG0Slgp5BasxoQJwJBn3BxXTFQSCeaCqnIIU/UUAc7DDNHmWJlbZztYioZLh5HJkUKzAgbeldLNErx7doAPXiqP2CAkb4csM4waAMxZ2O5lZgxGCx6YxUiQQmMrG3mFsEt05rSXT7ZB0bPpnipzZ28eZCNigZ69KAMORoELGRADjAwehqOWdxDiIAkHAGP1q1eNYbH8vLSjkZ5B96z2u1TACgKeWGetAFK+NwytvwST1rPg0/YjPMGfOME54Nal5rFvEY2byogo6f4g1y+u/ECxtZyHkWQjqFPH6UAdlZ22+AmNFAA5YnrTYUdLgK0qgDkEt0rzi1+JcEkhWC3wCOmelU7/xbeTSt5UbbB0NAHtVvdxKsZeVX5wDmnXOvWcJOWGO2a8Qs/FV1uxIpBpbvW7i6jLFgoHvmgD2dfEdoFyzxjvjdjiqc/jGzwywSR/UmvFL2/kMWWfBx61gzXUvPz4z70AeweKfGdvZ2+xJI5ZGz9015tHfXOu6rErcKW6Vyc0xklw5JPtXc+BLHEySsCcc8jJoA9Ss0FvYJbAAYHLA96p3Uvlo7FgAvP1q/ERGAxypPrXL6/OwWWNWC45OKAC3ZrzUVwON24/T3rt7H7+BtP0rgPDF3mN5eSzcA57V2lnMViWQjdnuaAMXx7L5kkMZJIX5iM1ioQtqWUHgdD6VL4ouBJduc5wcDNVJJSun4XuKAOF8VyNuYrk8eteJ67Luvm5xivYfF0p8l244HrXiGpSB7tyPmyaAPp5GMdyuGwCeldK1zl4CQOABx3rl7sGOcgj6CtWwkaSNcnge9AHT3UoWGMgYOM8dqz45TLNuI4PrV4x+ZaxH5sYwcVmbCJCqt09aAOk0udMhE3I2OK1rTVpoZAGO9Oh3Vz+nK8kKlmGR05rWW12gS4VlIwcHpQB1P2tBErkEA9ao32qiMZjVtvfilQIloq5YlBk8djVK+ZfkCuCpBxk9KAM6/wBUQRlmkdc+tQaX4thgfy5HLR9ME5qhfo0xYBc/3uM4rhdXhMMpaNgozzQB7Evi/TAwDuwz0xzWtpur2Oo5FpcI7jqmeRXzp53mEkMR75qxp95LBcK8UrxkHqhwaAPpAeneg5yCegrhtD1qXVNOVGupVkx1yOcU7zNUtrppo7hwh5CMcg0AdtjOf50dzWVp2rtNbhruAxSE446GtKKVJlVkOc9jQA/g9x1ozyc9D0pTwvIqK4IEZyQABzzQBLgntRg8CuJ1iC7i82eC4nhYjKkMcH8K54eINaiKf6U8sbdmX+tAHqw61m6ncWqho51DkryMdK811/xffrp8Hk3SI+CGTGT9axovGV8trH9o2SAnLAd6AOp8RWEGVezlHzdVyPlFcbqcmwSIrjkdGPSll8SCWR9iBQ3ZucVmPPFeOFIwx6nFAHIa9MYAdi7ix64rmzeMkmXz+NdnrGnSPk5+71rl7q1USfPggUAYurStJGCG+uO9YF1KSNg5IGcV1VykaggAYrHnswctt60Ac8wbkNn1+tRM/PTg9M1sXEKocADnrVEoCcAdKAKqkhgTn2rW0u5ZGIwcnpVRIz2wR/KtDS7dmn9uOtAGlfTOYlPIPc1kvM2/dmuru7ECyHI9eK5p4DljkDB496AJLO7G7Abr7VaFw5k+9hfUVmLGvmDtg9q0IxwOAMHvQBqQymI+YjMfb1qlrV/NGgHIJq1DnBU8cZrP1qIsM7cgcCgDmZZ5HYlmJ5qSOdlHTPPemtHiQ8d6eEOBgUAXIJpGBO3A9avxtMwyOGHAFUrRmQ5IGfQ1rWpLfMygD2oA6fwgs01yiyvjHFe2+GLW0tmR5mdiAOcV4p4blQXKkDkc5zXreg6/bSxJFJG7SRnPA4NAHpFpfRoibMrySM+ldLZ3C3EIIcFjjivPLaWa7lQrb+WjZAOeM10Wl77e5jUkdcUAdTzjgc1XvbyO1jLOQzjogPJqjquoJbRkeb8yjcSDxXnur+I0hLyiTdzgZ70Ad6+uBgcqqKemTyKgk1+ONWZpUBzya8P1rxxBGxBkYyY4VTiuK1nxncXeFg8wDO05OaAPf9V+INjbKY5JVZs9Q3Irmbvx3bC6zNcv5XXaG5PtXjdslxPFvYO7HqCM8Vo2ukTXEuZDsG3OTQB21/8AElS7Lp1swXkBnbvWVceLNZu1ZpJvKj6LtHIrNtrC3hmBwsjerdAaJlCvIgwRnt2oAo6pqt1cKHa6kZgeST1rkr64nklLK2455roL6HfHsZcOD1rGu4ha5LH951FAEdhqbQ3Cb1GR713WlagLsoVIC9CK8qurgNOTnB710Phe/YMqcgZ7UAesWtrG6vnqFyagmtlXJHOew6U/QbhtpYcv/tDtU97LuIwcHue1AHPX6sH+bBb1ArIuHGT7c8107xb+WH4is26sAxyoBB70AYVnC09yu1crnJr1bwrE9vEpT5R3OO1cz4b0MCQtIw+ld9ZweTsUDjp0oA24SGIyMk9N1efeLJn+3TEgAMdoUV3DyGNkyMheg55rgdedZtQclcDJOB2oA1vDzqscSqNpXr711wk22kjNggdD71yPhyB9gPTPNdDqDPFZOu7euMnA4oA5a/nWe9K4yQevrT9UbyrNU9qzllUXiEj3PtVrXnHlYUMDjJzQB5n43uALaXHHBrxublyT1r0r4g3W2N07mvMnOSDmgD6s1uPYQ4UYbp61Nor7gBnHfmjWBvsY2HzN0yDxVTSZTGp2sN2CMGgDtbR99oBnPPQdqo3kPlXBx+Apmmy7ImBYhmHSrV189qr4bcDgmgDW0hgtoBtAZhnOc1espCX2Hv6DvXKWM5jyGL7fritqymYOCM4JGB1NAHUm4ZCN2OPlINVbhGkB8obx6DtUNlPC8zRXBYKwPNJCUWcxxtuXPHOMigDLvMDeRuRsY571yGtWvmwuF5HqBzXe6pauBvhwwxyM9K5W7DLJtkI56gc0AeeOuyRlY7dv61PHMVaPA5zxVjWoFScyISVPBqjFIAyHIIBoA7vwhdBEaPdgmu8jc3ECJ1IHXNeY+HJgkjMV6132kyrhScHGCB1oA0nUCWIyK/l7cE5pst2YgqLxg4B6HFRX5dmZ0LEr1BGAM9qz7lwdrMzZIycdqANmDVZog218joAx4NUNa8SGzEskwQqPugc/hiqkEqxlTIzuhPHauc8b3e4bIlIX3FAG5pfjiyaMLf4MYOQNuCKnum0rU1V4LlYkb7q+/vXj93JIEMrEEYxiqFjeSxkhZWQe3agD0PxJ4fjkcOtyHGMDC8GuQutFmsyTknJxwcisy/8AEF+kO0ykhTxmuev/ABRqSgKJMZ680AdRDK8AkWZF8zPDVJZ6kscpDq3TpXCS+JJpVy6liOtM/wCEh2hTgqfWgD1G7ura5siUGHYY2kdK861aYRzssZ6U+28SI6je/FcvqmoiW5fa2RnigCdpQuSWJJ4FQXNz+74zmqBuFYZ71XuLnC47f1oAbdSliSc+lU2kCtyeaZPOGOACTVdpG445oAvLJ8wwTWxorHeWDHA7VzCzEZA61p6deeSMkc+1AHWX9ypUAE4rCnbrzjNVbjUS5NVJLp2IwMjuaANJJQOhqaOYFiS2KwhcMCe1Kt0wzwetAHXWE2MDJI6cmrF7DvTcTwea5e2vtpGQeK2otQjlhAyeBQBjyRF5sMMHPanpEV+993PSmSXCrO/Jxmo3uhxtyRQBcVVC4XP3q0rOVGGG6iude+AOPSozqDAcHFAHpmi3ESDK4DDmux03xBa24DzOin1yBXhNtqVwCQrHp2p5upXA3OWz2JoA+kYPiFZwxoqXAcA/dQ9DVqb4lSxWreSqhW/ibrivmu3umiYYJropZ3mtELk0Adrr/jjUNRlkVblgvTCHGayPtt/dosZZ8Mc561maVblmUqOCe4r0rwvpSTxlsDC89KAOQtvDc9w5Z1dveuh0b4fgOJLlSi/eCueTXotjFbWyoyRjcTk7hkCrs0Pmxq6qWZz2NAHCy6R9lULbpg4IrKneRFXe2GTggL1FdvfRKAdihSv3ucmsmTS1uWaRFyuOd3agDjp2eECUYKtyQBmoy5d1ZPvdM4rZvbDyWHlkEdCD6VBY20bNtJzg5oAdLpQFs9ySrgDv1rzTxdqIkuDGCF2+gr0nxLcJa6c6hhgjOAeleF6tcNLcynk5PWgBrSEvznpit7wscXark4+tcl53zd+tdB4cnEVwpYd+1AHt2jMqW4OTnGRVm4Hmc596zNAlWS2BBIOMirsrl0AY80AV3uxjbgkZxkVahiVymWHPao7e3CM0jjC9s1Y04F7jewIXoAKAOi0SBI1TIJJzyCK6WPaUyQRjGNx5rBs02qI05Gc89RWiG8iPe+efu/WgC3cSCJGbcdrAjiuF1nb9qUqfmLc10+oSjcMsMsM4FcdJMLnVUj6jcOnagDttBRRHlgV+XsKg16SRYmQHC7cA+ta9ivl2xAGz5QBgZzWHrrCSKYhsbe1AHPW0Ye9X1yO1L4glKq+ewxRpbs02QPlHPWqPiacBJD0yDxnNAHjXj24DzlFJz71w7/X9K6DxfP5uosFOQDXNuCT0oA+s7qUzadjGOcnFUtHmT7SqMM5OKmtHWWwcMDnbkYrDjm8m6+U/Nng0Ad3YNh2EvGDjBq/buZI/Kz8hzxXO6ffFZVLnLNzzWhbXW6Z1JOB0OKAHkiKby8/Q1paed8g3YHHBFZl1II2ztzzU2l3CuXBOGUbhQB0gcAqyncy/eqRpMSLJEQCeMVnW+pW43Ozqr56Zq6biGdFaFkYqOgYZNAF9FDxlzkZ4IrKv7KOUgsMZHDVon5IkbzDhh03cisy8vRGpVCSO/SgDmde0wGIqBnjtXGC2YT7QpGDjmvRprgSDLIT6ZNYup2iOoniUAg4IAoAoWrNGqMrEHuO1dVpV/sdDjjOc55rmVjdVXBGCcEGtGxVxneBweCDQB6H9pW4VstsUjsM5NUZ7dZVUIoVxwSM81JoW5oGVhvXHHsatvp7IwkLYVxnB5FAGKkUkUqrIMqvK+1cv4kXz5mzkjNegGCNg6RtiTGSxHBFcXqls8gfH3Q2ATQBxT2TSMUC7iPeqV7YeVtGzDdPxrsLO2jBkWROSMZU8VV1m0VY42CrtHGaAPPNW/cREOOTXGXjg7wTkHnFdl4klR7o4BAA4FcVdDEj5HGeKAKUh67TjNVHfJIfJANTyg4Bz+NQiGQk/KSKAI1kGflzjNU5X3PkEgg1ptauqbz396zJYtr855oAYsjYI75pjOWPPXFSmEbhnJp4gyvSgCpgntxTWXnmrX2VwhPOPWmmE89c4oAp4w4GOKtRrhCamitGOCRU6WrAYoAoE5YAYpp6g889avm324bGajEQOfSgCp8ucjOOlISwwCODVpoAFzjJFM8vDA44/lQAiDHC8HvVgPhO/4URQgkYPzVMsB3dCaAKFxvzuzUG5snnJ71fnh27sr27VnFSp570ANLBun86cpBHI5oGMjA+anlSMg9OKAJoBlhVyNTxuHHTiooR8vTmrkI5+tADo0Ix8uc8V1dtAJLRAQcjoMViWUatKg7g8+lei6ZZRPBGFVd1AFXR7R0SMBTz616JoML28D7xzt4rGsLQBo1UZHeuytYFWAbCA3HagCzCd1oE5JHJGcVBcakIlUHcuOwzUzREKqEguec+ntWRfplWyRknp6UANOoxtOGG3Bb7pqK81WRXZUQAHAOzoay0hlMpEiblBzxxUClkkmwCB25+7QAt1dC4m2bgGXpiqluvlPlSSST9aelqXdiHBIGSwp07G3UY5JGQaAOZ8aSObeQE84wc15Fdjc5J69K9R8ZyF4N753dxXmtx8zZIAoAyWLBunNbvh/wCaRcjGDWd5QY5rpfDEK+cMgYyKAPTNBgY2kRUkfXvW/ZhBIBIPl6c0zSwq2ESKQRjJNEkgPGcY6AUAaOoR7raJYFG4nk5qbS7NowpfOCO4703T/wB8uZEY8cHNbdrIkChWKqpGMNzQBJDbPu+TuAc5NSeU0kmAMBOST0FXBqduE4HzdM57VnalrFqQI4gQ+fmPtQBlanK3nknjHUjpWTom1tXRyDnJzxUmr6tAXZI+VA6+tQ+Epllv2+YKaAPQ0kK2g+YgKONw61yutXAFrKDxuPWulvJcWOG5A4BrivEUgdMJnigCDScZOeg5PvWF4vuALaRh1wehrb0nb9jkfB3A1xnjW4MdvKBnv1oA8d1uUyXzse549qzm68fjU942+dyeeetVznaNooA+pPDsnmRKrn5WGDWHrAa3v2wRtzxT/DF3+6UEkccEUeLcR3ayDnIFAFqzum3R8ggDrWrHdMLhdrEL9a5axnEjYwV561rO4Rl55FAHX3MsckK7fvetZEd1LbX6kYwwwRT7adXtxkZbHGDTbkKSpTAPcelADLuYocjqeetWdOu2U48xghGeBVCUh1BYKMcZxUEWYiFxzQB1Gn6pc7ZoQ+VxkZqpPqbAEFeRwfeqQnKSjYoBxg4ovFR7hWLEHGTQBJNqGI+AwJ981RXWHhYgDII+YHoaZduSi4Ax9azZ8ElR270Ab+m3SXcojUhT1w54FdLb2u5lPykYzle1eQXk81pMskBI2nP1rsfCviqO6RUmO2TOOtAHrfhwskqJgrlh+Fb9zHtdhtYAnHXiuV0O8E7K24kA84PWutkv0IAZjuP3RigCldwIEK7cPzyD1FYV7YeYgwrFTwT2rVvtWCKyOAFB64qi+oblOGJTspoAzpdNWPdhQQB2rC1jRbmdBGCQhGVIHSuqS6UnLqpU5OM1TvNQQfIzkJjgZoA8k1vwrKyt5itvB61xl74amSVldW/4EOte63V7CiPjhD75FcD4q1qzgUmP96x4wT0oA8+/sMIoHl9D6VFcWsNuSZCqnH1zRqviOedTFDtRMngDn865yZ5JT8zFj7mgCzdyxb2C5rLaPr3J/Sr9pps9w+EVsetbdr4fwQ0zZOelAHNQ2cjkBUPoTitm00MgEyAg9q6O204Q4G04qy0WRjvj8qAObbSsrs2g+hxUA0Tndt/Sus+zkRqc59MdqZPtXPynpQBywsNrgECqtxB5cpGK6O6VECucMceuKzLpTJhsHDDjFAGNNGAVAB59KhMKg4YfStby2JYcbarTw8hRyetAGaVBb5hz60zy8nGRzU8qHLDAxTIojvzg+9AEsES7enzdq0Et97AqnBGOlQxQbWBHQe9bNgqs2PyNAFC50wujbRjFZE2jyF8onX1r0K1hyDuAZCcVct7KEPl4wfQUAeZJorqMhf0px0mQEAJn3xXqMFvalWDw4OTimQ2tmRloznvQB52uiybfu4JpkunTwcOhI9cV6bBaQGT5lOw9KkudKjlUbdje1AHmFoGWToVrrtE1JkVdxPHAq5c+GlkJIAU5wPas2bRbu0wyjcg9KAPQtGv1JTK7XByc966+2uwArKy4J5UV5Vo12UGybgjuT0rpra4G1SsvPtQB2In3yE5A/Tiq9wsi/dUMeufQViRTGUgZzxkVpI8nTaWAxQBm3KSLcbwTt5zjjNVjZypI7Anaw710y24lkUyABzxgdqSXT1G9UyWP8RFAHNQWxjPL8saz9YZ0df4iO49K7ePSmiBY4LHvmuX8TwrGwWEjI64oA4HxQry2G8gHPb0rzecYYjnr6V6jq8sZt3RuTg9a8t1Fdk7Y9aAId+WwcYHoa3vDlwBKB0HGa5sEbsHitPTZvJkUjqaAPb9OuAtpHhsDFLJKocc59xXNaHftLZR54J4Na1iGeVmJytAHTW14xhCKSBSu0jksXbI75qvaISmAMYxjNXZgqKyk5U88DvQAgmZUcMzDjNZEk5kcs2R6dqs3DDJOTj1qmqnawOGBz36UAYt7cbVYseT1Oa1PA0pa+Zw3fjmuZ1PckmAODmuq+HseLhcrwT160Ad/qkpEAwWUjk57muH1y6kBI6k967DVg/2aRyeCMHtXn2vzbQAOSe+aANTS/wDkHsdpyec54rz7x9NmJl3fUiuzsi6aaTvAzzXnPjuYiNsYPrQB5zMx3N05qLke9Obly1Rk5+6cUAe4+D7ky28YJ7Vv+KE/0ZJOp964LwTeZCjOMV3mrE3GmkjkAZNAHPWNx+9yOp7Vutd77dP7ymuNgnaO4G3oGrqLVPPiyg5PPBoA6a1m3WK4xkcmpQzSQFl645rGtZ3WAoeAD1rVglATb6igCCQkKBT1mV0L8F1IwPWiZkHAPIPJNQ2jhbgrydx/KgCcOfNWTHBPQVPfMVAkGQG65pIAY5WhkQZ7dKffHzIWUnpzQBmSTK3GGD9RVJpGaXC856k1GzlJgTzg1XnmLNlQOeaAFuovNjb5enXFc+4fT77coI+ldKsigBWGSfQ1R1O0E0WRyw5oA9I+FniBpsiULlDwSOM16TLdLKcho89Bha8W8C2f2eDPIZuTXZ2d9cQyHzpi8Q/hx0oA7Ujd02O2MnA61mXcSw4BC5/2azH8R28IK5Kn1LdRXOaj4rjyxZycDAAagDWvdQWFmjGQB6Vy2va20IypIx2NYt54hMzEIR15bvWVf3H2gfMSwNAFTUdfupiQN2D1rnL+WSdQGLFvY10EFlJMSIo2JPoK3dM8KK7b5wCxGcen1oA81ttKuruUCNGyT1NdJp3hsLIDKNzjqDXc/wBhJAwKABQccdDV6C0hTDMVHBNAHO22mRIDmMKPYdTSG3QS4MZA9cV0XlbmKg/KOfaoxB5zESfKmeD6UAYLQqCRkAA1C8QeMgDA9a6Mafb4I2OWPc9DUVxZRqhjRhjqcCgDnVt1EeNwXB9etQMPmZUXeD1yK3W0+MqDuGDnioniihRQE+cD5mzQByl5bcZIz7Vlyh1VtgbA5BrtJkjlXBCsvqBzWRdRr9wfKucYx1oA5wR/KzEknrioyokHy/K2M810TW6AnEfJ4HvVdtPTzMsDkDpQBy8kAOOOe9IkDA7eOK3prEiTIAK09dORhwOSevagDOjhQHbj5vUVoRRCNV5y1SR6dswA4Zjzg1YgtNrtl9zYoAltJdpG7IJrTW6DRqu3Dg9TWcnyvl/wrSUDqVJXrkCgB8n+pUsuXU9PalCHGUHBqREDAkBmbHHpVqFUCA8+9AEVpGJCuX2AdQatLHh2ZcYz2q9axIU37AeO9X7eMBVZUDKvbHegChDEjBVYL8x5Wp1tVf5ZF+U9qWSDc+SFU9x0xT7F3gkJTa2TtGaAM690aKWJcRBGPdapTaTe2gGz95EOu2un+1xySYQeXgfNnnn2q4l3CuFGVjPVfX3oA5CO+MDjfuU47jpWzaa0WQIDkEcnbWjPBZzq5CAk9AeTWZc6csSsLdyv+zjtQBoW2oMOrIR696svqrEBEOAOma5SUzRFjtJUVSuNcjhBDHB+vSgDs7jVdiBScN9a4TxBqyq7nfjuTmsLU/Eu5jsYk59a5PVNTkmdsnk8HPegC7q+orIG2yhh6g1yVzJLc3DpBFI7KAxCrnipZHOOMAelVBcyQXCTQtiROQex9QfY1M+blfLubYdUnViq9+Xrbe3kQGOZXzLFPH7vGy/zFWrGaMyqodS+egNdXa6lBPp5u8lUUfOOpQjqKwbySeSUXNwyS25zsniOUUen+z75/OuHD4yVSfJONj6nN+G6ODw6xGGqupdXsktu71ul52300O38LsXhVQck12tjASygnA6HniuD8GszSJj7vr2r0+yhztbGAV6V6B8gWgPKhJ44qvczHaCDgYp9+6x7dp3e/pWZezfIETntmgBzSgodxwOoqmbgMzuTwOKa5zCQCCT0FUWcBWjY/NjrQBV1GeN3wF6V2HgJd7OVUrhAfrXB3RwwGckHrXd+AV8wznn5VHAOKAOp8QuBp0fythjjGeteb6qA0mAcjOcV6B4kcx20WRj5ScHmvN7+QvcDKkKT6UAaiORpeCGVe2K8v8eSdQOnrXoe/Za4z26GvMvG8u4tgYxn8aAOKY880zJ69qcxJOcCm5GADnigDs/CtzsdATzmvTfOL6e3JBK9jkV4xocuy5Uhzj0r0/TLwG0C55x0FAGI8pW6J42g5OK7LwvPHIwyRhuDXFXoCXDDtmt3wtMFmQZGM0Ad5e2ywghUwpOQaarqoTrwOK15EiuNOVlQqVHJz1rIY4XZjOM9qAFZkL/NyG/SoVwlwuBuwfTrStkRBlIyPWo3l2jf/FQBpSSpcqsgyk0ZwRgcim3sxk7YAGfrVSwljaZjNnOOPSm3cuHKdAe9AGdcypuIK7Se9ZkshUqP1q1fghdwIyOpFUJWDBGXmgCZpCqb+TWzpUSXQiUZJY8g1gQNhzGTlHGMGuh8KsVu+R8i80AdRFD9gwuMfWs3VtWihDYznPbijxHqOYMK3K9K801nU3nDBTgZoAu674lZncRscetcnc6tPI2Q7YPvVaVmdyD1zUWN8gUYxQBq6dqMxlAGTmuy0xEk8p524PUDiub0uzUIpBG7rit3ynXadvyetAHbWYhhRPKwp9avLeoj7WYDf3B4/GuGgu5AQFckY4HrUFxezrJvI+TtQB3N5fbwdrLgHBIPWqYv4XjZWZdwPrXCT31yZVIYhD2Pem+aWuBnIOOpoA9GW8if5kK7tvODUf8AaEZ2qJFCg5+lcNBcOjCMOcnpipbhmERUPh/5UAdk2rLHEUEgABxnFZs2sKCRG/Qc4HauNM0kzHeWXHNU5ZHyNrkdc470AdZca8AflClR2IyapTaqGb5c/MfvZ4H4VzRkYE4JwOarNPg7d5JHNAHTSar5b/ujx3OaytQ1x2O9cZBrEuJmUna5OazpXIc7mzQB0ba/MQSQOmOaauvy9wDz1Nc08hz6+1RNIQRQB2I1cHqeP5VPb6mjDK4z71xLznAwxAPFNWdwDtZjz2oA79rv5s8Zz1FH2zaRgc9SR2riE1CUf8tfoKmXUbjbkmgDs3ui5DDgVegvtuULEgiuIj1WTbll+gFO/tR2Zsk57DFAHd/bAoHOAR1pU1JYuXPynjNcaL6VlAY/QHtViEtJIoBLE84oA7ix1IMhLM7D+Hmtmz1ElUABD9+ea5TT4yLYbvvCt6xP7tCqjcowT60AbfmOAxYnMg5zTiBvAQ5OOoNVWcM6jkseg9KUNsXp7cd6AJZA5QHGV6YHUVK843blJICbdp7VEGKwYU7mY85HIpsTtiRXXO0Z96AK4vGUglT1xkU4X4RyuCWz3qJgrzkg5C84psaqzEsDuY5JoAZc3MhDBG2lh07Vy+vxCTcZFAwK6i5MccbM2c9jXMaxKrxtknnrQBwOpN5czBTx169Kyppsc5znrVzWVxMeuD0rHlyO4yKAJjNuU+lVwwOcgVC7scCgEbsYOTQBPHLJCJUib5JQBIp6EZ6/WrNiWiffbSNFIeuOjfUdDVTbluPxrR0yE+cABnnrUuEXe63N4YqtBxcZtOO2u3XQ29OubnS3W5iVbbuzKpa3b/eXqh9xx7mvTfC/jGznaOC8xZXTjC+Y2Y5f9x+h+hwfauS0w7IV6DA6etXovCttqkMrWLpaSN96Mpuhf/eTtn1GPxrLknT/AIbuuz/Rnf8AWsPi9MVHll/PFf8ApUdE/VWfe52eoMftG1jjvWZcT5Hp/WuKa71fw7Kttc58k/Kkc8heJ/aOXqv+6w+gFalrrVvev5I3Q3GOYZRhvw7MPcZqoVYyfLs+zOfE4CrQj7VWlD+aOq+fVPyaTNTzfldiTnpWfPPtcsWJGOlTzbtpVOg5JrIu2LsSvIArU4Rgn8245JPPFem+AJVWGU7c5IXpXlVoA02ec/yr1Pwgfs+nI/8AExyVxQBo+MZyxwmAQvXpXn9zK3nqrNnJ/Kul8VaiHuGAJA6YrjEkL3W5vXA4oA0b2VVtTk8gda8y8XybnJ4xXf6pLsh+7u9Qa838Rne7ZPfOKAOcP3uuKTqe9I21Scck80udoB9aALmnkpMPQn8q7/RZi0WM49686tjtlDZH4Cu28PS/Lj2oAsaj/wAfHynIq7oM+y7Rc9+1UtVIARxz2+tV9NuBFMvOCefpQB7/AKCTPpjKBxjrj2rBn+WRlOeCau+Cb9fsC+ZycdKp6mrfbnAODnpQBGxjVSX6Y4xUE5QwgqSfw6U+Rwh2seGFU8sVMZORnrQAsLDfvLY7YqyXRwzMSNo9M1moGDAnIGcc00TCORlL9+vWgBbwlzwfl+lZ78qUXFaDFjEQDxVOdGkuIILOKSe6mO2OCFC8kjeiqOT/AE70AUXZoZRt5YVp6RqADkwOrgEoxU559K9R8C/Bh5gl/wCOHCR8ONMhk/8AR0g6+6qcerMDivJbOa3uPPubOGO2t7ieW5ihjQKsaO5dVAHQAEDHtQBcv5pLgkMenauS1OMq5OeK6KUAN93P41nXkAkjPy4OOlAHKMvXnvUIGyVTjFX5oyjlSPpUCqTKN4bjkCgDTjvvIZOTjHNb1lrKSqoOAB1yOtcfdHAxjBqOO5KkDsPegDunuI2d5IeAB16VSbUfNwpwR0rJtZXliGDgfWpkj+dcjBz2oAvB8EM3IHQGnOplcMQePSnLhkCEHjvjpV+0UzEQgZfsBQBRGAQwzlc0+aQvKGz1GSKvvb7U2umH9qpNABNwG+XrQBWlYBVYfKOmaosSX7Me2O1aF1EPKA3decVSQbFYlfxoAruDkAZ561TuUjMoIDBv0q24A5ByTVRyVfBHBHWgCneqFbavBrMkYFznNat0Buyc1nuvze1AERxtwBn2pmAOe/pUrJt5GSDSbSw6D8aAK/JLEDpzT8cEZxU8ds5P3Tx096mNlIOqHmgCjtHHY9elSjLLx271Ots+c7DxQLdxjjgnJoAYg+TJyKmjGW6CgQvk7VNXIbaRkBA578UAPiVeDnBHvVy1yJQOQfem2lo5IYrkVet7SUybwrGgDpNPkJgXaMkD5jWzayfKiR9ufesjT4njVWC546YrXtBmNTtw2TQBdyTgoTvJwT6VKzs33VwgABPXmrMEKnHBII5IqaG2LYBUrjoRQBWs9srBV3Fs46dKfdIizfKw3gbeO9Xoo/KA2kJJjkioQqqu6VA5PX1FAFEKkYIwNxqtcyRooyMHOTzV/wAsshDLgE8YrA8Qxt5TKDt9CKAKep6kmNhOcnr6VzeoyllJBODUFzKwJBJz71VaU4YA5HXmgDE1dcyZOfpWHMMAk59BXS6jAZVyvJ61gXEDh+Qc0AUiBnHNOQZxkGpfIdRyv04q9p1jJczoAvHoBQBTjiZm+TvW/pdsyEEnBrvvDHhKNoVaWLOeuRWxq/gtY0aW3XBA4AHXigDhy5XaqHOa6jSLg2sSKGOXrmzaywXGyVShXmnPev5o5wAeOaAOzvhFPbFJUSVHGGRwCCPTBritV8PIEzYFSm7ItpiSoP8AsN1Q/mPTFb9rd+ZBkkEkflS7Qbcu/wArZ4qJwjNWkjow2KrYWXPRlZ/g/JrZryZyFvqV7YztbzCSVsY8icgTAeqt0kH4/U097+O7hZYZDvX7yMNrL9Qea1tVghurYrMiyhjxuHf29D71zeoWTxFT81zGvTLbZo/91+/0P4k1napT295fj/wTu5sJjPi/dT7rWD9VvH5XXki/pWPtKqSeTXrugARWsWVztH0rxPRrz7Pcq7M1zCh+fCYlj/3k7/UfgK9g0C/t73TPNs7hJkPGVOfwPofatIVIz+E48Tg62Fa9qtHs90/RrRnP6/MXupWOevFZNqQbgH0NXNalAlY55yaz7RiZCxGBirOUr61IWLY44rgNcPzNnrXW63Od7AH61xuqOWNAGOcZz26YqMn6D2pzn5jxRGeOTQBInUY4xXWaLKFVSTx3rk4+ue56V0GmSFF/D1oA3NTYPb5HUc8ms6BwH5+7nip5X8yDPp2qnAfnHHegD1zwHO7xoC3Tpmuk1WP98ZCRz6V5x4Nu2SdV3H6V6JMwuLYHGOO9AGVe5dAcjNZkc7RT/L16ZNaNyAqEdvWsG7ypYpyQeKALFxdEqVYAVAjnG5QSO5qu0nmQgsRuHWnpKhgznDZ6ZoAurKcY52HrWh4OvNa0/wASR23g51i1rVGEKu8SSAqOSWLKSsagFjtx09TWJc3UUcLu7BFRdxPYAV0cvm+FfDptW3Q+Kdftg1x2fTtPJ4jB/hllIye4we6rkA9U1X4oWGpeDfGMGn3Be90+zeG2ujgLeMVEXnIo6KJWAx6FSDzXgungRBIlG1VUKOelLPbRSwRKUVI4ypVF4HykEdPcD8qeR5hYqQrUAWZQFb8KdFYvdvGIULEnpShfMVE/j6A13/g/QWi2yFT5hGRmgDkj4KLW4mdTu/lXO6l4akg8wqCcdBX0YdMjMOMcEAcHvWVqvhYyWu+SPJbnJHNAHy5c2c5kKlTlTTLfSZ55QEXAz1r2jUvCqq5Kxbs+1SW3hdYUUtGoGM5oA86ttBljhzjtmoGjMMm1hyDXr0mkBYtibckAYIrgPFGnvbXeAnJPXtQBQtIgzbye3Y1raZaBZhKAcjofSoNMijZlQg8dc811en2kUm3cGC5oAhl0vdCHb5sjtWLe2AiVn5PYivWtK0+B4CJkbyiMLzzWNr/hxLaRt4JUjcB6igDyY2bNIGYDHYVBdW8mCBHxXYX1htBaLbx2zWVLEEJzHzjFAHMS2j8MFAHqKi+xIMkjB610Bs1yGUNg9RRLbGRiNnA9KAOYubUMT3AGRkVQ+xlxnge1dVd2rEDcMBRxVF7fOM8CgDEGnM5xjGBmpYdNHAYADrk1spCVc4Py9Mmqjs32gjgqeD70AJbWsKswBywq5LbISD+GKjtbfJaRcjB557VJIpaRiGOB2NAEMtpHt+bjB6jvSx2MDrhSB35rRs4RPEI3Gc85FXo7GMOoCYxwc0AZH9nw4AGSfp1qSCxwyYQ7c81txWih2O4KB0wKnW22Lg9fSgDLSxUjOcBelXrK03AkjA9atm2UDJBJPGKs20QQYOcHAxQBPY2yI4Tgn271qxabsk/1ec5GCKgslAk3RxhceprotOkSQZxjjrnNAEGn6XKZ9uz5CMfSuntfDMgiJaQBOuK09AtFJ3ysCqDPA61rzSpHHiQdsk5xigDgb7SI4pd+CwHFZzWY8zcD8hP5V0Wq3hMjbQCh7A1jXBjJwp8tm5AzmgDLu4hbsVyGB5wDWLq0KTRnt6ZFa0zbbjzJRuXviqV/LGHAUhoz370AcJqen7hIVXB7Vzc0WxihB49K9Lu4UdWXvXMalpZOWXk56CgDO0zT/MiDMoIPcipLnw59qAKIOPQda9E8LeFpbqziLJswO/eukj8KywHCAEYzxQB4efDLeXggg+gWuh8H+FS8m4p8wPAxXp83htlbOzOPbium8LaJb2waSRcP2470AUdC8NbYEd0IIxkCr2p6KxhYqjeXjGMdK6kIREmNwLd8cYqMhxlQcn0PQ0AeIeNPDp8h5okwU/OvI7tMTkE4INfWet6bFe2rFAVdh9wCvm7x7o50/WJMptXOR6UAUdOY7QilSx4rTuW2kJngdRWDpk22TLcHH5VpI4ZmkfkdqAG3sqqFRc7VHFYNzM8meQfWtW6kJVmx8vSsGVtm446n1oAs6fZQXVzGl0CcfddG2sp9iORXeeHLCPRdOuQkjyy3D+ZJM4AZuMAHAxwBj8z3rh9BYNfICOM12txcAWTqn1/Clyq97amntZ8ns+Z8t726X727mLqkgkkJxg5OahtTtjdgfzNMlYPAcfTJqPdi3O0jn9KZmYetPlj35rlbxgzHHrXQ6s5Y5PYdq5i5YF+D7UAU2YlzTFPqKfIu0N6VHg45xQBKhy3H5VqWMuM8duc1lIDk44q3btg49BQB0FtKpBz0NVWO2fuOabbybhxxiiVjvJA4NAHTeHLrypUPGc16fZ3XmWahAenc141psvlOrA4Neh6LfmS0GR82MUAWNTuDHIfmIHcVly3e9SF7c5p2quZNpbt1rMOSxCY560AWLeZDLiXAyOlSecBEy7QSDxj0rOYYwX/h6Ctfw7o914j1i10fTWWOa4BeWd/u20K8vK3so/MkDvQBteEbe0gtrjxXrtuZdF0iVUtrcn/kI33WOEeqr95j04HUKwrIk1KfULu6v9TlM+pXkpmuJSOrHgAeigAKB2AAqTxfrlnql7a2OhRtF4Y0hDbaZGTzICfnuG9WkPOTzj0LNWagOFI4I6mgC2zDOcnNNLYlVuQO9MDDgryAetTPgoPlBGetAHTeD7QX+pRrjIXk5r2/RrNVjj+X23elecfDDTEmXzBnr1FeyabassTRhhhevuKALVjZKGGSH7/d4FaUkKSKyOoAPHFRw4woVSBjnPerPfHagDl7/wAOeaXZUDHOccVnnw+xjYBQNo/i4ruRk9BwOKa43Lg8j0oA4keHUijzMQGOD+Fcf4+8JpPp7TWSkyplipPavUtYBjKMvQjBH0rN1QL9gfHKspH1NAHzbBH9jnK4xIDzXS6Pc3ClGkRXVeelQeLLRLLUwR0YE496g0q+24VTg5xzQB6FouqrK3lum0r68g8d6u6w0MmnrLvTI45Ncp9pAQGJQjKOSOM1ka1qUlyoG9gF6CgC7exrIC2AoPTHU1ivasGZmBOOOOtMstQOQkpJwODnitc3MNwyruI/vEenpQBiGPySNyBlIwSR0qB0RWYq547Vbmb94ys/7sn5Ris6XKyFc717EUAU7lgGwwyrd6o3AVcLtytab7GJznd0AI61RuVc4AXyyTgg0AZ05JHIK85qCJMuScY7cVbkBUmN+QvFQsFk2nDAdKAJ1RjGrKAvr70fuy53tyR0HrT1Yqvlq3yn9KgMe+T5cZ68mgC5ZNIBjIGOV9627MmSPLg896wrJsMiMnX9a6G3LFCuQqjkLQBJJuZsDbjHykVYQJEuZN3mlcjAyKrQIuwFnIYn7pqSEnY/y5bPJPYUAOUhwCsrMM5wRgircUe7G0k1VjQMc7htHJFStceUpUY2HkY60AXombfsIwoPbrWnBdpGy+Wm0DjOawd4BEhk5HKgUkl8yJgtwSTgUAer6PrMP2Xy94WTb0zS3dyZY9wZSAcfWvIra/f7REyOevNdhaam00KhjwowCKANC7idJCSV57qRisq+VljbBHmk5JHYVJdS4jbLjaO4rMnkYMBHIhOc9eTQA7bulXksh4PPSqbxNFMwCjHXnmrEt04TBUAHkYFVRKzNuO7A45oAfPApTciFQe3XNR22mNc3cS7RsPXFa2nW63U6AZaPvzXfaXoltG0flwk+5FAGhpGlwizggRFQIg5J6mr0FoBIQPu+vatexQJDtZOexI/CnpEA4XYAvr6mgDHn03cn7lA5J546VYttNkhRBtAGMnithAFG0DHenfxE0AYN0zjcFICqOnrVCeQJgF+COeOa3dTtleNpMdBiuXvJM5wR6YJoAJpgACnJx9K8t+LelRXNl9pReQfm5rvmuChfcWIU5Ixmuf8AED/bdGvUlYHauQMdaAPAPJ2AFOeavs3l2q4AzTcfOwAAw1GoTMVjjwuB+tAFe7lRrQLjD5zntWFdk8Yxgda1roZhDhdozWNcsrdTwKALmhqTeKRwfUV2NydtuSxwQOlchorYmBGc/SuhvLstAV3fMBjpQBizXRMxjAHv71JM3+jZXgd6zYeb7d78g1euziBiucH1oA5vVJWZ2GMDtWBKfmwa1r88sT3rGl5bjvxQBC5+Yg00cHmh+eR0FC4K8igCRcfjU8Z7d6r4zjtUqED6igC/byZOD0AqxJg4IBJFU4pB8pOB2q0HDAZHHtQBctW+bpiut0S78uEgnBxXGQ4DZGfoa3tLlwOCenSgDfvZ94BGdpqkXw5J44qVpQYQMdKrAruxng9aAGzTKiMSGJzgBRkk+gHck9q7nWYX8IeGJPDETAeItWjWbXZVOTbQEZis1I7kHL/U9mXFfwXFb6BpknjfVIRMttMbfQ7WQcXd7zmU+scWCSfUHHKjPN/a5bma4uLuV7m9uJGmmnf70jk5LH/DoBwOKAII124GMEVfiIAJBzuHPtVaNQwB9T2qxDuBYhehoAntI9u4EZB6E1ZRU27cY9eadbspYFgcd6muI0EqkZwR0oA9c+F9r5ekGRcgFsZxxXpFpPJAoRRnd6DqK4D4dyj/AIRSEIW3ByMZ4FdgrMSCz8g8YHFAHQw3aE4IIAHerccgfd3Fc4sofa7HbnA4FbVg5cFTkkAkHFAF7HXOfrSMfy+lKTwTikxyR2NAGZrUbOIwmeO1YskUhSRcHAXJDHv0rqJ4vMX3HSs+7h8obscOCrE0AeLeO9LaS8RmZcgHiuPjilgnA2hffFen+JEa6vsLgxoNhNc9q+mFrQ/KfM9MUAYT3DNHjPQZznrWbM+8dSM1MgmCtG0bLgkZYYqtIpAO70oAosSi9DUVteyJMApYH3NWZ8qnArPmYLKMrn3oA6ANvhO5TvPTFVJfkiOchs03Tr2MsoYAjOK3P7LaZXlAzGR1PSgDnzCzuCScAZNQ6gjyruQfN3rcktSiEkAZrPWF2JBAAJ5oAxZol5bJL9hToLZgvmDAX3raXTmUyO5wM8ZHWop4FI2rxxQBjRxkyEqcse3pSQRO8sjOuQBgZNXjb4zsxnvmnvBKQT5YwAOlAFe3X95FkEY9a3oVXy3kbrjC1RjgJEZIGfU1p26uww4XDDaD70AVWR2OMhm65q4irtK5AcjGaBbuvzqDgHBFNKTSTgtjA746UASWygI6vwB09qgchsqmMDqSa0/KVEMs+0L29653UbyIyuI+OvegCC+1UW8mxcO38qqNfzXG1iQB6Csy6y+X6jPrRC5aRVjUbh70Ab1tLll5+YV0um3z+QE6HrXI2+VXDHDEVbtpXQgZOTQB1/2g7cDPzVTuVzllOfUis+G7dGxIPb2qSOQKZCH69s0AW4JzIvlKQGAwGJp0bnHls/B6nrVVG8zdtAB9KnVNphVc5PXigDrPA1rLeX8ixx71U9+Oa7+RbqwwXjYEEZA5qD4ZaaltYySlSXYbiT6118sMcsqh1z6g0AS2k6XFtHInCnqD2NTgZIx0qCG3WBCkY2pnOKmGO496AF4znpQACRxQORn8qXAz7igCG6H+juAa4/V4AmWQja1doRwc88Vh6pbkq0YAwx60AcNOjCVWwcEcEniuf1mTZBKgPzFT9K6i7RkO0jcqHoa5nxG8a2jEna7cAUAeRz26+e23HXnFQzwrtYyqSf4cGtgWgjnZt3BOc9apXSb5QhU8HOaAMG+GLdcflWDOOST1rodTXbkfw1guCXwBmgCzpvyEPk4q9cyho2wQOKqKAsAP3e1RSPwAxBFACWMbPc7s9KvaiAYSMnIp2lxLsZ+4qDU5NikHBz60Acrf4ZiAelZEpGeh9K1Lw5PByayp+GOe1AELYB7U3IyaX72cmm7fQ0AOJPGM5qVBk8cVF90jvzTlbbznvQBajwOT0FXodpAPX61mhhnofer9uw4yTmgC0oODg1q6UGHJ5NZUJOT+lalo2xBg0AdCEBjGTxir3hTw8/ifXVsfOFpYQxm61C9JwLW2X7756AnoPfnoDWGt15cQJUuSQqqO5JwB+JIFdn4zlj8LaEPBVhLFLfTMl14huoTkSTDmO1U/3IwQT6nHTLCgDI8Z68niPV43sYDaaHYwiz0qzxgQ269CR/fbG4556A9KybZ9mVI4IxmqyuQRzxU0AzuHNAGlbIGGVPT3q5ECrZ7HqKp2SkDG7OTWjAhJZTz70AWY4kbHLZ/Sp22BFLcsKbax4IU9SeOKvi0UOSfmP5UAd/8ADe4D6M8e/gSk7e/Su5s2DKRuwRzmvKfBV21peOhUhWNenW8rOqsoCqR1AoA0XvbeBGTyWaXbguG6Yq94Ume4DSMSBg8HuKxXRTKA5CyEY4Ga6fQoPIhAUZx36daANYemeKUcc9KTjOPWlxk98dKAE6dKq39sZ0YhjkLkD3q2OgJBNBwDx0oA4dNHkeUiZcLnkr1q3baVEpYSwq7L69hXUTxq6Nu2jjrXNT3LRSsqrgMeeaAOa8YaDbvb7o1QsVz8g6GvIdQj8udoyRle1e73LtJaygBQWG3ntk14X4iRYdTuEZ8EN2oAzriOQ7QpAJHFZ12rDIIIxwa0Ml9rZOBxV61SNyPOTcp9aAMOC3KsAnyjO7PtXY6FqciIsTJvQZJz0qodP83cY0+UenaoXgaDIXcGxzQB0lwbedQY4xGfQnrWNOn75ioQovWqAuCMBgxx71mzzuQQCcE45oA6OXUY1gEHykAbsnrWVLeR9GQZPesWUylSCST/AHhxioX8+TAdiSOMigDUOoIo+4mAOSafDfoQTwV9M1zF0WjzncOO9MiklBw2cHsKAO1F7C1v+7QDHU5p0GprhD3U+tcxFKdoILADqKlSVSWVc55NAHXrqEcrM3PPJ5p9xdRxH5YxtPIIOa5a2lYqQPvema1I3e6gEYOGVeBQA7VL7z4SGY8HnBxXMXOGkYg5HtWo0bGdlfqByD3pVsljyxXjH3aAMR4lJDBgAe1OgiUvuAKkd6fex/vS6phQahEo2KgbGTyfSgC+gPJdDgepqe2kUpnkgdOcVBA/7s85xxmidwy7FGCD1BoA0IbxpMB9pC+tWWJwjHBBPasKJJGkUkEMOuO9btmr7MEkDrigC3bFm6Dr0x2ratoidmTk4656VBaRKm3YRz14rThiO7aqkHuKAPW/Ax/4lcCgAMYhnnrW7sc3Rba2wHg1i/D+Jo9Gw3LDiuox8ooATJA5FGDjpmlPT0zQMmgAIOfUUZx7cUpwfakI9+tACAH0qGVVl3IQNp459amxu6mo2X515xznFAHBanG63Ey5AG8jiuR8Q2/2m2lDj5gPl7cV6Hqtuhvrj92fmbJx3Nczq1qFiYyAdMYoA8waz+zRkNtO4cZrGmgUluRkdK6zVwqKNwK9hXKXigBsD1O40AcxqCAswJzz3rFdFE/p+Fbl7hGOOc9RWRIA8u4DGO1ACAEoSM4A/Oq7nJ5PSpi+1fbNQoFdjtYGgC5YMfLIP41X1Q5DZ5GPyrSs0CxBducD86zNVwCyr06E0AcnecMQDxWbKD9a0L0/M2MVmyMenFAEeCD6UbfVsH0obo3tTSRnmgB5ORx68inqRjBFMzzgn/69IGJPbPpQBZUg9ODVuAkMMiqUXABq3C3zg5oA1IgDjb0rTs1QsN3TGazrXBGM81dhyCMdKAL9wiBMZzGeCD3qKNY4kEcKhV9veppx5lurKMYqtAQQwJye3tQBKCRgVdtDhhkjmqcaPjJPGeuKuRfu33nG0dBQBp2uFcY4rRhPz/e59ay4XJwcYFaUGGwwyMdaANVGHBXnHrWpp03muu8AANmufiYhjtBIFXrWQbtynvxQB2GjKgvQcgjd19K72x8wQ4IGD054FcL4aQOu8HkH0616FbRFUTB/+uPWgB0WwTKQ+WHqK7qyTy4EGew4PauMhiQSbyAOMc9q7W3fzLeJhzuUUAS8GgHnIpTxnApMYHWgBTjPtSdDz9cUv8Jz+dAHNADJF3qy5C7hjPeuUvoZreVlZD6hyMjFdaOcZodQ4ZHAKng5oA88uIJ3Q4OWb045rybxHo87arMXUDn05r6BurAQSGTOUAz7E1zN1oUc7SyyqTI7ZJoA8asNLZGAuBxngmtC8towgMKj8K6vxHax2ttJsiG1Oc1x1zICqkAquemaANPw2HjlIdMgjHNTahZQy7pH+X5uAOtULOdbZ45FcPz65rpikM1oZXVfXGeaAOHvbfyl3xxkoDzWQqb25Tr29K7u6hiEYRQpVhnaR1NZa2EEc/mLnd/ED0FAHNfYZWThD+VNlRYCBjDAV1U9zY2vyyPl/QVzt5c27OdrK2e/XFAGU0MVwTkjNU59OmhkU8mMjIxV55YbdmCkH8aswatbeWqMQx7ZPSgDLWEhSNp+hqLyTFkkde5rqrRbK+L7G2v1A7U2fTQMBgooAwbDllZc+YOpxW0ltLb3QIbhgDgHNJ9g8kqyct3ArYtLfe4CgleOSOaACXTkAWUjduGfXmmXMMO3DN8yjt6Vq67LBp9lGgyWYYCtxg1zFxc7GO2RBgfdPegClqFtHPuEfyEcgetc3cWc0LFmQlB1Irpo52cnmpFhEv3uB9KAOWtJTKXCgnb2xWjFA4bcFAB7ZrTTSilwXhGFJ9OtTNbhXAcjmgCK0h4LgfN2z3rUtIWcKCcLVe2PGwqNp74rb0+BGU4LZHbHWgCxaRBFJAB7YrZtmBdAoye5rPVAu7Bxn1q7p8waUKeGGMYoA9Z8K7liIA+Ur0z3rezgY7etY/heALpiy5y7962RyOvFAAwz9KOe1B60Z6cmgBAcjgUp6Z4FIBgDrR1PsaAExkCmyjrj/wDVT+3JPFQXeVjYjOPUUAY0wMl3MW9c8ngVhazCAr7QSCOmK3I5AkzZ2sGODk1Q1EKd7O22LOMrQB5F4iAaVwvQdB6VzEzKA4mI5HGK7zxLDEgJQ7s5Occ155q0ojJJwR2OKAOdvHBlYY4z1rKmUiUnHHrWi7ByzEdBWddsQD2BGaAKN0/y4IOe9Ms03SBl4FR3T7xuPB6UttIVTb0yc0AbcLtjdjI9O1Zuo58kuVwM9K07N91qoK4JrK15wsJAJBoA4+9YFiFHes9jjIBFWbo/Nw3equOCaAEHqKCM4yPzoxnnIHtSN7HNACnGeuDRnn5cUduetKMH2NAD4yc4PSrMR3cDg1TBPWp4W5yp4FAGzYt+nU1sRHLKTkL9KwbNwTkGuhtcPGMGgDQtgD+7bIBHemPbBGIGAB+tNUhVyGJIqQyebzyCPSgBFJ6E8Cp1QZJXkEVAgGfn7VMGKouOmaANK2TIwMfjWkjIqlQazbJvnB6jHetGNlHUD5qALKuCpwAQeBUVvIyzffGM4qe2CRgkkZ7GmTxs04CkFc9RQB3HhOVvMWLocbq9LsmO0gBSVxzXmHh1zDJAoIaRup9BXp2nOrxAuwQkcYNAF5PvF8gN6ds10uiSBrBVySymuWgcNKEdxgD73rXQaXI0LCMgYY80AbOetB5OfbGKO3rSAcnjtQAvXnHsKXPTI/WjtyaTnkDqKAClx1pB+dHGeOufzoAiuYBcQ7TwOvIqi+mkAhXU85PFamD+lKAMj1oA8Z+Jhay010CEktuyK8iN9K4UFcd8Gvp/xton9saftQAt0xivGNV8K/Z5HTyGDjrxQBwVtrW12jb5SD0rd/tmYWy7ZSpI9a5nW9MurLUctE6xtyDjrUkUsrIBtYDHcUAbba1dS4DTZI4GKntmkdWmlY7AMkmsqCIgYkTHpxTNVvhFH9njY4PUZ6UAUdXvhc3DYbaAf0rMVc8iTPXvVoRI688nGenWmvCqr90DPWgChMgI5fBPr3qskZ+95nB961pLfMeNh68Zqt9nEZG1COe4oAm026a1kDRsSRztzXb2d9HqNqJVBEigBh71xUMGQWbC49q3fDtz9muAG4UnnigDUmMgdSGKr1II71LZ30gY4bBpb5UMvy/cJ9Kzo/luSgTJagCprl3NPOpLEqpzyaynlZiCZCW9K6C/sTtwy/MKzjZkAAIM5oAopNKp4JyvUVes72ZmO44x2qGZJVc4QDtV22t/lQHnd3FAHRaIY7pQGU7iccmprzTiHYbcY4zU/h2wKS5G4c56V111pyTWyOzYdxxxQBwaw4XB45wcitKyQx5ZCBk8YrSl0nBZQwYoOR+NOitEXlj8uOcD9KAIlDFWLYyepNaOiWxmu4Qis4LheO9P0rTvtXIJVSec13PhfR4obyLaM7DvORz7UAdTplubaxiixggZxVvt05pP4qU9D0zQAHkcGgduaTPXJo9aAFGOaac/hSjpn1NA69c0AIeMnsBmqszh0fB+nNWJCACCTzVKZ8JheRnOPWgDOlQpuMa4LHknms/UpX8sRkAKOM4yCau36hSvlk4YfSsjUj8jDdwAT16GgDhfEbDfIwx6YrzfVP3jOu0cGvQvEQYoXABz2zXn9+MSZI5PvQBhXUYgXoOeaxL58qCBmt7UAZEyF6VzmoHAIBJGKAMe5kJbgY9qWKRt4BGAahlI/LpV2yiDzJnpkUAbsafZ7Rd20kjPvXL69OwByevSuk1GXyYOD2xXE6vPnIzQBjyNl8+9MYHPzcGlYk8AUnXr+dADR/OlXgdM0DocHGP1oyRnFACkgEZBpeh4pPmxkY/GgtjAxzQA7AOPWnD5Tjn3pq452ik6nrQBo2kgDDnArqNJZTkHpXHQvtYY610OkTMdgA+agDdlhxgqDtqvu2S4wR9DWlG3mRbT97tVC9G09PmPHFACGX5wQScnp6VZDg/e/IVmByoyo6dqsW8oZevPcUAbdvjy89jU4cKpHP8AhVCylUIRnnpVoOGwO1AFxbjqCfSrKTsmTn6e9ZKkAnPSrCSBmXBwM80Ad74clGYZjhQDg5NegQXIDBi4yRgAV5Bpl2R8oJ9hXoWkDzrZWwWxzx2oA7HT74POAFBw2DXXWimQxZY8sD1rgtJysuAMehrv9GHmRx8crySKANr1z2pec++KAMAjtSMQOetADh3PrRjPTsKBnHB96QEk5BxQAde/FLkgY7/Sgc8HrQBwMUAA7Z64oOc8UDrj1pfqDQBSvLgRsUJbJ6EVnPYwXeJHO5z2YEVoaghGHAHvUltjyl47ZxQBw/jnwta3NqsgjTdtyWPWvLZNF8k4SPPHUive/EaBrNBjOTyK4e+05lBGw469KAPN7m0C2zEIfl68VxOp2Usdwz8svXNew3mnOeedhHNYdzoBu5GjCEjn8KAPL4WGeRyf0q7BCGIDFST1xW5N4cMUrKFGF6etT2+hMMFeDjJ56CgDOgs0ZWA2nHPNR3NgGCybRz2rq4dEYIOvIyAO/vTJNIOCoznpQBxK2oG4nr2FTwqUbcq5bsK6qy0J9rEjJU9Mdas/2GGDttCgdKAMaMyXVuucD6VJHYFTuHJ9fSuq0jQVVGXbubsK1U0KIrtkjZR6nsaAOOlt8wb2wSO/rVOO1L8lQF68V1WpWapI0a7QuMYzzms1LVn2KuQwoA5i+ttqbgvGetTacgKglSW44robvS5JI2Tb71d0DQjJMu4ZORkdKANDSEkFkrhGCE4PHStWRB9mRge3SryWXl7Y+BGh9etJcx+XDhACzHGO3FAGQ0IBy3DEZzmrlrZpc3KxIDt4zimfZHZtu1sY5NdL4Q0/eZJX7Hg9QQKAI7TTHt5zGq4GeBiuw06zFtFksTI4GTjpSwwIZNwQKB71aB5PJ60AAGM0Dr/9el7+1Nzxk+vagBTSDHpTieCO9J24BOBxQAZA470E7fpikz25qK4k2RN1yRxigBs8gRep3E4GKrM4IOBwARnNVzOHKgnLHr6imXEw27UOV6t2oAqXhZyQwwtYmqPiFt3CjjpWrPON3DfLXP8AiC9G0xrtbIzkUAcJ4julSZVU8YxXG343MeO9dTrLReYOMqeT9a52dwobK8dqAMC7BO4KO2cVzOoDCkjGe9dRdlSrE5zntXLaoSCR70AYUz/vCcceta2kLnkjgc1myAmUAcZrWtCYIW3c5FAEGtXHBAOBXI37+Yx3d+BWzqkpJPOO2K5+4LBsZGKAIOMkCilPC+9JkEgd6AEY9PWk5IyKAME88/yoI3AfyoAVh259aB97gYxQDwO9K3XNACg8ZH5UgPPSlFGQB8y+1ADkOMHtWvpspDDa2MVjHgg4wBVm2m+b8aAO8sZd6Lg8rTtTJJDdj3rJ0qcfLnj61uSossIyOAKAMP7rEdcnNSW7YZt3fim3cZjduOtNi5OaANGFiOmSKsxyMMKD1qnb5JGKtHbGpB5JoAsNKFTntUkcgYqB0JzVQncBgjip7fG4dcetAHR6SCuGVt2a9J8LcQEsQSe1eb6Q6xlFzkHsa7vRbhIpQQOeMYNAHomnRINvQnGeldjomI4gFZRu7VyeiTEorHZlh1IrpNNlVWA43H0oA392CR1xyajU72Pp71DNIuwF3ALcDBpI5MxKFAZicfKeaAJFJjlIcgDHGTTTcqWwRj1JrN1CdftQZw4I4qUKW5C7g3QH0oAuJJulBY/IR1q31+g9O9ZqlmXbtAVR2FaMZyowOMUAKSCo9OtKexz1o59KXp15NADCFKlWGV78VFEjRLtypBPHtUx/XNHXFAGNq8oklhVMNjJOeKyp42BcsCAe3UVf1iCU3G45bGDwOgrMd9kbFizDd37UAQtbIWGEX5lz0703T4Y2vV+ReTtbjtVpJAdvzY9KWONfPWYPt55AHAoA4nXbJE1CZFTvkHpxVdbVdi4Ue+a7HWbOOfUJFA3DgBzxTo9KjUqgXrgA56mgDl4Ydqneu5WHy4PSo3t9uGdMV2EunRhgPJ2nocGoL2wj3EKPlJwMjpQBzVuriMGJAHJOAKsw22GAcDcR1xVxrdo7limFO3tWjFbsuwNhnxnk5oApxWoVwQxbAq68TAKrg5bkbulWUg3FWI+nuamaAtKUK8+/QUAclremN9uPyhnB6r3plhpjSEswORweK7K3sfPl8yZtqt3Vc9K0YbdEI8lREOxHf60AcpHpC/KzR4Q8UtnZrFdKoUL82OO9dTMjE/O4Ix6Ultbg3cZkAwvOP60AMXRjM6O2xc9h6VJNo0QDMcMB7Vs5wW9vT0qtczKjEHOT0oA56505E8plBJwSRmtjQ4hFaEKNrM5yMUySUOighRg8cd6uaep8oFupNAFlVAA6c05cCgjgYGfwo6j+lAC+vWjp7UgztzzSjp/jQAh46fWjHXPT60p78imMOD3oAazfQ1m6nNuVQFKspxx3rSbGx+MHFc9qrrHECpGSeh60ANcrDM0ZYEjnr1rIv77y8452+tQtcF1cqcPnpWFfyyB2EhJoAl1LWnQFAQFJGfasfUr1fnTOWbGMHiqGsOQd0nQ9KzLqfMQYHOOOlADdRKyNhWBFYOoKqq2B83fmtLeWbGRmszVWG84H5UAYF6o24DZHWsDUV3cjt1rfu0MjMVyBWLdKc4J46UAZNtb+ZJzjirF+3lxbR1q1bQeW7MOnrWXrMpVulAHP38paQgHmsyTJbOefSrVy435xzmqklADW574pgB5NOycYb8KQt2AoAQL/ABZ60uOp3e1AOMbvyoxnOeB7UAC5wP0pW5IFIoFKVJGO9AAeTjIo29Tnj3pduMAkZp2PpQA3AK9vWnRkjp35o28Egc0gzgjFAGzYXJBA7iuu066EiBZDXB20hXae1dBY3ABXmgDW1ePdlhjC9Kylc7uPSt0fvovmxg1iXMJjlYZ6GgCzasVZeccVbaRSSGOR2rMjY/jVuFSykE+9AF6MA4q3EoDYB96z4nOPmwT7VcgYgZX86ANqzkI9Sa67R7sbUVmVWz0rjLcllOTgZFa8DeU6bsnB4waAPWdPvSIlZWOM9BXZWcjRwRuzLkjOK8g0e+Pyjc20noa7aPU3JjjBVgABnpQB2Ud0GkXcCVH8JOK0bZVDI6uN3YA881zVlJvjy4G8cY9a17aYWq+Z1bHAoA1r2OL5sr82erGliEa4Qgcckg5rCa9mlUtI7YPqansrncATuJUckmgDoYVURkjoOfenxMv8PU81TjmBx5ZG3HHNKsj9grYbk0AaPBPBpc4bBwDUaHIyD16VFPIUUnco5xQBPn8u9J6AdetZovmEiqWTYxwSTWipG0YIPpQAMqktu/i4I9ayb/S8qWgVTx0IrZ5zkCmgA9DigDjwjeYQy7WC9h3pJo2WIHBEg6HNdHe2iSSKVwrgZwO9VGtWWTYyY3HPr+FAGW0crIJGblhk5PWprSXad7Rnd256Y9KimPnMQGO5OKfax7/v5CqOMDJoAlz5t0XdsKTnJ9arSgrPJjhScZPSrCsTN5RHTsRjFMulVom+XGP50AY7XKzayUbYsapkheuRWirMNzRRgswx06CuftombVnlz8qnmushgAhjkZS5H5CgCG2HzHBII46VL8qlyQQVU5bPFEIPnSKWVU6jjv70akWW3IwQmMH60ALot1HcWKA5IRiOeOK1GBkLEbVQDv2rE0BNk7x5UK+CoYcVvTRgrtJXI546GgCttLR4J9wapXlytugbcN/f3FXXkESkOoZeuPT0rH1DbL5jlQPlyB70AXYNQlu1DjK7RjilnuJpWO5twGM8iszRncW6hgoBPSr6hROrbfTpz+dAF+C3ilAwhHOTlq04lVECL0FV4PLiTKAncc1Z3cZOAaAHDpgUA4OKbxtyf50qnJoAXJz6UA5x1zQMZ5pDgYPGaAFPOeKjyGyoGD6mpD96oZCVB6haAK9zuCHaxJ/lXJ6zMSHO/Pbg5rd1WTyicMdxXgDpXHalMV3F1G30B70AZcE7+djdnLdaLs8NjJY9gKqi5RLhvl4xTvtCzBpHYgUAYmu8FQx3AVl/KVJ/hHABrT1YiRjsH51mSHCBRjPcUAUbjKgN0J7Vl3QdiSpz64rTvSeKyLyXYmelAGPfXIDYQYA4Oaz5YfMIx908iluTumOVq1p6eYvzH5FoAguYhawEE44rjdXmO45PWuu16UeWVUk8Y5rgdTfc/wBKAM65bLHkVX2gc9qkfBJJGeKjI4oAAM9CKTbjINHAFISMigBGx0o+71NKe9IRwM0APBPQetLgBjk9Kbjr60oCjk5zQAZGc9qd1pOxzQvQ9qADvxnI70E8euaUDjB70bcDGOe9AD0JC9fyrSs5OV54rMxlflG01PCdoGcZoA7LT7nKBWOR6U7UEDKXWsXT5xtwOnfNb1sRLGFboaAMn7je+KvWrjvz71BdQFJSOelNTKjPcdOaANNQASV9KsrlEyc81QhfJGSfwrRtmDEDv70AWopc4z+ta9nIZCoPasJzggD1rZ0VlMq7+3b1oA67Q4ykm984Hb1rq7AF5gfeuesgpRTkKMdM1vacxRlJzlh1oA6y0cp85JCdBk1I90dq8E9wKzkikZMfeBweDzxUU1y6grlh68dKANpb4vb7TtyvIyKW2umGduCvTOeDXMi9WRAvLlcnAFSWOotE0kYZtr8hcZoA7eznCvuLdRwM1uQsrgYLNgE8H2rkrK7QxRjZk7ecetbdm5BjC8AnBAPWgDfgfEZVsZXjrzVS9k3EZyRinCRYwwwVZjxnmqlwxCtng9MZ60AUmbcQuCNvOD3NamnXRL7XcDA4Ld6owLkEsQRwemagEnlzq64JXOeKAOpBA4AFIOcj04qva3MdzErxnLbeQB3qwpyM9O+aAAJ0PcCopQoSQnHTBPQ1N15qOUDyyWAI/ioA5aYhNQxkIGbHJq3t2S4Rwu3kY71BfxjzzIE24bPzVcZxIiyEbQRgY6UAV0VzeqrDJfuTSTyKIWXowBwPU0jf8fsIyecA54wM028MgEgBDqMkBeeKAOb3ssjt0dn/ADrqtLaSWMKGPqV7VzF+D5Y2HlmyAcZUV0nh+ceUCFySB36UATeVtufkXjqQ3rUOqzeZEU+ULnPArVRIxdbSF3Y9azNRChtuByTQBFYEQTwuGBB7jtW+ACjBmJLDqOwrnICB5fGDk5JrUmu44bUuHUEqQBigCHUHCssakYxyO9Zt6WETcFuDioo5WlG7gnofWqV9MvQELk4IbigC7b7sRbOARk9q0bLa0o2Z3deelUbXa9sgUAkD+90pbZmEzbW78UAdCrsq4+6wPINS+ZuZFbjPc9KxFmIYDOTnk1dt3DzMUOFBxyf5UAXpJtqoCQexI9KtRYwOfx9ay558Phvveuau2T5jAxmgC11JApG4x+Ro+mfpSNnue3SgAB9OPxqtO4UHop69aSSXDYVsc9aqzMkj53AgcZPXFAGZqjlCzIOQOCea4fxHcO0ZK5BByTXaapJvV2AHpnPWuM1WQHeGGWIwcCgDlZ795HAK4OMZBqSC7yED5KjPAOM0y4tFeTMYwPrUQtTjbzke9AE9xIsqKY1wD196zWUFskYxWgkQVQrA1CsWzlhgdKAMm8U4JBJAHWuZ1NWAbH51110hlB3DheCawr623cAcDtQBywjL5Zsk+1aMEYitGJ+UkVctNPJk74HtSarGBAe2OKAOJ1yU/NjIH864y8bLnnP0rqtcfrg1yVwQzHAxQBWxg9fwpCdw6HFOU4zwDTQD1oAaeaMZ4zxSnr7elJjABHHNACAZPIpDz1zx6UuMc460mCRgDkUAPUAkdqTgqPWnAUZGe1AA31oGSDmgjI7elKAvA6mgBcEqCOooBPPqe1IeOvbtRnGW7UALuxT1wCOM03JPUfjRjcRjrQBoWkoUjLHntXQ6fcDjdjFcnG21hWvYSHPJAx6UAdPcRLNCGUgmsl0Kv1PWtWwlDKAOpOKS9tipDKvHcUAZ6EhRz1NXbVirZJJz0qqeGyB17YqaElTyBxQBpR/NnvVyzkZJAVJqhaOrE7uhq7bhVfI5X3oA6ywuHcKSTxXo2iqLmyVZVUsoG33rzTR5EUDPJr0PQHZUUsdvf6UAdC1v9kAO5lbPaqGoBnVeck8nPpWyJY5YgJTuBHGT0rFvbVkkAyuT6ntQBluCgAiYdew6U63keKSNnTjrmpkdkYqqqTjuOtWYUD7Fk+VgOtAG7pspcfveFI4I710VsEJXbKMADjFc/pkIkhXa3zg4A9K2IlZGVjkn1x0oA24nRyvmLux3FQXckUjsBkDPU81C0jxxseSrDPSqTTAhSGBzyRQBcjcrGyxEHnOe9MlLFGYZAwMgd6ZYyKsyEkMD2rTlCY2AAc5yDQBm2ly0MqGFmIB5XtXQ2N1HcruBCEcba5fyyLljGNoHOKLS9wGxw2cgUAdkCCMn9KSUhUYMwUkcE1hWupsu3JdkxzVy4uxNZlkBJPoc4oAo3gDhSXUuTyfaltfmITcXxnAFZ9w7yzRKWCYGOuDUMLvtfbKwbdgEGgDQnTzWXby+7ucUt3Cdj4baVAGM/nWZco+YmbLMDkbetMlZ/KYqHU4POaAK10sO1Ngw2e1bXh5dssO1ty84U1yly0vmL8xUdOnWt7RNyxoyuc9MigDqpvLE4kcZLL2Hesu/nhVlyeVU5x61Uv7xRccMeOnvXP6rqQ/eZ5IH0oAutqqBXEKZwefpTZpnuIxtyFxnmuWtZTLcOSCqkc49a6bT0U2yozEORmgC9Zx7Lb5C+/r7Vhaq2dSR9w29x6V0lrEZEXOcYwK5fXIGjuGZgQCeAaAN20Aa1B3HcMkkCnIu2XdnAxn6mqeiSI9soYgn1IzV2HdI/TPpyBQBIsi7G9M8H0NaNgrSAMfzxWdGjGN1xzmtWyjLDJHOec0ATyqGIwoYY59au2ShVOcEelQeTlMvw2f09avQqoXjn6UAOwcZ5yKGOB83GRQRxjHPrSsPlJoAzL0CMhueuBnvVckHGQpO3HNXbtRKpQ5wpzz0qkWwgYAthsH2oAz73asbrsyp5wRjFclqVuZZSFGA36V2moHezbuhORisG6gDDG0DvknrQBycFiQxB5GcVI1l5ZOVAzyM96347IBwQuFxkmrEtsnlkbM5/lQByMlr+74we30qGa0/dhgQSf0rpHtCchMAnnBqOW0GMDPuQKAOQltG+Y8AHvWfNZ7lII5zXY3NqPut1xUa2AbGUOAOw60AckLFbaHBGCeeK5bXdoVwRxXo2p248tsDkevWvOfExxHJn5eKAPL/ABDIMlQeDXMyDDcHtzW1rB8y4bHQGsdsj65oAhxzx0pD16nrTz1+lM2kj3oAacc55oA+X1HWlCkZHegA4PB47ZoARunpSAY5PU+lPAzgikGckDGKAGr+HTinYznAFIvYHmjB39sCgAwcdBSqMg45/pSZ5yKUHgn3oAVR1H6+tB4GOMUmOvPelPDDjtmgAwCMYNHIxikLkHIpRyAfegB4zkHpnjFXbOTafUd/aqR5wRUikqwGcfSgDqdPmwwx0z1roItrLtY7ge9cfp7NhfmPWuo0wlxk/SgCK8tArfKDioGztyFBx6V0/wBlWWLL9eADWVNaKGGOOccUAUoi4xgfhWzYrmVO+eoqg0ABxk5Her2njE6jOfegDqNPt2Rxt9ua6/T5ZYo9245HT3rB00ZjXp+Nb4kJhjXAAXpigDUjvnIAONp7mrCSO0i7hhT3rLtUL554U9PWr9qB5qnnnnFAFkRAjL9OgqVLZsZbjA6+1NVPm4xyehrSjbYu3JKtwR7UAT6Ksi4BPy56+tdLB86l2HQge9YtlEYASm0gjIBFbFiVIMZHJ5yDQBPJse3cs21wMD5u1YckyJOF6dgcitOViyHIXpjAFZc0Cm9jRsZHQ0AaVgjS7JOMA9D3rSuQEuSpGCQcCr1rbrBEEUKcAdRUNxACQ+eTg0AYkyvBcNknGPSq3lo8xMYdSR26Vr36rJuLj5sdaztPGbna3bnjvQA4RvEMudsY6H+8afHefJtGQpHrTruVpWO4DAHBz0rKkBMTYZs5oAbdzM14ih8NnPsafERHcNgYJ9qwpWY6ggY55q610Q467ycZzQBtiZvIUsxC7ulLO6eWQWLKB257VkxSvJG+ZGIDYwe9RMW4AOAT2oAu4gnuAu3HTipFH2Z1IwynOAK5USyrOdsjAjvmuk06V5TAkmG4ySetACOcTFjnHf2qneWnnZdiQpOfqK2RB5KlnOQTyBVSeLrz8oOQKAMWKMRkYAHfpWzpalpG8wE5OAR6VTnjU3CvgAgcYrXtlCMrBQSSM5/pQBYgXaMEvtz0PGKo6zZ+ZB85GSpPrWkFU43ZJJz16U67RGZVUEZHegDltIlaJTG+eOhrftsMgIGAetVvsaq4xgHnnFaFlDtiU5yc0ASwKSknAKg8YrT08CRCfm3cYYdqrRkRhRjqc4q9pceIyTj72eKALYRh3zn1FS8jIIwKTHXNOKjoQD3oAaMkEYxx0pTnGOv4UHkY98daUcHJ7mgCNlUg7ue3NZd1EAzbW+UnPStduhaoLhAwDdvT1oAxZYyUGTkdKg+zJ5Y24LnPHpW1HbDBAIJ9xTxaoHOOoOOaAOfjtWYjK5HT2qK4hGflHPOR6V0skCquF6Dmsx4wc7OMnnNAGNHZncWBGfT1okthgkrkH26VtQwp5q/ewQcYNEkSL0BKsM4JoA5xrM9SFIb1FNmtCIugVR6HFdDFBHMzEDaB261Uu4vkIJ6UAcHrcfDCMc9c5ryPxu4SF1Aw31r2rXowY2bpgdq8V8aDzro84HpQB5TdodzHmsyRCM/WukvYhlhWTPDknnrxQBlMhGcDmm49Ktbd0mBxUbKeRnkUAQYK8+vekAznJqXGQcdRTNuDQBHtOf8APNABx0wakwQOvtSDOaAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP open mouth view of C1/C2 intervertebral joint space and the odontoid reveals an obvious offset of the right lateral mass of C1 (white arrow) over the corresponding lateral mass of C2. There is more subtle malalignment of left C1 lateral mass (red arrow) relative to C2. These findings suggest a Jefferson fracture of  C1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7348=[""].join("\n");
var outline_f7_11_7348=null;
var title_f7_11_7349="Serous cancer histology";
var content_f7_11_7349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histologic patterns of endometrial carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serous carcinoma at high power (A) showing a complex branching pattern forming irregular spaces into which tumor cells exfoliate.&nbsp;Neoplastic cells have high nuclear to cytoplasmic ratio, and the nuclei show size and shape variation (pleomorphism). Serous carcinomas typically overexpress an abnormal form of the p53 gene product as demonstrated by immunohistochemistry (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lesley Lomo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7349=[""].join("\n");
var outline_f7_11_7349=null;
var title_f7_11_7350="Thioridazine: Pediatric drug information";
var content_f7_11_7350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thioridazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"    see \"Thioridazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/36/19013?source=see_link\">",
"    see \"Thioridazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Typical, Phenothiazine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phenothiazine Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"      see \"Thioridazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;2 years: Initial: 0.5 mg/kg/day in 2-3 divided doses; range: 0.5-3 mg/kg/day; usual: 1 mg/kg/day in 2-3 divided doses; maximum dose: 3 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Behavior problems: Initial: 10 mg 2-3 times/day, increase gradually",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe psychoses: Initial: 25 mg 2-3 times/day, increase gradually",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schizophrenia/psychoses: Initial: 25-100 mg 3 times/day with gradual increments as needed and tolerated; maximum daily dose: 800 mg/day in 2-4 divided doses; maintenance: 10-200 mg/dose 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depressive disorders, dementia: Initial: 25 mg 3 times/day; maintenance dose: 20-200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with water, food, or milk to decrease GI upset; dilute the oral concentrate with water or juice before administration; do not administer liquid thioridazine simultaneously with carbamazepine suspension; do not mix liquid thioridazine with enteric formulas",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to prolongation of the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, thioridazine is currently indicated only for the treatment of refractory schizophrenic patients [FDA approved in pediatric patients (age not specified) and adults]; in the past, the drug had been used for management of psychotic disorders; depressive neurosis; dementia in elderly; severe behavioral problems in children",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F227127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thioridazine may be confused with thiothixene, Thorazine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mellaril may be confused with Elavil, Mebaral&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F227125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: ECG changes, hypotension, orthostatic hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, EPS (akathisia, dystonias, pseudoparkinsonism, tardive dyskinesia), impairment of temperature regulation, lowering of seizure threshold, neuroleptic malignant syndrome (NMS)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Discoloration of skin (blue-gray), increased sensitivity to sun, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast pain, libido (changes in), changes in menstrual cycle, galactorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: constipation, diarrhea, nausea, stomach pain, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficulty in urination, ejaculatory disturbances, priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Seizure, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cornea and lens changes, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thioridazine or any component; cross-sensitivity to other phenothiazines may exist; concurrent therapy with propranolol, pindolol, fluvoxamine, fluoxetine, paroxetine, drugs that inhibit cytochrome P450 isoenzyme CYP2D6, drugs that prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, and patients with reduced levels of CYP2D6, a history of cardiac arrhythmias, congenital long QT syndrome, or a QT",
"     <sub>",
"      c",
"     </sub>",
"     interval &gt;450 msec (adults); severe CNS depression; avoid use in patients with narrow-angle glaucoma, blood dyscrasias, severe liver or cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe cardiovascular disorder or seizures",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose-related prolongation of the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval may occur and may be associated with torsade de pointes arrhythmias and sudden death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; reserve use for schizophrenic patients who do not respond to adequate treatment with other antipsychotic agents. May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is low relative to other neuroleptics, and is dose-dependent; to decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible; evaluate continued need periodically; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients). May cause neuroleptic malignant syndrome; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3.",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature; thioridazine is not approved for this indication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F227115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2D6 (strong), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors: May decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moclobemide: May increase the serum concentration of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May increase dietary requirements for riboflavin; liquid thioridazine formulations may precipitate with enteral formulas",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12586216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice or hyper-/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic ECG and serum potassium; periodic eye exam, CBC with differential, blood pressure, liver enzyme tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 25% to 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 9-30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable: (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/36/19013?source=see_link\">",
"      see \"Thioridazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; avoid skin contact with oral liquid preparations, may cause contact dermatitis; do not discontinue or alter dose without physician approval. May rarely cause photosensitivity reactions; avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); use a sunscreen; contact physician if reaction occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In cases of overdoses, cardiovascular monitoring and continuous ECG monitoring should be performed; avoid drugs (such as quinidine, disopyramide, and procainamide) that may further prolong the QT interval",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     All Mellaril&reg; (brand name) products have been discontinued; Mellaril&reg; suspension was discontinued October, 2000; oral concentrate 100 mg/mL was discontinued March 2001; tablets and 30 mg/mL oral concentrate were discontinued in January 2002.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aman MG, Marks RE, Turbott SH, et al, &ldquo;Clinical Effects of Methylphenidate and Thioridazine in Intellectually Subaverage Children,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1991, 30(2):246-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/11/7350/abstract-text/2016229/pubmed\" id=\"2016229\" target=\"_blank\">",
"        2016229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12837 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-08F48505D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7350=[""].join("\n");
var outline_f7_11_7350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708963\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055663\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055656\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227057\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227041\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055667\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055666\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227127\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227125\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055670\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055655\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055654\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227115\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227050\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055673\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227053\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586216\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055662\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055653\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055669\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055661\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055671\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=related_link\">",
"      Thioridazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/36/19013?source=related_link\">",
"      Thioridazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_11_7351="Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)";
var content_f7_11_7351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7351/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7351/contributors\">",
"     Jean Lee Lim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7351/contributors\">",
"     Maryam Asgari, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7351/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7351/contributors\">",
"     Robert S Stern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7351/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7351/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/11/7351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 17, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21299818\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous squamous cell carcinoma (SCC) presents with a wide variety of clinical manifestations, including papules, plaques, or nodules, and smooth, hyperkeratotic, or ulcerative lesions. Skin biopsies are required to confirm the diagnosis. Biopsies also provide information that is useful for staging.",
"   </p>",
"   <p>",
"    The clinical presentation and diagnosis of SCC will be reviewed here. The epidemiology and risk factors for the development of SCC and the treatment of cutaneous SCC are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21299826\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574142\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCC can develop on any cutaneous surface, including the head, neck, trunk, extremities, oral mucosa, periungual skin, and anogenital areas (",
"    <a class=\"graphic graphic_picture graphicRef74240 graphicRef65527 graphicRef81810 graphicRef66886 \" href=\"UTD.htm?35/12/36042\">",
"     picture 1A-D",
"    </a>",
"    ). In fair-skinned individuals, SCCs most commonly arise in sites frequently exposed to the sun. In a cohort of 145 patients with SCC in Australia, the following distribution of SCC was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Head and neck (55 percent)",
"     </li>",
"     <li>",
"      Dorsum of the hands and forearms (18 percent)",
"     </li>",
"     <li>",
"      Legs (13 percent)",
"     </li>",
"     <li>",
"      Arms (3 percent)",
"     </li>",
"     <li>",
"      Shoulder or back (4 percent)",
"     </li>",
"     <li>",
"      Chest or abdomen (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of SCC on non-sun-exposed skin is less common overall, but represents the most common distribution in individuals with dark skin. This finding is likely related to the protective effect of epidermal melanin against the carcinogenic effects of ultraviolet light. In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Lesions that develop in relation to chronic scarring processes account for 20 to 40 percent of SCCs in black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Ethnicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Chronic inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genital and periungual SCC lesions are rare and are usually related to infection with high risk human papilloma virus (HPV) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/5\">",
"     5",
"    </a>",
"    ]. Genital lesions may also arise as a consequence of the administration of psoralen plus UVA (PUVA) phototherapy without genital shields [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/6\">",
"     6",
"    </a>",
"    ]. Of note, tumors arising on the ear, preauricular surfaces, or at mucocutaneous interfaces (ie, lips, genitalia, and perianal area) tend to be more aggressive with rates of metastasis estimated to range from 10 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574559\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical appearance of cutaneous SCC is influenced by the lesion type and site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574597\">",
"    <span class=\"h3\">",
"     SCC in situ (Bowen's disease)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous SCC in situ typically presents as a well-demarcated, scaly patch or plaque (",
"    <a class=\"graphic graphic_picture graphicRef82358 \" href=\"UTD.htm?38/34/39464\">",
"     picture 2",
"    </a>",
"    ). Lesions are often erythematous, but can also be skin-colored or pigmented. SCC in situ lesions tend to grow slowly, enlarging over the course of years. Unlike the inflammatory disorders that may resemble SCC in situ, lesions are usually asymptomatic. (See",
"    <a class=\"local\" href=\"#H575170\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574649\">",
"    <span class=\"h4\">",
"     Erythroplasia of Queyrat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroplasia of Queyrat is a term used to describe SCC in situ involving the penis. This condition presents as a well-defined, velvety, red plaque (",
"    <a class=\"graphic graphic_picture graphicRef66886 \" href=\"UTD.htm?20/32/20996\">",
"     picture 1D",
"    </a>",
"    ). Patients may experience pain, bleeding, or pruritus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42328?source=see_link&amp;anchor=H282022525#H282022525\">",
"     \"Carcinoma of the penis: Clinical presentation and diagnosis\", section on 'Premalignant lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574689\">",
"    <span class=\"h3\">",
"     Invasive SCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical appearance of invasive SCC often correlates with the level of tumor differentiation. Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules (",
"    <a class=\"graphic graphic_picture graphicRef60026 graphicRef74240 graphicRef52178 graphicRef64981 \" href=\"UTD.htm?38/49/39706\">",
"     picture 1A, 1E-G",
"    </a>",
"    ). Lesions are usually 0.5 to 1.5 cm in diameter, although some are much larger. Ulceration may or may not be present.",
"   </p>",
"   <p>",
"    In contrast, poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions (",
"    <a class=\"graphic graphic_picture graphicRef75816 \" href=\"UTD.htm?32/41/33428\">",
"     picture 3",
"    </a>",
"    ). Poorly-differentiated tumors may have ulceration, hemorrhage, or areas of necrosis.",
"   </p>",
"   <p>",
"    Lesions of invasive SCC are often asymptomatic, but may be painful or pruritic. Local neurologic symptoms (eg, numbness, stinging, burning, paresthesias, paralysis, or visual changes) occur in approximately one-third of patients with histologic perineural invasion by the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/10\">",
"     10",
"    </a>",
"    ]. Perineural invasion is a poor prognostic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H575011\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574759\">",
"    <span class=\"h3\">",
"     Other variants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574767\">",
"    <span class=\"h4\">",
"     Oral SCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral SCC usually presents as an ulcer, nodule, or indurated plaque involving the oral cavity (",
"    <a class=\"graphic graphic_picture graphicRef81810 graphicRef74239 \" href=\"UTD.htm?39/57/40854\">",
"     picture 1C, 1H",
"    </a>",
"    ). The floor of the mouth and lateral or ventral tongue are the most common sites for these tumors. Lesions may arise in sites of erythroplakia (premalignant persistent red patches in the oral cavity) or leukoplakia (oral persistent white plaques) (",
"    <a class=\"graphic graphic_picture graphicRef60939 \" href=\"UTD.htm?35/48/36608\">",
"     picture 4",
"    </a>",
"    ). Oral SCC is often associated with a history of tobacco or heavy alcohol use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25786?source=see_link&amp;anchor=H3#H3\">",
"     \"Oral lesions\", section on 'Squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574777\">",
"    <span class=\"h4\">",
"     Keratoacanthoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratoacanthomas are keratocytic epithelial tumors that clinically and histologically resemble SCC. It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Keratoacanthomas are usually found on actinically-damaged skin. Lesions typically exhibit rapid initial growth, manifesting as dome-shaped or crateriform nodules with a central keratotic core that develop within a few weeks (",
"    <a class=\"graphic graphic_picture graphicRef55042 \" href=\"UTD.htm?34/33/35347\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574785\">",
"    <span class=\"h4\">",
"     Verrucous carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Verrucous carcinoma is a subtype of SCC that presents with well defined, exophytic, cauliflower-like growths that resemble large warts. Lesions are subclassified according to site:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Oral florid papillomatosis &ndash;",
"      </strong>",
"      verrucous carcinoma of the oral mucosa (",
"      <a class=\"graphic graphic_picture graphicRef57350 graphicRef55834 \" href=\"UTD.htm?24/24/24967\">",
"       picture 6A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Anogenital",
"      </strong>",
"      (also known as giant condyloma acuminatum of Buschke-Loewenstein)",
"      <strong>",
"       &ndash;",
"      </strong>",
"      verrucous carcinoma involving the penis, scrotum, or perianal region (",
"      <a class=\"graphic graphic_picture graphicRef55098 \" href=\"UTD.htm?5/28/5572\">",
"       picture 7",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42328?source=see_link&amp;anchor=H282022453#H282022453\">",
"       \"Carcinoma of the penis: Clinical presentation and diagnosis\", section on 'Pathologic features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Epithelioma cuniculatum &ndash;",
"      </strong>",
"      verrucous carcinoma on the plantar foot",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Verrucous carcinoma may also occur in other locations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574823\">",
"    <span class=\"h4\">",
"     SCC of the lip",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCC of the lip primarily occurs on the lower lip. Lesions may present as nodules, ulcers, or indurated white plaques (",
"    <a class=\"graphic graphic_picture graphicRef59057 \" href=\"UTD.htm?35/59/36786\">",
"     picture 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25786?source=see_link&amp;anchor=H3#H3\">",
"     \"Oral lesions\", section on 'Squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H575100\">",
"    <span class=\"h3\">",
"     Wounds and scars",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sites of chronic inflammation, chronic wounds, or scars are susceptible to the development of SCC. SCC in these settings may initially present as ulcerations that fail to heal; nodules may develop as lesions progress.",
"   </p>",
"   <p>",
"    The possibility of SCC should be considered whenever chronic wounds fail to heal with appropriate therapy. The term Marjolin&rsquo;s ulcer has been used to refer to tumors arising in sites of ulcers or scars. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Chronic inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574816\">",
"    <span class=\"h3\">",
"     Cutaneous metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes; other potential sites for metastasis include the lungs, liver, brain, skin, or bone. Metastases to the skin can present with erythematous papules or nodules that resemble primary lesions of cutaneous SCC (",
"    <a class=\"graphic graphic_picture graphicRef60608 \" href=\"UTD.htm?25/23/25970\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574869\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical findings may strongly suggest a diagnosis of SCC, histopathologic examination is necessary to confirm the diagnosis. Histopathologic examination is also useful for assessment for perineural invasion, tumor differentiation, and tumor depth, factors that are important for tumor staging and prognosis. (See",
"    <a class=\"local\" href=\"#H575011\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574903\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shave, punch, or excisional biopsies may be used for diagnosis. Regardless of the biopsy technique selected, for lesions that are papular, nodular, or otherwise suspicious for invasive SCC, biopsies that extend at least into the mid-reticular dermis are preferred to allow for adequate evaluation of invasive disease. More superficial biopsies may be performed in patients with lesions that are suggestive of in situ SCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link\">",
"     \"Skin biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574910\">",
"    <span class=\"h3\">",
"     SCC in situ",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCC in situ (Bowen&rsquo;s disease) is diagnosed when histopathologic examination reveals keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis. The keratinocytes are pleomorphic with hyperchromatic nuclei and numerous mitoses are present. Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial thickness epidermal dysplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H574917\">",
"    <span class=\"h3\">",
"     Invasive SCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive SCCs have dysplastic keratinocytes involving the full thickness of the epidermis that penetrate the epidermal basement membrane to involve the dermis or deeper tissues. Well-differentiated cutaneous SCCs contain atypical keratinocytes that are slightly enlarged with abundant amounts of cytoplasm. Keratinization is usually present.",
"   </p>",
"   <p>",
"    In poorly differentiated SCC, keratinocytes are anaplastic with little evidence for differentiation or keratinization. Multiple mitoses are often seen. Occasionally, the keratinocytic origin of the cells can only be determined by immunohistochemical stains. &nbsp;",
"   </p>",
"   <p>",
"    Several histopathologic variants of invasive SCC exist including spindle cell SCC, acantholytic (adenoid) SCC, clear cell SCC, adenosquamous (mucin-producing) SCC, desmoplastic SCC, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H575170\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other skin disorders can resemble cutaneous SCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343590\">",
"    <span class=\"h2\">",
"     Actinic keratoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical diagnostic dilemma involves actinic keratoses. Actinic keratoses are rough, scaly, erythematous macules that develop on sun-damaged skin and demonstrate keratinocytic atypia on histopathologic examination (",
"    <a class=\"graphic graphic_picture graphicRef50949 graphicRef53177 \" href=\"UTD.htm?11/29/11737\">",
"     picture 10A-B",
"    </a>",
"    ). Although only a fraction of 1 percent of actinic keratoses progress to SCC, approximately 60 percent of SCCs arise from actinic keratoses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=see_link&amp;anchor=H422059#H422059\">",
"     \"Epidemiology, natural history, and diagnosis of actinic keratosis\", section on 'Progression to skin cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of actinic keratosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Actinic keratoses are often found in close proximity to SCCs, and can resemble SCC in situ or early SCC. Tenderness, bleeding, and palpable underlying substance suggest the possibility of SCC, and indicate the need for biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343597\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The well-demarcated, scaling, pink plaques of SCC in situ can resemble inflammatory skin disorders or other malignancies. The differential diagnosis often includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nummular eczema (",
"      <a class=\"graphic graphic_picture graphicRef58067 graphicRef66792 \" href=\"UTD.htm?33/55/34679\">",
"       picture 11A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Psoriasis (",
"      <a class=\"graphic graphic_picture graphicRef54581 \" href=\"UTD.htm?32/28/33219\">",
"       picture 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inflamed seborrheic keratosis (",
"      <a class=\"graphic graphic_picture graphicRef52360 \" href=\"UTD.htm?23/17/23827\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Viral warts",
"     </li>",
"     <li>",
"      Superficial basal cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef57990 \" href=\"UTD.htm?16/50/17188\">",
"       picture 14",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Amelanotic melanoma (",
"      <a class=\"graphic graphic_picture graphicRef51998 \" href=\"UTD.htm?41/38/42595\">",
"       picture 15",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Paget&rsquo;s disease (",
"      <a class=\"graphic graphic_picture graphicRef61775 \" href=\"UTD.htm?19/58/20391\">",
"       picture 16",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Well-defined papules or nodules of well-differentiated SCC can resemble:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Viral warts (",
"      <a class=\"graphic graphic_picture graphicRef58825 graphicRef70615 \" href=\"UTD.htm?12/42/12967\">",
"       picture 17A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prurigo nodules (",
"      <a class=\"graphic graphic_picture graphicRef53475 graphicRef66268 \" href=\"UTD.htm?20/48/21255\">",
"       picture 18A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Merkel cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef50573 graphicRef70535 \" href=\"UTD.htm?39/12/40135\">",
"       picture 19A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Basal cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef65704 \" href=\"UTD.htm?16/56/17283\">",
"       picture 20",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atypical fibroxanthoma (",
"      <a class=\"graphic graphic_picture graphicRef62531 \" href=\"UTD.htm?42/39/43635\">",
"       picture 21",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Amelanotic melanoma (",
"      <a class=\"graphic graphic_picture graphicRef62791 \" href=\"UTD.htm?23/57/24464\">",
"       picture 22",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cutaneous metastases of internal malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Granulomatous or verrucous lesions may mimic:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pyogenic granuloma (",
"      <a class=\"graphic graphic_picture graphicRef67395 graphicRef52128 \" href=\"UTD.htm?4/40/4742\">",
"       picture 23A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mycobacterial or deep fungal infections (",
"      <a class=\"graphic graphic_picture graphicRef71630 \" href=\"UTD.htm?31/4/31810\">",
"       picture 24",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis for SCC manifesting as nonhealing ulcers includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basal cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef68274 \" href=\"UTD.htm?42/13/43217\">",
"       picture 25",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyoderma gangrenosum (",
"      <a class=\"graphic graphic_picture graphicRef52291 graphicRef72260 \" href=\"UTD.htm?31/17/32024\">",
"       picture 26A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Venous stasis ulcers",
"     </li>",
"     <li>",
"      Traumatic ulcers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H575011\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of diagnosis, patients with SCC should be given a full-body skin examination that includes palpation of regional lymph nodes to evaluate for additional cutaneous SCCs and clinical signs of metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link&amp;anchor=H19785703#H19785703\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\", section on 'Squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The seventh edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual reflects changes to the staging of cutaneous SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7351/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. The updated TNM staging system is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef78140 \" href=\"UTD.htm?5/0/5134\">",
"     table 1",
"    </a>",
"    ). In addition to tumor size and lymph node status, other factors that affect prognosis, including lesion thickness, location, and level of histopathologic differentiation are included in the staging criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H575177\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squamous cell carcinoma (SCC) is a common cutaneous malignancy that can occur on any surface of the skin. Sun-exposed sites are the most common locations for SCC in fair-skinned individuals; involvement of other areas is more common in people with dark skin. (See",
"      <a class=\"local\" href=\"#H574142\">",
"       'Location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical findings of cutaneous SCC depend on the type of lesion and location of involvement. SCC frequently manifests as erythematous papules, plaques, or nodules. Hyperkeratosis, ulceration, or hyperpigmentation also may be present. (See",
"      <a class=\"local\" href=\"#H574559\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCC can develop in sites of chronic wounds, chronic inflammation, or scarring. Nonhealing ulcers or nodules in these sites can be a manifestation of SCC. (See",
"      <a class=\"local\" href=\"#H575100\">",
"       'Wounds and scars'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy is necessary to confirm the diagnosis of SCC. For lesions clinically suspected to be invasive, a shave, punch, or excisional biopsy that extends at least into the mid-reticular dermis is preferred. (See",
"      <a class=\"local\" href=\"#H574903\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Actinic keratoses can resemble lesions of SCC. Lesions that are tender, painful, or that have underlying substance should be biopsied to evaluate for SCC. (See",
"      <a class=\"local\" href=\"#H575170\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/1\">",
"      English DR, Armstrong BK, Kricker A, et al. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer 1998; 76:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/2\">",
"      Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006; 55:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/3\">",
"      Asuquo ME, Ngim O, Ugare G, et al. Major dermatologic malignancies encountered in a teaching hospital surgical department in South Nigeria. Am J Clin Dermatol 2008; 9:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/4\">",
"      Mora RG, Perniciaro C. Cancer of the skin in blacks. I. A review of 163 black patients with cutaneous squamous cell carcinoma. J Am Acad Dermatol 1981; 5:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/5\">",
"      Eliezri YD, Silverstein SJ, Nuovo GJ. Occurrence of human papillomavirus type 16 DNA in cutaneous squamous and basal cell neoplasms. J Am Acad Dermatol 1990; 23:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/6\">",
"      Stern RS, Bagheri S, Nichols K, PUVA Follow Up Study. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002; 47:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/7\">",
"      Veness MJ. Defining patients with high-risk cutaneous squamous cell carcinoma. Australas J Dermatol 2006; 47:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/8\">",
"      Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg 2007; 33:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/9\">",
"      Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/10\">",
"      Reule RB, Golda NJ, Wheeland RG. Treatment of cutaneous squamous cell carcinoma with perineural invasion using Mohs micrographic surgery: report of two cases and review of the literature. Dermatol Surg 2009; 35:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/11\">",
"      Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 2011; 64:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/12\">",
"      Yanofsky VR, Mercer SE, Phelps RG. Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer 2011; 2011:210813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/13\">",
"      Petter G, Haustein UF. Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma. Dermatol Surg 2000; 26:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/14\">",
"      Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/15\">",
"      Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/16\">",
"      Jeffes EW 3rd, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol 2000; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7351/abstract/17\">",
"      Buethe D, Warner C, Miedler J, Cockerell CJ. Focus Issue on Squamous Cell Carcinoma: Practical Concerns Regarding the 7th Edition AJCC Staging Guidelines. J Skin Cancer 2011; 2011:156391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16225 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-78.134.254.52-5CE980D4F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7351=[""].join("\n");
var outline_f7_11_7351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H575177\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21299818\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21299826\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H574142\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H574559\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H574597\">",
"      - SCC in situ (Bowen's disease)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H574649\">",
"      Erythroplasia of Queyrat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H574689\">",
"      - Invasive SCC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H574759\">",
"      - Other variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H574767\">",
"      Oral SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H574777\">",
"      Keratoacanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H574785\">",
"      Verrucous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H574823\">",
"      SCC of the lip",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H575100\">",
"      - Wounds and scars",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H574816\">",
"      - Cutaneous metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H574869\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H574903\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H574910\">",
"      - SCC in situ",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H574917\">",
"      - Invasive SCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H575170\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343590\">",
"      Actinic keratoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343597\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H575011\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H575177\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16225|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/63/25587\" title=\"picture 1A\">",
"      Cutaneous squamous cell carcinoma - cutaneous horn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/4/31811\" title=\"picture 1B\">",
"      Periungual squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/47/44784\" title=\"picture 1C\">",
"      Squamous cell carcinoma - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/32/20996\" title=\"picture 1D\">",
"      Erythroplasia of Queyrat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/37/41553\" title=\"picture 1E\">",
"      Cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/48/20227\" title=\"picture 1F\">",
"      Cutaneous squamous cell carcinoma - leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/26/40358\" title=\"picture 1G\">",
"      Cutaneous squamous cell carcinoma - dorsal hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/38/8802\" title=\"picture 1H\">",
"      Squamous cell carcinoma - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/34/39464\" title=\"picture 2\">",
"      Squamous cell carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/41/33428\" title=\"picture 3\">",
"      Cutaneous squamous cell carcinoma - poorly differentiated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/48/36608\" title=\"picture 4\">",
"      Leukoplakia - palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35347\" title=\"picture 5\">",
"      Keratoacanthoma - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/25/19856\" title=\"picture 6A\">",
"      Verrucous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/63/7156\" title=\"picture 6B\">",
"      Verrucous carcinoma - oral florid papillomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/28/5572\" title=\"picture 7\">",
"      Verrucous carcinoma aka Giant condyloma of Buschke-Lowenstein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/59/36786\" title=\"picture 8\">",
"      Squamous cell carcinoma - lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/23/25970\" title=\"picture 9\">",
"      Skin metastasis of squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/27/23988\" title=\"picture 10A\">",
"      Actinic keratosis - dorsal hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/19/26932\" title=\"picture 10B\">",
"      Actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/8/11394\" title=\"picture 11A\">",
"      Nummular eczema legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/46/38626\" title=\"picture 11B\">",
"      Nummular eczema legs 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/28/33219\" title=\"picture 12\">",
"      Psoriasis plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/17/23827\" title=\"picture 13\">",
"      Seborrheic keratosis inflamed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/50/17188\" title=\"picture 14\">",
"      Superficial basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/38/42595\" title=\"picture 15\">",
"      Amelanotic melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/58/20391\" title=\"picture 16\">",
"      Pagets vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/22/8546\" title=\"picture 17A\">",
"      Verruca vulgaris - finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/28/34241\" title=\"picture 17B\">",
"      Verruca vulgaris - hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/32/5633\" title=\"picture 18A\">",
"      Prurigo nodularis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/51/12083\" title=\"picture 18B\">",
"      Prurigo nodularis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/41/8852\" title=\"picture 19A\">",
"      Merkel cell carcinoma - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/61/2001\" title=\"picture 19B\">",
"      Merkel cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/56/17283\" title=\"picture 20\">",
"      Nodular basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/39/43635\" title=\"picture 21\">",
"      Atypical fibroxanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/57/24464\" title=\"picture 22\">",
"      Amelanotic melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/19/23859\" title=\"picture 23A\">",
"      Pyogenic granuloma - chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/2/38958\" title=\"picture 23B\">",
"      Pyogenic granuloma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/4/31810\" title=\"picture 24\">",
"      Verrucous lesion in blasto",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/13/43217\" title=\"picture 25\">",
"      Large basal cell carcinoma on nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/57/2964\" title=\"picture 26A\">",
"      Pyoderma gangrenosum - close view of ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/11/17587\" title=\"picture 26B\">",
"      Pyoderma gangrenosum - ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16225|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/0/5134\" title=\"table 1\">",
"      TNM stage cutaneous SCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42328?source=related_link\">",
"      Carcinoma of the penis: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=related_link\">",
"      Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=related_link\">",
"      Keratoacanthoma: Epidemiology, risk factors, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25786?source=related_link\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_11_7352="Gardner syndrome";
var content_f7_11_7352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gardner syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7352/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7352/contributors\">",
"     Randall W Burt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7352/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7352/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/11/7352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gardner, in the early 1950s, described a kindred with intestinal characteristics of familial adenomatous polyposis (FAP), but also with a number of extracolonic growths, including osteomas, epidermal cysts and fibromas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/1\">",
"     1",
"    </a>",
"    ]. Dental abnormalities, desmoid tumors and other lesions were later recognized as additional manifestations of the underlying genetic defect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The constellation of inherited colonic adenomatosis together with these extracolonic lesions has become known as Gardner syndrome (GS).",
"   </p>",
"   <p>",
"    This topic review will discuss each of the extraintestinal manifestations of FAP that historically have defined GS. Gastric, duodenal, and colonic polyp and cancer issues are discussed in a separate section on FAP. Genetic testing is now also available for FAP and GS since both arise from mutations of the same gene. Issues related to genetic testing are also presented in the section on FAP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shortly after discovery of the adenomatous polyposis coli (APC) gene, the gene responsible for familial adenomatous polyposis (FAP), it became apparent that both FAP and Gardner syndrome (GS) arose from APC mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. FAP is characterized by hundreds to thousands of colonic adenomatous polyps that most often emerge in the second and third decades of life. Colon cancer is inevitable if the colon is not removed. Polyposis is also usually observed in the stomach, duodenum, and small bowel, although the cancer risk in these locations is far less than in the colon. Inheritance is autosomal dominant with near complete penetrance of the gastrointestinal phenotype but with variable penetrance of the extraintestinal manifestations of the disease.",
"   </p>",
"   <p>",
"    GS cannot be separated from FAP when considering studies that describe its overall prevalence. Estimates for the combined syndromes vary from 1 in 6850 to 1 in 31,250 people (2.29 to 3.2 cases per 100,000 persons) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Prevalence appears fairly constant throughout the world with men and women affected equally. Twenty to 30 percent of newly diagnosed cases, ie, those not belonging to previously identified families, appear to represent new mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/4\">",
"     4",
"    </a>",
"    ]. New cases may also arise from mosaic inheritance, which implies that a mutation occurred in parent's sperm or egg cells, but not in other cells of the body, so the parent did not have clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was once believed that GS patients exhibited fewer and more distinct colonic polyps. However, continued study has demonstrated that the gastrointestinal polyp and cancer phenotypes, although variable, are identical for both GS and FAP. Colonic polyp number depends to some degree on where the mutation occurs in the APC gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/8\">",
"     8",
"    </a>",
"    ]. Mutations in the center of the gene (often called the mutation cluster region) give rise to dense polyposis, with 5000 or more colonic polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/9\">",
"     9",
"    </a>",
"    ] when the disease is fully developed. If mutations occur proximal or distal to this central gene location, colonic polyps average approximately 1000 with full expression. Mutations in the extreme proximal or distal locations of the APC gene, or in certain areas of exon none, are associated with many fewer polyps (often less than 100). This clinical variation is referred to as attenuated FAP. Extraintestinal growths do not correlate with polyp density but have some correlation with mutation location [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common extraintestinal manifestations associated with GS have been described in approximately 20 percent of patients with FAP. However, many more patients with FAP have these features if they undergo detailed physical and radiologic examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the difference between FAP and GS is somewhat semantic and GS is usually considered a subset of FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2\">",
"     2",
"    </a>",
"    ]. On the other hand, the term GS continues to be commonly applied, particularly in families that exhibit frequent and obvious extraintestinal lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BENIGN EXTRAINTESTINAL LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gardner syndrome (GS) is associated with several benign extraintestinal growths including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Osteomas and dental abnormalities",
"     </li>",
"     <li>",
"      Cutaneous lesions",
"     </li>",
"     <li>",
"      Desmoid tumors",
"     </li>",
"     <li>",
"      Congenital hypertrophy of the retinal pigment epithelium",
"     </li>",
"     <li>",
"      Adrenal adenomas",
"     </li>",
"     <li>",
"      Nasal angiofibromas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Osteomas and dental abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomas, the first described extracolonic lesions of GS, are found in about 20 percent of families with familial adenomatous polyposis (FAP). They are benign bone growths found most commonly on the skull and mandible but may occur on any bone of the body [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/1,4,11,12\">",
"     1,4,11,12",
"    </a>",
"    ]. The size ranges from less than a millimeter to several centimeters in diameter, and they number from one to dozens. These lesions may occur in children before colonic polyposis is present, and may continue to appear and grow throughout life. They have no malignant potential but may occasionally be of cosmetic concern.",
"   </p>",
"   <p>",
"    Dental abnormalities of GS include unerupted teeth, supernumerary teeth, dentigerous cysts, and odontomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ]. Osteomas and dental abnormalities may precede the development of colonic polyposis. The prevalence of clinically apparent lesions is estimated at 17 percent in FAP compared to 1 to 2 percent in the general population. Radiopaque jaw lesions not apparent on physical examination are evident by panoramic dental radiographs in up to 90 percent of FAP patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/15\">",
"     15",
"    </a>",
"    ]. Surgical or orthodontic management is needed when lesions are associated with cosmetic or dental problems. There is some correlation of bone, cutaneous and desmoid tumor occurrence with location of mutation in the distal or 3' portion of the APC gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Desmoid tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cutaneous lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermal cysts, fibromas, lipomas, and pilomatricomas can all occur in GS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2,3,17-19\">",
"     2,3,17-19",
"    </a>",
"    ]. All of the cutaneous lesions can cause cosmetic problems.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidermal cysts occasionally become infected necessitating operative removal. Cysts are most common on the legs, face, scalp, and arms, in that order, but they may be found anywhere on the surface of the body [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/17\">",
"       17",
"      </a>",
"      ]. Their size ranges from millimeters to several centimeters. While they are also common in the general population, in GS they often appear before puberty and precede the onset of polyposis.",
"     </li>",
"     <li>",
"      Fibromas range in size from millimeters to centimeters and occur on the cutaneous surfaces of the scalp, shoulders, arms, and back. Fibromas appear to be the cutaneous equivalent of desmoid tumors.",
"     </li>",
"     <li>",
"      Lipomas are so common in the general population that they are not a helpful diagnostic feature of GS, and there is even some question as to whether there is actually an increased incidence of these lesions in GS compared to the general population.",
"     </li>",
"     <li>",
"      Pilomatricomas are rare but when present may be millimeters to centimeters in size and are often multiple.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the cutaneous lesions progress to malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Desmoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors (also referred to as desmoid fibromatosis) may represent a somewhat different disease in GS than in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=see_link\">",
"     \"Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone\"",
"    </a>",
"    .) They are rare in the general population (5 to 6 per million per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/20\">",
"     20",
"    </a>",
"    ] but in FAP affect from 5 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The peak incidence of desmoid occurrence in GS is between 28 and 31 years, although they may occur at any age. Independent predictors of their occurrence include APC gene mutations 3' of codon 1444 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/8,24\">",
"     8,24",
"    </a>",
"    ], a family history of desmoids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], female gender, and the presence of osteomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/25\">",
"     25",
"    </a>",
"    ]. Surgery (including colectomy) also appears to be an independent risk factor for desmoid disease in FAP, particularly with mutations in certain regions of the APC gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/23,26,27\">",
"     23,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When extraintestinal lesions are present in any member of an FAP family, the family has traditionally been said to have GS, since all members of the family segregate the same APC mutation. Desmoids may be the first manifestation of GS. Families have also been reported that exhibit desmoids as the only manifestation of an APC mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Desmoid tumors can arise in all musculoaponeurotic structures throughout the body but are most common in the abdomen where they begin as mesenteric plaque like lesions that may progress to mesenteric fibromatosis and finally to desmoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/30\">",
"     30",
"    </a>",
"    ]. About one-half of abdominal desmoids occur intra-abdominally while the other one-half are found in tissues of the abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/22\">",
"     22",
"    </a>",
"    ]. Approximately one-third of abdominal desmoids cause pain. In a series of 38 patients, the most common presenting feature was small bowel obstruction (58 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Desmoid tumors are considered to be benign because they do not metastasize. The tumors may enlarge gradually or stop growing. Surgery appears to stimulate their growth; an increased frequency of the lesions is observed following abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Pregnancy may slow desmoid growth in some of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although benign, desmoid behavior can cause substantial morbidity and mortality. They may infiltrate adjacent structures, extend along fascial planes, attach to and erode bones, and engulf and compress blood vessels, nerves, ureters, small bowel, and other hollow organs of the abdomen. Severe and sometimes fatal problems can arise especially if the mesenteric vessels or other hollow abdominal organs become obstructed. Intra-abdominal desmoids may grow to massive sizes, sometimes occupying much of the abdominal cavity and encasing viscera (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54879 \" href=\"UTD.htm?1/23/1392\">",
"     image 1",
"    </a>",
"    ). Desmoid tumors are a common cause of mortality after colectomy. Mortality is as high as 10 to 50 percent in patients who have a desmoid tumor. However, progression is often gradual and survival 10 years after the diagnosis is approximately 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/22,30,32\">",
"     22,30,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GS associated desmoids are histologically indistinguishable from sporadic desmoids, although there may be some differences between fibroblastic growths in GS and sporadic desmoids. A distinctive fibroblastic growth, called Gardner associated fibroma, may be seen in young patients and appears to be the precursor lesion of desmoids in GS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/35\">",
"     35",
"    </a>",
"    ]. Desmoid tumors in GS are monoclonal growths, implying that they are true neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/36\">",
"     36",
"    </a>",
"    ]. Desmoids in FAP also arise from APC inactivation and subsequent accumulation of beta-catenin in cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, APC mutations are uncommon in sporadic desmoids, which usually arise from beta-catenin mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific location of mutations within the APC gene correlates with the occurrence of desmoid tumors, although desmoids can occur with mutations in any APC gene location [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/8\">",
"     8",
"    </a>",
"    ]. Desmoid tumors occur more frequently when mutations were in the 3' end of the APC gene, specifically distal to codon 1444 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. As a general rule, desmoid tumors are more common with APC mutations between codons 1444 to 1578 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/40\">",
"     40",
"    </a>",
"    ]. Mutations between codons 1310 and 2011 are associated with a six-fold risk of desmoid tumors relative to the low-risk reference region (159 to 495) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the specific phenotype varies with mutations within these regions as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 269 patients found that tumors were present in 20 percent of patients with mutations 5' to codon 1444 compared with 49 percent of patients with mutations 3' to that codon [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/41\">",
"       41",
"      </a>",
"      ]. In addition, desmoid tumors were present in 61 percent of patients with mutations between codons 1445 and 1580 compared with 18 percent of patients with mutations at sites 3' to that region.",
"     </li>",
"     <li>",
"      Another study demonstrated that patients with APC mutations between codons 1395 to 1493 had higher rates of desmoids, osteomas and epidermal cysts compared to patients with mutations between codons 177 to 452 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/42\">",
"       42",
"      </a>",
"      ]. In addition, significantly more desmoids and osteomas were present compared to patients with mutations between codons 457 to 1309. None of 79 persons with mutations between codons 177 to 452 developed osteomas, hepatoblastomas, periampullary tumors or brain cancers, while hepatoblastomas and brain cancers were seen only in patients with mutations between codons 457 to 1309.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The molecular events that lead to desmoid tumor formation in patients with APC mutations are incompletely understood. However, increasing evidence points to involvement of the APC gene and beta-catenin (both components of the Wnt signaling pathway) in the molecular pathogenesis of desmoids both in Gardner syndrome as well as in sporadic desmoids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of desmoid tumors is indicated only when they cause symptoms, there is imminent risk to adjacent structures, or they create cosmetic concerns. Surgery is generally performed initially for extra-abdominal desmoids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/39\">",
"     39",
"    </a>",
"    ]. By contrast, a more conservative approach is usually recommended for intra-abdominal and abdominal wall desmoids (such as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    or increasing doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ). Tyrosine kinase inhibitors have also been suggested as possible treatment agents in combination with nonsteroidal anti-inflammatory medicines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/43\">",
"     43",
"    </a>",
"    ]. In patients who do not respond or who lose response, options include chemotherapy (similar to that used for sarcomas), radiation therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery. When combination chemotherapies are used, those including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    have been associated with the most favorable outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/44\">",
"     44",
"    </a>",
"    ]. The choice and order among these should be guided by a multidisciplinary team, all of whom should have experience with this difficult tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/39,44-46\">",
"     39,44-46",
"    </a>",
"    ]. It is recommended that patients with desmoid tumors be referred to specialty centers in view of the difficulty in treatment and the multispecialty approach needed for optimal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Congenital hypertrophy of the retinal pigment epithelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple and bilateral patches of congenital hypertrophy of the retinal pigment epithelium (CHRPE), also called pigmented ocular fundus lesions, are a common manifestation of GS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/48\">",
"     48",
"    </a>",
"    ]. The lesions are discrete, darkly pigmented, round, oval, or kidney shaped, ranging in size from 0.1 to 1.0 times the diameter of the disc. The presence of bilateral or multiple (more than four) lesions is specific (94 to 100 percent) but only moderately sensitive (58 to 84 percent) for GS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/49\">",
"     49",
"    </a>",
"    ]. These lesions may exhibit an association with disorder of the cilia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CHRPE lesions appear to be congenital and have been detected in patients as young as three months. Slit-lamp examination is usually required for detection. CHRPE is observed with mutations between codons 311 and 1444, although this varies somewhat depending on the study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2,8,10\">",
"     2,8,10",
"    </a>",
"    ]. CHRPE is not known to cause clinical problems, although one case of malignant transformation was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adrenal adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal adenomas have been reported in 7 to 13 percent of patients with GS (compared with approximately 3 percent in the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/52\">",
"     52",
"    </a>",
"    ]. Most adrenal masses in GS are found incidentally (as they are in the general population) and should be managed using similar principles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .) Adrenal adenomas in FAP harbor a somatic as well as germline APC mutation, indicating these tumors arise as part of FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/55\">",
"     55",
"    </a>",
"    ]. Malignancy of the adrenal is rare in FAP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nasal angiofibromas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal angiofibromas have been described in some patients with GS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/56\">",
"     56",
"    </a>",
"    ] and mutational studies indicate they are part of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXTRACOLONIC MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Gardner syndrome (GS) are at increased risk for several extra-colonic malignancies. The following malignancies (and proportions of affected patients with GS) have been described in various studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duodenal and periampullary (3 to 5 percent)",
"     </li>",
"     <li>",
"      Thyroid (2 percent)",
"     </li>",
"     <li>",
"      Pancreatic (2 percent)",
"     </li>",
"     <li>",
"      Gastric (0.6 percent)",
"     </li>",
"     <li>",
"      Central nervous system (&lt;1 percent)",
"     </li>",
"     <li>",
"      Hepatoblastoma (1.6 percent)",
"     </li>",
"     <li>",
"      Small bowel distal to the duodenum",
"     </li>",
"     <li>",
"      Possibly adrenal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Thyroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid cancers occur in two percent of persons with familial adenomatous polyposis (FAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/58\">",
"     58",
"    </a>",
"    ]. The risk is increased approximately eight-fold compared with the general population (RR 7.6, 95% CI 2.5 to 17.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/59\">",
"     59",
"    </a>",
"    ]. The mean age of diagnosis is 33 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/58\">",
"     58",
"    </a>",
"    ]. There is a greater risk in families where one member has the malignancy. The histology is predominantly papillary, commonly with a cribiform pattern. Thyroid cancer is associated with APC mutations in the 5' end of exon 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/60\">",
"     60",
"    </a>",
"    ]. The thyroid in",
"    <span class=\"nowrap\">",
"     FAP/GS",
"    </span>",
"    patients is frequently nodular; as a result, ultrasound screening, in addition to palpation, should be used for thyroid surveillance in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pancreatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of pancreatic adenocarcinoma in GS has been estimated to be increased more than fourfold compared with the general population (RR 4.46, 95% CI 1.2 to 11.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, duct obstruction has been described from benign and malignant tumors, sometimes giving rise to pancreatic cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatoblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatoblastoma occurs in 0.75 to 1.6 percent of children with FAP. The risk of hepatoblastoma in children with FAP is 800-fold greater than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/62\">",
"     62",
"    </a>",
"    ]. It occurs more commonly in boys and has some association with APC mutations in the 5' end of the gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/2\">",
"     2",
"    </a>",
"    ]. This cancer usually occurs in the first five years of life but some risk remains up to 15 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neoplasms of the gallbladder and bile ducts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomatous change and cancer have been described in the gallbladder and bile ducts both of which may lead to biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Neoplasms in these locations are unusual and their precise frequency is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SCREENING FOR EXTRAINTESTINAL MALIGNANCIES AND DESMOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus has not been achieved on optimal strategies for screening patients with Gardner syndrome (GS) for extraintestinal malignancies and desmoids. However, general screening recommendations for extracolonic malignancies have been suggested for patients with familial adenomatous polyposis (FAP) and should be applied to those with GS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The thyroid should probably be subject to physical examination and ultrasound annually, starting at age 10 to 12 years.",
"     </li>",
"     <li>",
"      It is generally accepted that other possible extraintestinal cancer sites should be evaluated only if symptoms occur or if these cancers have occurred in relatives. This recommendation is provisional and not accepted by all investigators in this area. &nbsp;",
"     </li>",
"     <li>",
"      Patients should be questioned regularly regarding neurologic symptoms. In addition, a periodic head MRI is recommended if any family member has had CNS malignancy. The appropriate frequency is not known, but intervals of one to three years have been discussed, depending on the family history and presence of any possible related symptoms.",
"     </li>",
"     <li>",
"      Every six month liver palpation, together with liver function tests, abdominal ultrasound exam, and alpha fetoprotein levels, should be performed to screen for hepatoblastoma, especially during the first five years of life. This can be safely discontinued after age 15, and probably after age 10. The risk of occurrence of this tumor in neonates and children provides a rationale for performing genetic testing in the first year of life to determine which persons should have the screening. Although formal recommendations have not been given in this regard, genetic testing may be useful in patients if liver screening is to be considered.",
"     </li>",
"     <li>",
"      Biliary evaluation should be performed only for symptoms or abnormal liver function tests. Upper endoscopy every one to three years, with side viewing capability is indicated for screening the stomach and duodenum (as discussed in the section on FAP). Obvious papillary abnormalities will be observed with this screening. We perform annual liver function tests to screen for biliary tumors, although the sensitivity of this approach is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening is not routinely undertaken for desmoids, but evaluation should be pursued for palpable masses or symptoms. On the other hand, it is reasonable to obtain an abdominal computed tomography (CT) with oral contrast every three years beginning at age 20 to 25 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7352/abstract/65\">",
"     65",
"    </a>",
"    ]. Particular attention should also be given to the biliary tree, gallbladder, pancreas, small bowel and adrenal glands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gardner syndrome refers to the constellation of inherited colonic adenomatosis polyposis (familial adenomatous polyposis, FAP) together with a number of extracolonic lesions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gardner syndrome arises from a mutation in the adenomatous polyposis coli (APC) gene. As in FAP, the number of colonic polyps is related to the locus of the mutation in the APC gene. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several benign extraintestinal growths are associated with Gardner syndrome, including osteomas and dental abnormalities, cutaneous lesions, desmoid tumors, congenital hypertrophy of the retinal pigment epithelium, adrenal adenomas, and nasal angiofibromas. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Benign extraintestinal lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Gardner syndrome are at increased risk for extracolonic malignancies, including neoplasms of the thyroid, pancreas, liver, gallbladder and biliary tract. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Extracolonic malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Gardner syndrome should be screened for extracolonic malignancies, as recommended for patients with familial adenomatous polyposis. Desmoid tumors, including intra-abdominal, abdominal wall, and extra-abdominal, are a common feature of Gardner syndrome, similar to FAP, and may result in significant morbidity and even mortality. Screening for these tumors is usually indicated if signs or symptoms occur and a multidisciplinary approach is indicated in their treatment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Screening for extraintestinal malignancies and desmoids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"       \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/1\">",
"      GARDNER EJ. Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. Am J Hum Genet 1962; 14:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/2\">",
"      Bisgaard ML, B&uuml;low S. Familial adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. Am J Med Genet A 2006; 140:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/3\">",
"      Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101:385.",
"     </a>",
"    </li>",
"    <li>",
"     Bussey HJR. Familial polyposis coli. In: Family Studies, Histopathology, Differential Diagnosis and Results of Treatment, Johns Hopkins University Press, Baltimore 1975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/5\">",
"      J&auml;rvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. Gut 1992; 33:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/6\">",
"      B&uuml;low S, Faurschou Nielsen T, B&uuml;low C, et al. The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register. Int J Colorectal Dis 1996; 11:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/7\">",
"      Aretz S, Stienen D, Friedrichs N, et al. Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum Mutat 2007; 28:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/8\">",
"      Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 2007; 61:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/9\">",
"      J&auml;rvinen HJ, Peltom&auml;ki P. The complex genotype-phenotype relationship in familial adenomatous polyposis. Eur J Gastroenterol Hepatol 2004; 16:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/10\">",
"      Bertario L, Russo A, Sala P, et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/11\">",
"      GARDNER EJ, PLENK HP. Hereditary pattern for multiple osteomas in a family group. Am J Hum Genet 1952; 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/12\">",
"      Bilkay U, Erdem O, Ozek C, et al. Benign osteoma with Gardner syndrome: review of the literature and report of a case. J Craniofac Surg 2004; 15:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/13\">",
"      Kubo K, Miyatani H, Takenoshita Y, et al. Widespread radiopacity of jaw bones in familial adenomatosis coli. J Craniomaxillofac Surg 1989; 17:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/14\">",
"      Wijn MA, Keller JJ, Giardiello FM, Brand HS. Oral and maxillofacial manifestations of familial adenomatous polyposis. Oral Dis 2007; 13:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/15\">",
"      Giardiello FM, Hylind LM, Trimbath JD, et al. Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology 2005; 128:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/16\">",
"      Oku T, Takayama T, Sato Y, et al. A case of Gardner syndrome with a mutation at codon 1556 of APC: a suggested case of genotype-phenotype correlation in dental abnormality. Eur J Gastroenterol Hepatol 2004; 16:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/17\">",
"      Bussey HJ, Veale AM, Morson BC. Genetics of gastrointestinal polyposis. Gastroenterology 1978; 74:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/18\">",
"      GARDNER EJ, RICHARDS RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 1953; 5:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/19\">",
"      Sener SF, Miller HH, DeCosse JJ. The spectrum of polyposis. Surg Gynecol Obstet 1984; 159:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/20\">",
"      Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/21\">",
"      Sturt NJ, Clark SK. Current ideas in desmoid tumours. Fam Cancer 2006; 5:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/22\">",
"      Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 1999; 86:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/23\">",
"      Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A, et al. Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/24\">",
"      Sinha A, Tekkis PP, Gibbons DC, et al. Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 2011; 13:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/25\">",
"      Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001; 95:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/26\">",
"      Durno C, Monga N, Bapat B, et al. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol 2007; 5:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/27\">",
"      Sinha A, Gibbons DC, Phillips RK, Clark S. Surgical prophylaxis in familial adenomatous polyposis: do pre-existing desmoids outside the abdominal cavity matter? Fam Cancer 2010; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/28\">",
"      Scott RJ, Froggatt NJ, Trembath RC, et al. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. Hum Mol Genet 1996; 5:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/29\">",
"      Eccles DM, van der Luijt R, Breukel C, et al. Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the APC gene. Am J Hum Genet 1996; 59:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/30\">",
"      Heiskanen I, J&auml;rvinen HJ. Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis 1996; 11:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/31\">",
"      Soravia C, Berk T, Cohen Z. Genetic testing and surgical decision making in hereditary colorectal cancer. Int J Colorectal Dis 2000; 15:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/32\">",
"      Soravia C, Berk T, McLeod RS, Cohen Z. Desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum 2000; 43:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/33\">",
"      Clark SK, Smith TG, Katz DE, et al. Identification and progression of a desmoid precursor lesion in patients with familial adenomatous polyposis. Br J Surg 1998; 85:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/34\">",
"      Church JM, McGannon E. Prior pregnancy ameliorates the course of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis. Dis Colon Rectum 2000; 43:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/35\">",
"      Coffin CM, Hornick JL, Zhou H, Fletcher CD. Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. Am J Surg Pathol 2007; 31:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/36\">",
"      Middleton SB, Frayling IM, Phillips RK. Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br J Cancer 2000; 82:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/37\">",
"      Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol 1998; 153:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/38\">",
"      Giarola M, Wells D, Mondini P, et al. Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumours. Br J Cancer 1998; 78:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/39\">",
"      Escobar C, Munker R, Thomas JO, et al. Update on desmoid tumors. Ann Oncol 2012; 23:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/40\">",
"      Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995; 4:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/41\">",
"      Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001; 48:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/42\">",
"      Wallis YL, Morton DG, McKeown CM, Macdonald F. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 1999; 36:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/43\">",
"      Signoroni S, Frattini M, Negri T, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res 2007; 13:5034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/44\">",
"      Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG, et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 2011; 104:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/45\">",
"      Bertagnolli MM, Morgan JA, Fletcher CD, et al. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer 2008; 44:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/46\">",
"      Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/47\">",
"      Vasen HF, M&ouml;slein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/48\">",
"      Touri&ntilde;o R, Conde-Freire R, Cabezas-Agr&iacute;cola JM, et al. Value of the congenital hypertrophy of the retinal pigment epithelium in the diagnosis of familial adenomatous polyposis. Int Ophthalmol 2004; 25:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/49\">",
"      Wallis YL, Macdonald F, Hult&eacute;n M, et al. Genotype-phenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis. Hum Genet 1994; 94:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/50\">",
"      G&oacute;mez Garc&iacute;a EB, Knoers NV. Gardner's syndrome (familial adenomatous polyposis): a cilia-related disorder. Lancet Oncol 2009; 10:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/51\">",
"      Shields JA, Eagle RC Jr, Shields CL, et al. Malignant transformation of congenital hypertrophy of the retinal pigment epithelium. Ophthalmology 2009; 116:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/52\">",
"      Smith TG, Clark SK, Katz DE, et al. Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum 2000; 43:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/53\">",
"      Ferr&aacute;ndez A, Pho L, Solomon C, et al. An evidence-based, multidisciplinary approach to the clinical considerations, management, and surveillance of adrenal lesions in familial adenomatous polyposis: report of three cases. Dis Colon Rectum 2006; 49:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/54\">",
"      Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/55\">",
"      Bl&auml;ker H, Sutter C, Kadmon M, et al. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes Cancer 2004; 41:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/56\">",
"      Giardiello FM, Hamilton SR, Krush AJ, et al. Nasopharyngeal angiofibroma in patients with familial adenomatous polyposis. Gastroenterology 1993; 105:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/57\">",
"      Valanzano R, Curia MC, Aceto G, et al. Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumour. Gut 2005; 54:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/58\">",
"      Herraiz M, Barbesino G, Faquin W, et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 2007; 5:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/59\">",
"      Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/60\">",
"      Cetta F, Curia MC, Montalto G, et al. Thyroid carcinoma usually occurs in patients with familial adenomatous polyposis in the absence of biallelic inactivation of the adenomatous polyposis coli gene. J Clin Endocrinol Metab 2001; 86:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/61\">",
"      Pho LN, Coffin CM, Burt RW. Abdominal desmoid in familial adenomatous polyposis presenting as a pancreatic cystic lesion. Fam Cancer 2005; 4:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/62\">",
"      Giardiello FM, Petersen GM, Brensinger JD, et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut 1996; 39:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/63\">",
"      Trimbath JD, Griffin C, Romans K, Giardiello FM. Attenuated familial adenomatous polyposis presenting as ampullary adenocarcinoma. Gut 2003; 52:903.",
"     </a>",
"    </li>",
"    <li>",
"     Spigelman AD, Phillips RKS. The upper gastrointestinal tract. In: Familial Adenomatous Polyposis and Other Syndromes, Phillips RKS, Spigelman AD, Thomason JPS (Eds), Edward Arnold, London 1994. p.106.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7352/abstract/65\">",
"      Healy JC, Reznek RH, Clark SK, et al. MR appearances of desmoid tumors in familial adenomatous polyposis. AJR Am J Roentgenol 1997; 169:465.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2598 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7352=[""].join("\n");
var outline_f7_11_7352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BENIGN EXTRAINTESTINAL LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Osteomas and dental abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Desmoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Congenital hypertrophy of the retinal pigment epithelium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adrenal adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nasal angiofibromas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXTRACOLONIC MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Thyroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pancreatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatoblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neoplasms of the gallbladder and bile ducts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SCREENING FOR EXTRAINTESTINAL MALIGNANCIES AND DESMOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2598\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2598|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/23/1392\" title=\"diagnostic image 1\">",
"      Intraabdominal desmoid tumor in familial polyposis CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=related_link\">",
"      Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_11_7353="Tetanus";
var content_f7_11_7353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tetanus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7353/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7353/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7353/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7353/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/11/7353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus is a nervous system disorder characterized by muscle spasms that is caused by the toxin-producing anaerobe, Clostridium tetani, which is found in the soil. The clinical features of tetanus and its relationship to traumatic injuries were well known among the ancient Greeks and Egyptians and to many clinicians before the introduction of vaccination with tetanus toxoid in the 1940s. The term \"lockjaw\" (now called trismus) lives in modern parlance as a reminder of one of the cardinal features of tetanus: intense painful spasms of the masseter muscles.",
"   </p>",
"   <p>",
"    Tetanus can present in one of four clinical patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Generalized",
"     </li>",
"     <li>",
"      Local",
"     </li>",
"     <li>",
"      Cephalic",
"     </li>",
"     <li>",
"      Neonatal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although tetanus is now rare in the developed world, the disease remains a threat to all unvaccinated people, particularly in developing countries. Since C. tetani spores cannot be eliminated from the environment, immunization and proper treatment of wounds and traumatic injuries are crucial for tetanus prevention. The epidemiology, pathogenesis, clinical features, diagnosis, and management of tetanus will be reviewed here. The principles of prevention of tetanus and management of tetanus-prone wounds are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25158?source=see_link\">",
"     \"Overview of puncture wounds\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Developed countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of almost universal vaccination of children with tetanus toxoid in developed countries, the incidence of tetanus in these regions has dropped dramatically and steadily since 1940. During the period between 2001 and 2008, the US Centers for Disease Control and Prevention (CDC) reported that there were 233 cases of tetanus in the United States, with an annual incidence of 0.10",
"    <span class=\"nowrap\">",
"     cases/million",
"    </span>",
"    population overall, and 0.23",
"    <span class=\"nowrap\">",
"     cases/million",
"    </span>",
"    among individuals &ge;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/1\">",
"     1",
"    </a>",
"    ]. The case-fatality rate was 13.2 percent overall, but was 31.3 percent among individuals &ge;65 years of age.",
"   </p>",
"   <p>",
"    Most patients with tetanus lack a history of receipt of a full series of tetanus toxoid immunization and receive inadequate prophylaxis following a wound. Approximately three-fourths of the patients who acquired tetanus recalled an acute injury prior to the onset of their symptoms, but approximately two-thirds of these individuals did not seek medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/1\">",
"     1",
"    </a>",
"    ]. Among 51 patients who sought care for an acute wound and had a sufficiently thorough surveillance report to allow evaluation, 49 (96 percent) did not receive adequate tetanus toxoid prophylaxis or tetanus toxoid prophylaxis plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     tetanus immune globulin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/1\">",
"     1",
"    </a>",
"    ]. However, occasional patients with pre-existing anti-tetanus antibodies (as measured by guinea pig or mouse protection assays) have developed tetanus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link&amp;anchor=H10#H10\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link&amp;anchor=H11#H11\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike in developing nations, neonatal tetanus is extremely rare in the United States. Only one case of neonatal tetanus was reported between 2001 and 2008; this case occurred in an infant whose mother had not been vaccinated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/3\">",
"     3",
"    </a>",
"    ]. Fifteen percent of patients with tetanus had diabetes mellitus, which is three times the estimated prevalence of diabetes in the United States. Another 15 percent of patients were injection drug users.",
"   </p>",
"   <p>",
"    The annual incidence of tetanus in other developed countries is also low and declining due to vaccination programs. In England and Wales, for example, the annual incidence was 0.2",
"    <span class=\"nowrap\">",
"     cases/million",
"    </span>",
"    population with the highest incidence in patients above the age of 64 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/4\">",
"     4",
"    </a>",
"    ]. Italy reported the highest number of cases among the countries of Europe, but the annual incidence decreased from 0.5 to 0.2 per 100,000 from the 1970s to the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/5\">",
"     5",
"    </a>",
"    ]. The case-fatality ratio decreased from 68 to 39 percent over that same period; women &gt;64 years of age were disproportionately affected.",
"   </p>",
"   <p>",
"    Despite the low rate of clinical disease in developing countries, many adults are inadequately vaccinated against tetanus. In the serologic survey cited above in the United States between 1988 and 1994, fully protective levels of antitetanus antibody were present in 72 percent of individuals &ge;6 years of age and only 31 percent of adults over the age of 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/6\">",
"     6",
"    </a>",
"    ]. Not surprisingly, protective antibody levels are more likely in adults with a history of military service, higher levels of education, and higher incomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Developing countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to developed nations where tetanus is rare, tetanus remains endemic in the developing world, and the incidence often increases following natural disasters such as earthquakes and tsunamis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"     8",
"    </a>",
"    ]. Approximately one million cases of tetanus are estimated to occur worldwide each year, with 300,000 to 500,000 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"     8",
"    </a>",
"    ]. Among patients admitted for neurologic conditions to one hospital in Nigeria, for example, tetanus was the second most common cause (14 percent) after stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonatal tetanus, which the WHO targeted for elimination by 1995, accounted for approximately 59,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/10\">",
"     10",
"    </a>",
"    ]. While this represents a decrease in mortality of 92 percent compared with 1988, as of 2010, 39 countries had still not eliminated maternal and neonatal tetanus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Neonatal tetanus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus occurs when spores of Clostridium tetani, an obligate anaerobe normally present in the gut of mammals and widely found in soil, gains access to damaged human tissue. After inoculation, C. tetani transforms into a vegetative rod-shaped bacterium and produce the metalloprotease, tetanospasmin (also known as tetanus toxin).",
"   </p>",
"   <p>",
"    After reaching the spinal cord and brainstem via retrograde axonal transport [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] and binding tightly and irreversibly to receptors at these sites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/11,13\">",
"     11,13",
"    </a>",
"    ], tetanus toxin blocks neurotransmission by its cleaving action on membrane proteins involved in neuroexocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The net effect is disinhibition of neurons that modulate excitatory impulses from the motor cortex. Disinhibition of anterior horn cells and autonomic neurons results in increased muscle tone, painful spasms, and widespread autonomic instability.",
"   </p>",
"   <p>",
"    Muscular rigidity in tetanus occurs though a complex mechanism that involves an increase in the resting firing rate of disinhibited motor neurons and lack of inhibition of reflex motor responses to afferent sensory stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/11\">",
"     11",
"    </a>",
"    ]. Lack of neural control of adrenal release of catecholamines induced by tetanus toxin produces a hypersympathetic state that manifests as sweating, tachycardia and hypertension. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Generalized tetanus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tetanus toxin-induced effects on anterior horns cells, the brainstem, and autonomic neurons last are long-lasting because recovery requires the growth of new axonal nerve terminals. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Duration of illness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mechanisms of binding to and inhibition of neural cells is related to specific portions of the tetanospasmin (tetanus toxin) molecule. Tetanus toxin is produced initially as an inactive polypeptide chain by actively growing organisms. This synthesis is controlled by genes located in an intracellular plasmid.",
"   </p>",
"   <p>",
"    After death of the clostridial bacterium, the toxin is released and then activated by bacterial or tissue proteases into its active form, which contains a heavy chain necessary for binding and entry into neurons and a light chain responsible for its toxic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/11,13,15,16\">",
"     11,13,15,16",
"    </a>",
"    ]. Heavy chains are further cleaved by pepsins into specific fragments, which individually mediate binding to specific types of neural cells. Presynaptic inhibition of neurotransmitter release is mediated via light chains.",
"   </p>",
"   <p>",
"    Tetanolysin is another toxin produced by C. tetani during its early growth phase. It has hemolytic properties and causes membrane damage in other cells, but its role in clinical tetanus is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because C. tetani will not grow in healthy tissues, a convergence of factors must be present in order for tetanus toxin to be elaborated in the human host. This combination of factors usually includes two or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A penetrating injury resulting in the inoculation of C. tetani spores",
"     </li>",
"     <li>",
"      Coinfection with other bacteria",
"     </li>",
"     <li>",
"      Devitalized tissue",
"     </li>",
"     <li>",
"      A foreign body",
"     </li>",
"     <li>",
"      Localized ischemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above factors explain why tetanus-prone injuries include splinters and other puncture wounds, gunshot wounds, compound fractures, burns, and unsterile intramuscular or subcutaneous injections (that often occur in IDUs). These predisposing factors can also explain why tetanus can develop in unusual clinical settings such as in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neonates (due to infection of the umbilical stump)",
"     </li>",
"     <li>",
"      Obstetric patients (after septic abortions)",
"     </li>",
"     <li>",
"      Postsurgical patients (with necrotic infections involving bowel flora)",
"     </li>",
"     <li>",
"      Patients with dental infections",
"     </li>",
"     <li>",
"      Diabetic patients with infected extremity ulcers",
"     </li>",
"     <li>",
"      Patients who inject illicit",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      contaminated drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tetanus in patients without an identifiable cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;An identifiable antecedent cause for tetanus is obvious in more than 90 percent of patients presenting with tetanus, but no cause can be identified in a small percentage of patients with classic signs and symptoms of tetanus. Presumably, minor unnoticed abrasions or skin injuries are responsible for most or all of these \"cryptogenic\" cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period of tetanus can be as short as one day or as long as several months, with most cases occurring within 8 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/11,17-20\">",
"     11,17-20",
"    </a>",
"    ]. Inoculation of spores in body locations distant from the central nervous system (eg, the hands or feet) results in a longer incubation period than inoculation close to the central nervous system (eg, the head or neck).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Generalized tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common and severe clinical form of tetanus is generalized tetanus. The presenting symptom in more than half of such patients is trismus (lockjaw), although patients with generalized tetanus sometimes present with cephalic or localized tetanus. Patients with generalized tetanus typically have symptoms of autonomic overactivity that may manifest in the early phases as irritability, restlessness, sweating and tachycardia. In later phases of illness, profuse sweating, cardiac arrhythmias, labile hypertension or hypotension, and fever are often present.",
"   </p>",
"   <p>",
"    Patients with generalized tetanus characteristically have tonic contraction of their skeletal muscles and intermittent intense muscular spasms. Since patients with tetanus have no impairment of consciousness or awareness, both the tonic contractions and spasms are intensely painful. Tetanic spasms may be triggered by loud noises or other sensory stimuli such as physical contact or light. Tonic and periodic spastic muscular contractions are responsible for most of the classic clinical findings of tetanus such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stiff neck",
"     </li>",
"     <li>",
"      Opisthotonus",
"     </li>",
"     <li>",
"      Risus sardonicus (sardonic smile)",
"     </li>",
"     <li>",
"      A board-like rigid abdomen",
"     </li>",
"     <li>",
"      Periods of apnea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      upper airway obstruction due to vise-like contraction of the thoracic muscles",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glottal or pharyngeal muscle contraction, respectively",
"     </li>",
"     <li>",
"      Dysphagia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During generalized tetanic spasms, patients characteristically clench their fists, arch their back and flex and abduct their arms while extending their legs, often becoming apneic during these dramatic postures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Local tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, tetanus presents with tonic and spastic muscle contractions in one extremity or body region. Local tetanus often but not invariably evolves into generalized tetanus. Diagnosis in local tetanus can be difficult. For example, rarely patients with early tetanus may develop board-like abdominal rigidity that mimics an acute surgical abdomen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cephalic tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with injuries to the head or neck may present with cephalic tetanus, involving initially only cranial nerves. Like other forms of local tetanus, patients with cephalic tetanus often subsequently develop generalized tetanus. Prior to the appearance of the typical features of generalized tetanus, patients with cephalic tetanus may manifest confusing clinical findings including dysphagia, trismus and focal cranial neuropathies. The facial nerve is most commonly in cephalic tetanus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/21\">",
"     21",
"    </a>",
"    ], but involvement of cranial nerves VI, III, IV, and XII may also occur either alone or in combination with others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neonatal tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal tetanus typically occurs in infants 3 to 21 days following birth (median 8 days), although incubation periods as short as one day or longer than one month have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/16\">",
"     16",
"    </a>",
"    ]. It is manifested by rigidity, spasms, trismus, inability to suck, and seizures. Neonatal tetanus occurs as a result of the failure to use aseptic techniques in managing the umbilical stump in offspring of mothers who are poorly immunized.",
"   </p>",
"   <p>",
"    The application of unconventional substances to the umbilical stump (eg, ghee, or clarified butter, juices, and cow dung) have been implicated as common cultural practices that contribute to neonatal tetanus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/22\">",
"     22",
"    </a>",
"    ]. Neonatal tetanus can also result from unclean hands and instruments or contamination by dirt, straw, or other non-sterile materials in the delivery field.",
"   </p>",
"   <p>",
"    The onset of illness is typically more rapid in neonatal tetanus than in older individuals and may progress over hours rather than days, probably because axonal length is proportionately shorter in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Severity of illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity and frequency of the clinical features of tetanus may vary from case to case, depending upon the amount of tetanus toxin that reaches the CNS. Symptoms and signs may progress for up to two weeks after the disease onset. The severity is related to the incubation period of the illness and the interval from the onset of symptoms to the appearance of spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/11\">",
"     11",
"    </a>",
"    ]; the longer the interval, the milder the clinical features of tetanus. In addition, illness may be milder in patients with preexisting but non-protective levels of anti-tetanus antibodies. In one study of 64 patients with tetanus, serum obtained prior to the institution of treatment contained detectable levels of antibody in 35 percent of patients, and the severity of tetanus in these patients appeared to be inversely related to the level of pretreatment anti-tetanus toxin antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Duration of illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus toxin-induced effects are long-lasting because recovery requires the growth of new axonal nerve terminals. The usual duration of clinical tetanus is four to six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of tetanus is usually obvious and can generally be made based upon typical clinical findings outlined above. Tetanus should especially be suspected when there is a history of an antecedent tetanus prone injury and a history of inadequate immunization for tetanus. However, tetanus can sometimes be confused with the following mimics:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drug-induced dystonias such as those due to phenothiazines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced dystonias often produce pronounced deviation of the eyes, writhing movements of the head and neck and an absence of tonic muscular contraction between spasms. By contrast, tetanus does not produce eye deviations and the muscles are characteristic tonically contracted between spasms. Finally, administration of an anticholinergic agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"     benztropine",
"    </a>",
"    mesylate will usually immediately reverse the spasms seen in drug-induced dystonias. Such therapy has no effect on patients with tetanus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Trismus due to dental infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental infections may produce striking trismus that may rarely be confused with cephalic forms of tetanus. However, the presence of an obvious dental abscess and the lack of progression or superimposed spasms usually make the distinction between the two diseases apparent after initial evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a period of observation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Strychnine poisoning due to ingestion of rat poison",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accidental or intentional strychnine poisoning may produce a clinical syndrome similar to tetanus. Supportive care for both conditions is critical; thus, the initial treatment of both conditions is identical. Assays of blood, urine, and tissue for strychnine can be performed in special reference laboratories. Such tests should be obtained when there is any suspicion of accidental or intentional poisoning or when a typical history of an antecedent injury or infection for tetanus is lacking or the patient has been adequately immunized for tetanus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40022?source=see_link\">",
"     \"Strychnine poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Malignant neuroleptic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with malignant neuroleptic syndrome can present with striking symptoms of autonomic instability and muscular rigidity. However the presence of fever, altered mental status, and recent receipt of an agent with a propensity to cause this complication usually makes the distinction from tetanus relatively easy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Stiff-person syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stiff-person syndrome (SPS) is a rare neurologic disorder characterized by severe muscle rigidity. Spasms of the trunk and limbs may be precipitated by voluntary movements, or auditory, tactile or emotional stimulation, all of which can also occur in tetanus. The absence of trismus or facial spasms and rapid response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    distinguish SPS from true tetanic spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, SPS is associated with autoantibodies against glutamic acid decarboxylase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/665?source=see_link\">",
"     \"Stiff-person syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of tetanus is best performed in the intensive care unit in consultation with an anesthesiologist or critical care specialist trained in the management of the complications of this disease, including early and aggressive airway management. Unfortunately, little evidence exists to support any particular therapeutic intervention in tetanus. There are only nine randomized trials reported in the literature over the past 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/25\">",
"     25",
"    </a>",
"    ]. The goals of treatment include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Halting the toxin production",
"     </li>",
"     <li>",
"      Neutralization of the unbound toxin",
"     </li>",
"     <li>",
"      Airway management",
"     </li>",
"     <li>",
"      Control of muscle spasms",
"     </li>",
"     <li>",
"      Management of dysautonomia",
"     </li>",
"     <li>",
"      General supportive management",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Halting toxin production",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Wound management",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with tetanus should undergo wound debridement to eradicate spores and necrotic tissue, which could lead to conditions ideal for germination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antibiotics probably play a relatively minor role in the management of tetanus, they are universally recommended. However, is important to emphasize that appropriate antimicrobial therapy may fail to eradicate C. tetani unless adequate wound debridement is performed. This was illustrated by one study in which 45 isolates of C. tetani were obtained at the time of wound debridement from 84 Vietnamese patients with severe tetanus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/26\">",
"     26",
"    </a>",
"    ]. All 45 isolates were susceptible by disc diffusion and E-test to penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and all were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . However, C. tetani was isolated from the wounds of two patients who underwent debridement after more than two weeks of high doses of penicillin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    (500 mg IV every six to eight hours) is the preferred treatment for tetanus, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2 to 4 million units IV every four to six hours) is a safe and effective alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"     8",
"    </a>",
"    ]. We suggest a treatment duration of 7 to 10 days.",
"   </p>",
"   <p>",
"    The first study to compare penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    found a greater reduction in mortality in the metronidazole group (7 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/27\">",
"     27",
"    </a>",
"    ]. However, in two subsequent studies, there was no difference in mortality in patients treated with penicillin and those treated with metronidazole [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. In one of the former studies, patients receiving metronidazole required fewer muscle relaxants and sedatives [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/3\">",
"     3",
"    </a>",
"    ]. It is possible that the observed difference in outcomes may not be due to differences in the antimicrobial activity of the two agents but rather may be explained by the GABA antagonist effect of penicillins and third-generation cephalosporins, which may lead to CNS excitability.",
"   </p>",
"   <p>",
"    If a mixed infection is suspected, a first-, second- or third-generation cephalosporin such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g IV every eight hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    (2 g IV every six hours), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 to 2 g IV every 24 hours) can be used.",
"   </p>",
"   <p>",
"    An alternative agent is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg every 12 hours); other agents with activity against C. tetani are macrolides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8,28\">",
"     8,28",
"    </a>",
"    ]. The efficacy of these agents has not been evaluated, but based upon in vitro susceptibility data, it is likely that they are effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Neutralization of unbound toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since tetanus toxin is irreversibly bound to tissues, only unbound toxin is available for neutralization. Unbound toxin has been demonstrated in 10 percent of serum samples and 4 percent of CSF samples of cases upon presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/29\">",
"     29",
"    </a>",
"    ]. The use of passive immunization to neutralize unbound toxin is associated with improved survival, and it is considered to be standard treatment.",
"   </p>",
"   <p>",
"    In the United States, human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     tetanus immune globulin",
"    </a>",
"    (HTIG) should be readily available and is the preparation of choice. A dose of 3000 to 6000 units intramuscularly should be given as soon as the diagnosis of tetanus is considered.",
"   </p>",
"   <p>",
"    Intrathecal administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     tetanus immune globulin",
"    </a>",
"    is of unproven benefit. A randomized trial from Brazil compared intramuscular plus intrathecal administration of immunoglobulin (n = 58) to intramuscular therapy alone (n = 62) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/30\">",
"     30",
"    </a>",
"    ]. The patients receiving intrathecal therapy had a shorter duration of spasms, shorter hospital stay, and a decreased requirement for respiratory assistance. Mortality was not significantly affected.",
"   </p>",
"   <p>",
"    However, a number of methodologic issues might have affected this study. The mortality rate for tetanus patients fell during the study period from 35 percent in historical controls to 12 percent among control patients in this study. While tetanus cases were graded upon admission, these grades were not reported and the only note of more patients with grade III and IV disease among the controls compared to those receiving intrathecal immunoglobulin implies that these differences arose during the course of therapy. The investigators refer to tetanus hyperimmune globulin but merely list a lyophilized human immunoglobulin in the methods section.",
"   </p>",
"   <p>",
"    In countries in which HTIG is not readily available, equine antitoxin is used in doses of 1500 to 3000 units intramuscularly or intravenously in order to achieve a serum concentration of 0.1",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    which is considered the minimal protective concentration. When equine antitoxin is used, an intradermal test dose of 0.1 mL in a 1:10 dilution should be administered prior to giving the full dose in order to evaluate for hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, antecedent skin testing is not needed if a human preparation is to be used.",
"   </p>",
"   <p>",
"    Infiltration of antitoxin, either human or equine, into the wound has sometimes been advocated but is of unproven value. The use of pooled intravenous immune globulin (IVIG) has been proposed as a possible alternative to HTIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Active immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since tetanus is one of the few bacterial diseases that does not confer immunity following recovery from acute illness,",
"    <strong>",
"     all",
"    </strong>",
"    patients with tetanus should receive active immunization with a total of three doses of tetanus and diphtheria toxoid spaced at least two weeks apart, commencing immediately upon diagnosis (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ). It should be assumed that anyone who is not adequately vaccinated or protected against tetanus is also inadequately protected against diphtheria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/6\">",
"     6",
"    </a>",
"    ]. The tetanus-diphtheria-acellular pertussis vaccine (Tdap) may be used instead of Td, but if used, recommendations are for this formulation to be used only once in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882660#H12882660\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent tetanus doses, in the form of Td, should be given at 10-year intervals throughout adulthood. Tetanus toxoid alone should be given only to those patients with documented allergy or untoward reactions to diphtheria toxoid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Control of muscle spasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized muscle spasms are life-threatening, since they can cause respiratory failure, lead to aspiration and induce generalized exhaustion in the patient. Several drugs may be used to control these spasms. Attention to placement of the patient and control of light or noise in the room in an effort to avoid provoking muscle spasms was an important component of care for patients with tetanus in the past before the availability of drugs to prevent spasms. These measures are still vital in regions where the availability of neuromuscular blocking agents may be limited [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Sedatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines have been used traditionally and are generally effective in controlling rigidity and spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"     8",
"    </a>",
"    ]. They also provide a sedative effect. For tetanus, the usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    is 10 to 30 mg IV, although doses as high as 120",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day have been used. Ventilatory assistance is imperative at these higher doses. Caution should be used with higher doses of the IV formulation since the vehicle, propylene glycol, may produce lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/31\">",
"     31",
"    </a>",
"    ]. Other benzodiazepines are equally effective as diazepam. Since these drugs may be required for a prolonged period of time (often weeks), they should be tapered gradually to avoid withdrawal reactions.",
"   </p>",
"   <p>",
"    Infusion of the anesthetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    may also control spasms and rigidity. Its prolonged use has been associated with lactic acidosis, hypertriglyceridemia and pancreatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Neuromuscular blocking agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular blocking agents are used when sedation alone is inadequate.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"     Pancuronium",
"    </a>",
"    , a long acting agent, has been traditionally used. However, it may worsen autonomic instability because it is an inhibitor of catecholamine reuptake.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"     Vecuronium",
"    </a>",
"    can also be administered and is less likely to cause autonomic problems, but since it is short acting, it must be given as continuous infusion to provide adequate effects. Monitoring of patients on these drugs is extremely important to avoid or recognize complications, and these drugs should be stopped at least once a day in order to assess the patient's status.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    , which stimulates postsynaptic GABA beta receptors, has been used in a few small studies. The preferred route is intrathecal, and it may be given either in a bolus of 1000 mcg or by continuous intrathecal infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/32\">",
"     32",
"    </a>",
"    ]. Intrathecal baclofen given as an initial bolus in a dose ranging from 40 to 200 mcg followed by a continuous infusion of 20",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    was found to control spasms and rigidity in 21 out of 22 patients with grade III tetanus in a retrospective outcome study from a single medical center in Portugal. One of 22 patients developed meningitis secondary to infection of the intrathecal catheter despite the fact that most patients required such therapy for at least three weeks (range 8 to 30 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/33\">",
"     33",
"    </a>",
"    ]. In some cases, baclofen has been used without the need for artificial ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/34\">",
"     34",
"    </a>",
"    ]. Phenothiazines and barbiturates were used in the past to control spasms but have largely been displaced by neuromuscular blocking agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Management of autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs have been used to produce adrenergic blockade and suppress autonomic hyperactivity; only treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    has been studied in a randomized clinical trial in tetanus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/35\">",
"     35",
"    </a>",
"    ], because of its use in clinical series for the management of autonomic dysfunction and as adjunctive treatment for controlling spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/35-38\">",
"     35-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Magnesium sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    acts as a presynaptic neuromuscular blocker, blocks catecholamine release from nerves, and reduces receptor responsiveness to catecholamines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/39\">",
"     39",
"    </a>",
"    ]. It has the advantage of worldwide experience in the treatment of eclampsia.",
"   </p>",
"   <p>",
"    In a randomized, double blind trial in 256 hospitalized patients with severe tetanus in Vietnam,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    infusion compared to placebo controlled autonomic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/35\">",
"     35",
"    </a>",
"    ]. The patients were randomly assigned to magnesium sulfate (loading dose 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 30 minutes, followed by continuous infusion of either 2 g per hour for patients over 45 kg or 1.5 g per hour for patients &le;45 kg) versus placebo (5 percent glucose in water) infusion. The primary outcomes were requirement for mechanical ventilation and drugs to control muscle spasms and autonomic dysfunction. Magnesium infusion significantly reduced the requirement for other drugs to control muscle spasms and patients treated with magnesium were 4.7 times (95% CI, 1.4-15.9) less likely to require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    to treat cardiovascular instability than those in the placebo group. Magnesium sulfate infusion did not reduce the need for mechanical ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Beta blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    (0.25 to 1.0",
"    <span class=\"nowrap\">",
"     mg/min)",
"    </span>",
"    has frequently been administered because of its dual alpha and beta blocking properties. Beta blockade alone with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , for example, should be avoided because of reports of sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/40\">",
"     40",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine sulfate",
"    </a>",
"    (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour by continuous intravenous infusion) is commonly used to control autonomic dysfunction as well as to induce sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs for the treatment of various autonomic events, which have been reported to be useful, are:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and epidural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Airway management and other supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since tetanus toxin cannot be displaced from the nervous system once bound to neurons, supportive care is the main treatment for tetanus. In patients with severe tetanus, prolonged immobility in the intensive care unit is common, much of which is on mechanical ventilation and may last for weeks. Such patients are predisposed to nosocomial infections, decubitus ulcers, tracheal stenosis, gastrointestinal hemorrhage, and thromboembolic disease.",
"   </p>",
"   <p>",
"    Endotracheal intubation is justified initially, but early tracheostomy is frequently indicated because of the likelihood of prolonged mechanical ventilation. The latter allows better tracheal suctioning and pulmonary toilet.",
"   </p>",
"   <p>",
"    Energy demands in tetanus may be extremely high, so early nutritional support is mandatory. Enteral feeding is preferred if enough calories can be administered by this route. Placement of PEG tubes is commonplace, since this route may prevent gastroesophageal reflux, which may be induced by nasogastric tubes. Prophylactic treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    or acid blockers may be used to prevent gastroesophageal hemorrhage from stress ulceration.",
"   </p>",
"   <p>",
"    Prophylaxis of thromboembolism with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight heparin or other anticoagulants should be administered early.",
"   </p>",
"   <p>",
"    Physical therapy should be started as soon as spasms have ceased, since tetanus patients often are left with disability from prolonged drug-induced paralysis and immobilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435843195\">",
"    <span class=\"h2\">",
"     Considerations in the developing world",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical care services are often unavailable or rudimentary in many developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"     8",
"    </a>",
"    ]. When intensive care units (ICUs) are not available, acute respiratory failure is a leading cause of death from tetanus. In the absence of an ICU, a separate ward or room should be designated for patients with tetanus and sensory stimuli should be kept to a minimum, since loud noises, physical contact, and light can trigger tetanic spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"     8",
"    </a>",
"    ]. Nondepolarizing paralytic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    , are not safe to use in the absence of ventilatory support. However, benzodiazepines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    can be used in such situations, if doses are carefully titrated to avoid respiratory depression.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    may be used to manage autonomic dysfunction. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Control of muscle spasms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H32\">",
"     'Magnesium sulfate'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case-fatality rates for non-neonatal tetanus in developing countries range from 8 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/16\">",
"     16",
"    </a>",
"    ], whereas the majority of patients with tetanus recover when modern supportive care is available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonatal tetanus, once nearly always fatal, now has mortality rates of 10 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients with shorter incubation periods (eg, &le;7 days) have increased disease severity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/16,42\">",
"     16,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among neonatal infections, survivors may recover fully or have varying degrees of neurologic damage ranging from minor intellectual deficits to cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/43\">",
"     43",
"    </a>",
"    ]. The prognosis appears excellent (mortality 2 percent in a study from India) with infections not associated with spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7353/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=see_link\">",
"       \"Patient information: Tetanus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetanus is a clinical diagnosis and must be considered in patients with muscle spasms and an inadequate vaccination history.",
"     </li>",
"     <li>",
"      Supportive care is the mainstay of management to avoid complications such as respiratory failure, nosocomial infections, and thromboembolism. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since the disease is mediated by a toxin, one aspect of therapy is to eliminate ongoing toxin production, neutralize unbound toxin usually with human",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"       tetanus immune globulin",
"      </a>",
"      , and immunize against tetanus since natural disease does not confer immunity. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Halting toxin production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimicrobials play an adjunctive role in the therapy of tetanus. We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every six to eight hours) for the treatment of tetanus. We suggest a treatment duration of 7 to 10 days. &nbsp;(See",
"      <a class=\"local\" href=\"#H25\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscle spasms are controlled with sedation (usually benzodiazepines) or neuromuscular blockade. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Control of muscle spasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autonomic hyperactivity can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine sulfate",
"      </a>",
"      . Beta blockade without concomitant alpha blockade should be avoided. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for both autonomic dysfunction and additional control of muscle spasms has generated considerable interest. This drug is readily available and is used worldwide for the treatment of eclampsia. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Management of autonomic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with shorter incubation periods have increased disease severity and mortality. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Tetanus surveillance --- United States, 2001-2008. MMWR Morb Mortal Wkly Rep 2011; 60:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/2\">",
"      Berger SA, Cherubin CE, Nelson S, Levine L. Tetanus despite preexisting antitetanus antibody. JAMA 1978; 240:769.",
"     </a>",
"    </li>",
"    <li>",
"     Yen LM, Dao LM, Day NPJ. Management of tetanus: a comparison of penicillin and metronidazole. Symposium of antimicrobial resistance in southern Viet Nam, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/4\">",
"      Rushdy AA, White JM, Ramsay ME, Crowcroft NS. Tetanus in England and Wales, 1984-2000. Epidemiol Infect 2003; 130:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/5\">",
"      Pedalino B, Cotter B, Ciofi degli Atti M, et al. Epidemiology of tetanus in Italy in years 1971-2000. Euro Surveill 2002; 7:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/6\">",
"      McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/7\">",
"      Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995; 332:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/8\">",
"      Afshar M, Raju M, Ansell D, Bleck TP. Narrative review: tetanus-a health threat after natural disasters in developing countries. Ann Intern Med 2011; 154:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/9\">",
"      Talabi OA. A 3-year review of neurologic admissions in University College Hospital Ibadan, Nigeria. West Afr J Med 2003; 22:150.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Immunization surveillance, assessment and monitoring. Maternal and Neonatal Tetanus (MNT) elimination. file://www.who.int/immunization_monitoring/diseases/MNTE_initiative/en/index.html (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/11\">",
"      Farrar JJ, Yen LM, Cook T, et al. Tetanus. J Neurol Neurosurg Psychiatry 2000; 69:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/12\">",
"      Lalli G, Gschmeissner S, Schiavo G. Myosin Va and microtubule-based motors are required for fast axonal retrograde transport of tetanus toxin in motor neurons. J Cell Sci 2003; 116:4639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/13\">",
"      Rummel A, Bade S, Alves J, et al. Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J Mol Biol 2003; 326:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/14\">",
"      Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/15\">",
"      Caccin P, Rossetto O, Rigoni M, et al. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett 2003; 542:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/16\">",
"      Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet 2007; 370:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/17\">",
"      Brauner JS, Vieira SR, Bleck TP. Changes in severe accidental tetanus mortality in the ICU during two decades in Brazil. Intensive Care Med 2002; 28:930.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Tetanus (lockjaw). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, American Academy of Pediatrics, Elk Grove Village, IL 2012. p.707.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/19\">",
"      Saltoglu N, Tasova Y, Midikli D, et al. Prognostic factors affecting deaths from adult tetanus. Clin Microbiol Infect 2004; 10:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/20\">",
"      Ergonul O, Erbay A, Eren S, Dokuzoguz B. Analysis of the case fatality rate of tetanus among adults in a tertiary hospital in Turkey. Eur J Clin Microbiol Infect Dis 2003; 22:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/21\">",
"      Weinstein L. Tetanus. N Engl J Med 1973; 289:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/22\">",
"      Idema CD, Harris BN, Ogunbanjo GA, D&uuml;rrheim DN. Neonatal tetanus elimination in Mpumalanga Province, South Africa. Trop Med Int Health 2002; 7:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/23\">",
"      Goulon M, Girard O, Grosbuis S, et al. [Antitetanus antibodies. Assay before anatoxinotherapy in 64 tetanus patients]. Nouv Presse Med 1972; 1:3049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/24\">",
"      Andreadou E, Kattoulas E, Sfagos C, Vassilopoulos D. Stiff person syndrome: avoiding misdiagnosis. Neurol Sci 2007; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/25\">",
"      Thwaites CL, Farrar JJ. Preventing and treating tetanus. BMJ 2003; 326:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/26\">",
"      Campbell JI, Lam TM, Huynh TL, et al. Microbiologic characterization and antimicrobial susceptibility of Clostridium tetani isolated from wounds of patients with clinically diagnosed tetanus. Am J Trop Med Hyg 2009; 80:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/27\">",
"      Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J (Clin Res Ed) 1985; 291:648.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson EA, Summanen P, Finegold SM. Clostridium. In: Manual of Clinical Microbiology, 9th edition, Murray PR, Baron EJ, Jorgensen JH, et al (Eds), ASM Press, Washington DC 2007. Vol 1, p.889.",
"    </li>",
"    <li>",
"     Veronose, R. Tetanus: important new concepts. Excerta Medica 1981; 183.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/30\">",
"      Miranda-Filho Dde B, Ximenes RA, Barone AA, et al. Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route. BMJ 2004; 328:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/31\">",
"      Kapoor W, Carey P, Karpf M. Induction of lactic acidosis with intravenous diazepam in a patient with tetanus. Arch Intern Med 1981; 141:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/32\">",
"      Engrand N, Guerot E, Rouamba A, Vilain G. The efficacy of intrathecal baclofen in severe tetanus. Anesthesiology 1999; 90:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/33\">",
"      Santos ML, Mota-Miranda A, Alves-Pereira A, et al. Intrathecal baclofen for the treatment of tetanus. Clin Infect Dis 2004; 38:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/34\">",
"      Engrand N, Vilain G, Rouamba A, Benhamou D. [Value of intrathecal baclofen in the treatment of severe tetanus in the tropical milieu]. Med Trop (Mars) 2000; 60:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/35\">",
"      Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet 2006; 368:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/36\">",
"      Attygalle D, Rodrigo N. Magnesium as first line therapy in the management of tetanus: a prospective study of 40 patients. Anaesthesia 2002; 57:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/37\">",
"      James MF, Manson ED. The use of magnesium sulphate infusions in the management of very severe tetanus. Intensive Care Med 1985; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/38\">",
"      Ceneviva GD, Thomas NJ, Kees-Folts D. Magnesium sulfate for control of muscle rigidity and spasms and avoidance of mechanical ventilation in pediatric tetanus. Pediatr Crit Care Med 2003; 4:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/39\">",
"      Lipman J, James MF, Erskine J, et al. Autonomic dysfunction in severe tetanus: magnesium sulfate as an adjunct to deep sedation. Crit Care Med 1987; 15:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/40\">",
"      Buchanan N, Smit L, Cane RD, De Andrade M. Sympathetic overactivity in tetanus: fatality associated with propranolol. Br Med J 1978; 2:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/41\">",
"      Trujillo MH, Castillo A, Espa&ntilde;a J, et al. Impact of intensive care management on the prognosis of tetanus. Analysis of 641 cases. Chest 1987; 92:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/42\">",
"      Patel JC, Mehta BC. Tetanus: study of 8,697 cases. Indian J Med Sci 1999; 53:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7353/abstract/43\">",
"      Barlow JL, Mung'Ala-Odera V, Gona J, Newton CR. Brain damage after neonatal tetanus in a rural Kenyan hospital. Trop Med Int Health 2001; 6:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5525 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7353=[""].join("\n");
var outline_f7_11_7353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Developed countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tetanus in patients without an identifiable cause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Generalized tetanus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Local tetanus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cephalic tetanus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neonatal tetanus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Severity of illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Duration of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drug-induced dystonias such as those due to phenothiazines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Trismus due to dental infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Strychnine poisoning due to ingestion of rat poison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Malignant neuroleptic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Stiff-person syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Halting toxin production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Wound management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Neutralization of unbound toxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Active immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Control of muscle spasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Sedatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Neuromuscular blocking agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Management of autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Beta blockade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Airway management and other supportive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435843195\">",
"      Considerations in the developing world",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5525\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5525|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=related_link\">",
"      Complications, diagnosis, and treatment of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25158?source=related_link\">",
"      Overview of puncture wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=related_link\">",
"      Patient information: Tetanus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/665?source=related_link\">",
"      Stiff-person syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40022?source=related_link\">",
"      Strychnine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_11_7354="Systemic treatment for metastatic breast cancer: General principles";
var content_f7_11_7354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic treatment for metastatic breast cancer: General principles",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7354/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7354/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7354/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/11/7354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/11/7354/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/11/7354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although metastatic breast cancer is unlikely to be cured, meaningful improvements in survival have been seen, coincident with the introduction of newer systemic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Median overall survival approaches two years, with a range from a few months to many years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection of a therapeutic strategy depends upon both tumor biology and clinical factors, with the goal being a tailored approach. Although a subset of patients with oligometastatic disease may benefit from an intensified locoregional approach, most patients with metastatic breast cancer receive systemic medical therapy, consisting of chemotherapy, endocrine therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biologic therapies, and supportive care measures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General principles of management of metastatic breast cancer are presented here. Details of single agent and combination chemotherapy, endocrine therapy, biologic therapy, and how to select among them, as well as locoregional approaches, osteoclast inhibitors (bisphosphonates and receptor activator of nuclear factor kappa-B [RANK] ligand inhibitors), and supportive care, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=see_link\">",
"       \"Metastatic breast cancer: Local treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=see_link\">",
"       \"Treatment of metastatic breast cancer in older women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"       \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130595\">",
"    <span class=\"h1\">",
"     THERAPEUTIC GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goals of systemic treatment for metastatic breast cancer are prolongation of survival, alleviation of symptoms, and maintenance or improvement in quality of life, despite the toxicity associated with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The median survival for metastatic breast cancer is 18 to 24 months, though this varies widely based on subtype of tumor, sites of metastatic involvement, and burden of metastatic disease, and some patients experience long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/1-4,10\">",
"     1-4,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No prospective randomized clinical trials have demonstrated that systemic therapy prolongs survival compared to best supportive care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/7\">",
"     7",
"    </a>",
"    ]. However, median survival for patients with metastatic breast cancer appears to have improved over time, a trend which has been attributed to the availability of new, more effective agents, including taxanes, aromatase inhibitors, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/1,2,11-13\">",
"     1,2,11-13",
"    </a>",
"    ]. As an example, patients from the British Columbia Breast Cancer Outcomes Database who were diagnosed between 1997 and 2001 had better two-year overall survival than patients diagnosed between 1991 and 1995 (45 versus 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The optimal measure of therapeutic efficacy is debated. Overall survival is the gold standard for comparing therapies, but it requires prolonged follow-up and may be diluted by the effects of subsequent treatment. However, no other endpoint, including progression-free survival, time to tumor progression, or objective response rate, has been shown to be a good surrogate for overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/14\">",
"     14",
"    </a>",
"    ]. Comparisons of objective response rates are often used to determine relative treatment efficacy, but high response rates do not necessarily translate into clinically meaningful increases in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In addition, symptom relief without measurable disease response and achievement of stable disease as compared to disease progression may be clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H134297\">",
"    <span class=\"h1\">",
"     TUMOR BIOLOGY AND RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic markers, such as hormone receptor status, human epidermal growth factor receptor 2 (HER2) overexpression, and tumor burden, have both prognostic and predictive value and are important factors in selecting appropriate treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361865859\">",
"    <span class=\"h2\">",
"     Disease assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete evaluation for the extent of metastatic disease includes confirmatory biopsy of suspected lesions and reassessment of molecular markers, particularly estrogen receptor (ER), progesterone receptor (PR), and HER2 overexpression. This is especially important if the primary cancer was deemed negative for ER, PR, and or HER2, since a conversion to positive would dramatically change therapy.",
"   </p>",
"   <p>",
"    There is a possible discordance of these markers between primary and metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. As an example, in a pooled analysis of two prospective studies, the rates of discordance in ER, PR, and HER2 between the primary and recurrent disease were 13, 28, and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/19\">",
"     19",
"    </a>",
"    ]. In this study, the number needed to biopsy to alter immediate patient management was 6.3. However, it is not clear that verifying receptor status in new metastases and the resultant management changes will ultimately lead to improvements in patient quality of life and survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131955\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical factors that predict the rate of progression and survival include the interval between initial therapy and relapse, the number of metastatic sites, the presence or absence of visceral involvement, and biologic markers. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse-free interval of &ge;2 years is more favorable than a shorter time to relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/23-26\">",
"       23-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with metastases involving the chest wall, bones, or lymph nodes may have prolonged progression-free survival, while those with hepatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymphangitic pulmonary disease have shorter progression-free and overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/23,24,27\">",
"       23,24,27",
"      </a>",
"      ]. Patients with lymphangitic lung metastases, bone marrow replacement, carcinomatous meningitis, or significant liver metastases are described as having visceral crisis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients without visceral crisis but with poor prognostic features represent an intermediate phenotype.",
"     </li>",
"     <li>",
"      Patients with hormone receptor positivity generally have a more favorable prognosis, and patients with ER- and PR-positive tumors have significantly longer survival than single hormone receptor-positive tumors",
"      <span class=\"nowrap\">",
"       (ER+/PR-",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       ER-/PR+)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients with either HER2 overexpression or triple (ER, PR, HER2)-negative metastatic breast cancer have a shorter median survival [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/25,30,31\">",
"       25,30,31",
"      </a>",
"      ]. The prognosis associated with particular molecular phenotypes is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41302?source=see_link\">",
"       \"Molecular intrinsic subtypes of breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other adverse prognostic features include weight loss, poor performance status (",
"      <a class=\"graphic graphic_table graphicRef57945 \" href=\"UTD.htm?3/29/3549\">",
"       table 1",
"      </a>",
"      ), and elevated serum lactic dehydrogenase [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/23,32\">",
"       23,32",
"      </a>",
"      ]. Age less than 35 years old is a poor prognostic factor for women with early stage breast cancer, but the effect of age on survival after recurrence is not established [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/25,33\">",
"       25,33",
"      </a>",
"      ]. Similarly, the stage at diagnosis does not reliably indicate prognosis after relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133804\">",
"    <span class=\"h2\">",
"     Prediction of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormone receptor status and HER2 overexpression are the most important predictors of treatment response in patients with metastatic breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133812\">",
"    <span class=\"h3\">",
"     Hormone receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormone receptor status is the most important predictive factor for response to hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The likelihood of response is 70 percent in patients with tumors that express both ER and PR, 40 percent in tumors that are",
"    <span class=\"nowrap\">",
"     ER-positive/PR-negative",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     ER-negative/PR-positive,",
"    </span>",
"    and less than 10 percent in",
"    <span class=\"nowrap\">",
"     ER-negative/PR-negative",
"    </span>",
"    tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The molecular basis by which ER status predicts response to endocrine therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional features that predict responsiveness to hormone therapy in patients with metastatic breast cancer include a long relapse-free interval, isolated bone and soft tissue involvement, and prior response to endocrine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some data suggesting that patients with ER-positive tumors are less likely to respond to cytotoxic chemotherapy than those with ER-negative tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/35,40-42\">",
"     35,40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133819\">",
"    <span class=\"h3\">",
"     HER2-overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overexpression of HER2 predicts response to therapies that target HER2, such as the humanized monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and the small molecule tyrosine kinase inhibitor lapatinib. These drugs are only effective for tumors that have high levels of HER2 expression (3+ by immunohistochemistry) or gene amplification (as detected by fluorescence in situ hybridization [FISH]).",
"   </p>",
"   <p>",
"    Some evidence suggests that tumors with HER2 overexpression are less responsive to endocrine therapy, although the available data are not sufficient to use HER2 status to predict resistance to endocrine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details of HER2 testing and the role of HER2-status in predicting the response to HER2-directed therapy, chemotherapy, and endocrine therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133826\">",
"    <span class=\"h3\">",
"     Chemotherapy response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent predictors of poor chemotherapy response are progression with prior chemotherapy for advanced disease, relapse within 12 months of completing adjuvant chemotherapy, poor performance status, and multiple disease sites, especially visceral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/23,24,32,45-52\">",
"     23,24,32,45-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Markers of increased cellular proliferation, such as high S-phase fraction by flow cytometry, increased uptake of radiolabeled thymidine, and immunohistochemical staining for the proliferation antigen Ki67, are all associated with higher chemotherapy response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In contrast, breast cancers that overexpress p-glycoprotein (gp170), a drug efflux pump that mediates multidrug resistance (MDR), or have a mutated p53 gene may be less likely to respond to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. At present, none of these markers should be used to make clinical decisions.",
"   </p>",
"   <p>",
"    Another possible approach is the use of chemotherapy sensitivity and resistance assays [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. However, the clinical utility of these assays remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/56,63,64\">",
"     56,63,64",
"    </a>",
"    ]. The detection and monitoring of circulating tumor cells during treatment for metastatic breast cancer is discussed below. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Circulating tumor cells'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H131585\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key points described above are important to keep in mind when selecting treatment for metastatic breast cancer. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The aim of treatment is to palliate symptoms, prolong survival, and maintain quality of life.",
"     </li>",
"     <li>",
"      Patients with visceral metastases and a short disease-free interval generally have an aggressive phenotype, while patients with soft tissue and bone metastases have a more indolent phenotype.",
"     </li>",
"     <li>",
"      Hormone receptor status and human epidermal growth factor receptor 2 (HER2) overexpression are important in estimating prognosis and the likelihood of response to therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hormone receptor (estrogen receptor [ER]",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progesterone receptor [PR]) status is the major determining factor for response to endocrine therapy.",
"     </li>",
"     <li>",
"      Likewise, HER2 overexpression is required for response to HER2-directed therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these principles, selection of treatment can be individualized. Endocrine therapy is best used for patients with hormone receptor-positive breast cancer and not for patients with hormone-negative breast cancer. HER2-directed therapy is only appropriate for patients with tumors that overexpress HER2. Lastly, chemotherapy is indicated for hormone-insensitive metastatic breast cancer (ie, patients with hormone-receptor-negative breast cancer and those with hormone-receptor-positive breast cancer who have become resistant to endocrine therapy). It is less clear is when to use endocrine therapy versus chemotherapy as initial treatment for patients with hormone receptor-positive metastatic breast cancer. Likewise, it is less obvious when to use single agent versus combination chemotherapy, how to best incorporate biologic therapies, and whether combined modalities are of benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endocrine therapy versus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is commonly thought that chemotherapy results in higher response rates and more rapid responses than endocrine therapy, and is often used as the initial treatment for patients with hormone receptor-positive metastatic breast cancer with a poor prognosis, especially those with visceral metastases. A meta-analysis that included eight small randomized trials, all published prior to 1995, compared the response rates for chemotherapy alone with those of endocrine therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/65\">",
"     65",
"    </a>",
"    ]. The pooled estimate of response rates showed an advantage for chemotherapy over endocrine therapy (relative risk 1.25, 95% CI 1.01 to 1.54), although the two largest trials had opposite findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. No significant difference was seen in overall survival (hazard ratio, HR 0.94, 95% CI 0.79 to 1.12), and on subset analysis, there was no obvious trend to suggest an effect of age, menopausal status, or pattern of metastatic disease on the efficacy of either therapy. There was minimal and contrasting information on quality of life and toxicity.",
"   </p>",
"   <p>",
"    A major limitation to these findings is that most patients in these trials had tumors of unknown hormone receptor status, since the predictive value of hormone receptor status on response to endocrine therapy was not yet appreciated. Nevertheless, chemotherapy remains the preferred modality for initial treatment of patients with rapidly progressive symptomatic disease or visceral crisis (end-organ dysfunction), given the higher likelihood of achieving a response with chemotherapy.",
"   </p>",
"   <p>",
"    No survival benefit has been seen when chemotherapy and endocrine therapy were combined. (See",
"    <a class=\"local\" href=\"#H361862540\">",
"     'Combining treatment modalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129020\">",
"    <span class=\"h2\">",
"     Sequential single agents versus combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared in a meta-analysis published in 2005, combination chemotherapy was associated with significantly higher overall response rates (odds ratio [OR] 1.28, 95% CI 1.15-1.42) and improved overall survival (hazard ratio [HR] for death 0.88, 95% CI 0.83-0.93), and a significantly lower rate of disease progression (overall hazard ratio HR 0.78, 95% CI 0.73-0.83) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/68\">",
"     68",
"    </a>",
"    ]. However, this modest survival improvement came with the cost of significantly worse toxicity, including leukopenia, nausea, and vomiting.",
"   </p>",
"   <p>",
"    The findings of this meta-analysis are limited in that modern chemotherapy agents were not well represented in the included trials and that the rate of cross-over was not known.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical trials with newer agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , have either found no difference in overall survival between combination and single agent chemotherapy, or a modest improvement of a few months, and again, worse toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/69-71\">",
"       69-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most trials compare single agent therapy to a combination of two drugs, rather than comparing the combination to sequential use of the two single agents. The modest survival benefits favoring combination chemotherapy may not have been seen if crossover to the experimental agent had been allowed. Several trials that directly compared combination versus sequential therapy failed to show a survival benefit for initial combination therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/72-75\">",
"       72-75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, Eastern Cooperative Oncology Group (ECOG) trial E1193 randomly assigned 739 patients with metastatic breast cancer to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    alone, or the combination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/72\">",
"     72",
"    </a>",
"    ]. Patients receiving single agent therapy crossed over to the alternative agent at the time of progression. Although initial combination therapy with doxorubicin and paclitaxel, compared to either agent alone, was associated with a significantly higher response rate (47 versus 36 and 34 percent) and time to treatment failure (8 versus 5.8 and 6 months), median overall survival was similar for all three (22, 19, and 22 months, respectively).",
"   </p>",
"   <p>",
"    Without an appreciable survival advantage with combination chemotherapy, sequential therapy with single agents is often preferred. Toxicity is less with single agent therapy and quality of life appears better [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. For patients in need of quick symptom control or those with rapidly progressive disease or visceral crisis, however, combination therapy may be a more appropriate first-line choice because of the greater likelihood of an objective response in a shorter time.",
"   </p>",
"   <p>",
"    Adding more agents to combination regimens has not led any further improvements in time to progression or overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/79\">",
"     79",
"    </a>",
"    ]. In fact, a review of all randomized trials comparing chemotherapy regimens for metastatic breast cancer that were reported between 2000 and 2007 found little evidence of major survival differences among many common chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361862540\">",
"    <span class=\"h2\">",
"     Combining treatment modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, combining chemotherapy, biologic therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrine therapy might have additive efficacy, but it might also lead to increased toxicity. Clinical trials have failed to show a survival advantage for the concurrent administration of chemotherapy and endocrine therapy over either single modality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/7,67,81\">",
"     7,67,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, HER2-directed therapy, namely,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and lapatinib, has been successfully combined as individual agents with chemotherapy and endocrine therapy, and with each other. (See",
"    <a class=\"local\" href=\"#H626742034\">",
"     'Biologic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626742034\">",
"    <span class=\"h2\">",
"     Biologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, the molecularly targeted agents (or biologic therapy) that have proven efficacy in metastatic breast cancer are the HER2-directed agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and lapatinib, and bevacizumab. The use of these biologic agents in metastatic breast cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691733994\">",
"    <span class=\"h2\">",
"     Osteoclast inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bone metastases should be treated with osteoclast inhibitors (bisphosphonates or RANK ligand inhibition) as these agents have been shown to reduce the risk of skeletal related events, such as fractures, the need for surgery or radiation to bone, spinal cord compression, and hypercalcemia of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361864730\">",
"    <span class=\"h1\">",
"     TREATMENT ALGORITHMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issues discussed above can be summarized and clarified into treatment recommendations for patients with metastatic breast cancer according to the hormone receptor and human epidermal growth factor receptor 2 (HER2) status of their tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361864767\">",
"    <span class=\"h2\">",
"     Hormone receptor-positive HER2-negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence, despite limitations described above, suggests that chemotherapy has higher response rates than endocrine therapy. Therefore, patients with rapidly progressive, symptomatic disease or visceral metastases with end-organ dysfunction may be best treated with first-line chemotherapy. After chemotherapy response stabilizes (usually four to six months), a switch to maintenance endocrine therapy is a commonly employed strategy, which can reduce the treatment side effects without compromising overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/7,82,83\">",
"     7,82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given its generally favorable toxicity profile, first-line endocrine therapy may be more appropriate for patients with asymptomatic or minimally symptomatic disease and those without visceral involvement. If the disease progresses rapidly (within a few months) following initiation of first-line endocrine therapy, chemotherapy is generally recommended as a second-line rather than switching to another endocrine strategy. If time to progression on first-line endocrine therapy is prolonged (greater than six months), then a switch to second-line endocrine therapy at progression is reasonable.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Selection of endocrine therapy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Selection of chemotherapy regimen is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459262353\">",
"    <span class=\"h2\">",
"     Hormone receptor-positive HER2-positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic options for these patients include chemotherapy, endocrine therapy, and HER2-directed therapy. HER2 directed therapy has demonstrated improved survival for patients with tumors that overexpress HER2 and thus should be part of first-line therapy for these patients.",
"   </p>",
"   <p>",
"    Whether it is better to use HER2-directed therapy combined with chemotherapy versus endocrine therapy as first-line treatment is unclear. HER2-directed therapy combined with chemotherapy or endocrine therapy are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361864774\">",
"    <span class=\"h2\">",
"     Hormone receptor-negative HER2-negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with triple- (ER-, PR-, HER2-) negative breast cancer have a particularly aggressive subtype, and first-line chemotherapy is recommended. Whether chemotherapy agents are given in combination or sequentially should be determined based on symptoms and location and burden of disease, as well as patient-related factors (ie, preferences, goals, and overall health).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Triple-negative breast cancer is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link\">",
"       \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Selection of chemotherapy regimen is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361864781\">",
"    <span class=\"h2\">",
"     Hormone receptor-negative HER2-positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of HER2-directed therapy and chemotherapy is recommended for these patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regimens combining HER2-directed therapy with chemotherapy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MONITORING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful assessment of the response to therapy will assist in decisions for duration of treatment and in selection of subsequent treatments. However, the best approach for monitoring patients with metastatic breast cancer is not well established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;If symptom palliation is the main objective, clinical history alone may suffice to determine the success of therapy. Physical examination may allow response quantitation if disease is easily accessible (eg, chest wall nodules, palpable lymphadenopathy). With a dramatic reduction in symptoms that were clearly disease-related or obvious shrinkage of palpable lesions, serum markers and radiographic tests are likely to be irrelevant.",
"   </p>",
"   <p>",
"    However, many patients have more subtle disease signs or symptoms that may be confused with treatment toxicity or other nonmalignant conditions. In addition, disease is not measurable by physical examination in nearly half of patients with metastatic breast cancer. In these patients, serial changes in tumor markers or radiographic studies are essential in establishing the response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial assay of serum tumor markers (eg, CA15-3 and CA27.29, both products of the MUC-1 gene, and CEA) can aid in response assessment, particularly if disease sites are not assessable by usual criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/43,84\">",
"     43,84",
"    </a>",
"    ]. Judicious use of serial tumor marker measurements may decrease the need for periodic radiographic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the American Society of Clinical Oncology (ASCO) expert panel suggest that it is reasonable to evaluate one of the MUC-1 assays and CEA initially in patients with metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/43\">",
"     43",
"    </a>",
"    ]. If the MUC-1 assay is elevated, there is no role for monitoring CEA, but if not, then serial CEA levels may be useful.",
"   </p>",
"   <p>",
"    Elevated tumor markers may occasionally be spurious. Up to 20 percent of patients successfully treated with systemic therapy may experience a transient increase (marker \"flare\") during the first one or two months after treatment initiation, presumably due to release of antigen by cytolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Patients with abnormal liver function may also have falsely elevated marker levels because they are cleared by the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/86\">",
"     86",
"    </a>",
"    ]. CA 15-3 levels may be aberrantly elevated in patients with vitamin B12 deficiency and megaloblastic anemia, as well as in patients with thalassemia or sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/88-90\">",
"     88-90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial plain radiographs, computed tomography (CT) scan, or magnetic resonance imaging (MRI) can permit assessment of tumor response. Periodic scintigraphic bone scans, while helpful, may also be misleading. Technetium (Tc99) phosphonate accumulates in areas of osteoblastic activity rather than in cancer cells. In a patient experiencing a response to therapy, a \"scintigraphic healing flare\" may appear as early as two months, and persist for as long as 12 months after initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Integrated positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/computed",
"    </span>",
"    tomography (CT) is popular as a whole-body examination in monitoring response to therapy in metastatic breast cancer, as it has demonstrated high sensitivity and specificity in detecting metastatic disease and can reliably assess response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. There is also some evidence that metabolic changes in bone metastases in response to systemic therapy (ie, a change in standardized uptake value [SUV]) can predict response duration or time to progression [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. However, many integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanners in clinical use provide a limited CT scan primarily for orientational purposes (determining where the PET abnormality is) and not a higher resolution, fine cut, contrast-enhanced CT scan. This should be kept in mind when evaluating response between modalities (standard CT and",
"    <span class=\"nowrap\">",
"     PET/CT).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Circulating tumor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of circulating tumor cells (CTCs) in blood samples of patients with metastatic breast cancer (&ge;five CTCs) has been shown to be a predictor of progression-free survival (PFS) and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/99-105\">",
"     99-105",
"    </a>",
"    ]. Immunological and RNA-based methods are used to detect CTCs in breast cancer. Although multiple commercially available methods for isolating CTCs exist, the CellSearch system (Veridex Corporation, Warren, NJ) is the only system approved in the US for clinical use to detect the presence of CTCs in patients with breast cancer. In a prospective trial of 177 patients who were beginning a new therapy for metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/100\">",
"     100",
"    </a>",
"    ], elevated CTCs at baseline (defined as &ge;5 CTCs per 7.5 mL of blood) compared with the finding of fewer or no detectable CTCs predicted a significantly shorter PFS (3 versus 7 months) and overall survival (10 versus 22 months). Patients with elevated CTCs at the first follow-up visit (within three to five weeks of initiating therapy) also had a worse PFS (2 versus 7 months) and overall survival (8 versus greater than 18 months), whereas those with a decrease in the number of CTCs from baseline had improved PFS and overall survival. Subsequent analyses from this trial and others have suggested that elevated levels of CTCs at any time point during treatment are associated with tumor progression and that CTC levels may reliably estimate disease progression earlier than imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/102,105,106\">",
"     102,105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ASCO expert panel on tumor markers in breast cancer, when convened in 2007, concluded that the data were insufficient and needed further validation prior to recommending routine measurement of CTCs in patients with metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/43\">",
"     43",
"    </a>",
"    ]. A prospective randomized trial is underway to test the clinical utility of changing therapy for patients with metastatic breast cancer who have not cleared CTCs after only one cycle of a new, first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/11/7354/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"       \"Patient information: Treatment of metastatic breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459263114\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of systemic treatment for metastatic breast cancer are prolongation of survival, alleviation of symptoms, and maintenance or improvement in quality of life.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hormone receptor status, human epidermal growth factor receptor 2 (HER2) overexpression, tumor burden, and disease-free interval have prognostic and predictive value and are important determinants in selecting appropriate treatment. (See",
"      <a class=\"local\" href=\"#H134297\">",
"       'Tumor biology and risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the importance of hormone receptor and HER2 status in selecting treatment, hormone receptor and HER2 testing should be repeated upon diagnosis of metastatic breast cancer in case there is discordance in expression between the primary site and metastases, especially if the primary cancer was deemed negative, since a conversion to positive would dramatically change therapy. (See",
"      <a class=\"local\" href=\"#H361865859\">",
"       'Disease assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hormone-positive metastatic breast cancer with rapidly progressive, symptomatic disease or visceral metastases with end-organ dysfunction, we recommend first-line treatment with chemotherapy rather than endocrine therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). All other patients with hormone-positive metastatic breast cancer should be treated first with endocrine therapy. (See",
"      <a class=\"local\" href=\"#H131585\">",
"       'Treatment selection'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      We suggest sequential single agent chemotherapy for most patients with metastatic breast cancer who require chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Combination chemotherapy may be preferable for select patients with rapidly progressive disease, visceral crisis, or if quick symptom control is desired. (See",
"      <a class=\"local\" href=\"#H129020\">",
"       'Sequential single agents versus combination chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with HER2-positive breast cancer, regardless of their hormone receptor status, receive HER2-directed therapy as first-line treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Careful assessment of the response to therapy will assist in decisions for treatment continuation and in selection of subsequent treatments. Tools that are potentially useful to monitor treatment response include history and physical examination, radiographic imaging, and assay of serum tumor markers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      circulating tumor cells (CTCs). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Monitoring therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/1\">",
"      Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/2\">",
"      Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/3\">",
"      Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010; 119:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/4\">",
"      Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/5\">",
"      Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 102:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/6\">",
"      Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/7\">",
"      Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000; 26:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/8\">",
"      Osoba D. Health-related quality of life as a treatment endpoint in metastatic breast cancer. Can J Oncol 1995; 5 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/9\">",
"      Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000; 18:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/10\">",
"      Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 2011; 29:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/11\">",
"      Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004; 100:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/12\">",
"      Mauri D, Polyzos NP, Salanti G, et al. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 2008; 100:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/13\">",
"      Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/14\">",
"      Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008; 26:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/15\">",
"      Ahmann DL, Schaid DJ, Bisel HF, et al. The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol 1987; 5:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/16\">",
"      Bruzzi P, Del Mastro L, Sormani MP, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005; 23:5117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/17\">",
"      Robertson JF, Howell A, Buzdar A, et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat 1999; 58:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/18\">",
"      Hull DF 3rd, Clark GM, Osborne CK, et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43:413.",
"     </a>",
"    </li>",
"    <li>",
"     Amir E, Clemons M, Freedman OC, et al. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies (abstract #1007). J Clin Oncol 2010; 28:15s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/20\">",
"      Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/21\">",
"      Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 2009; 10:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/22\">",
"      Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep 2011; 13:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/23\">",
"      Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/24\">",
"      Hortobagyi GN, Smith TL, Legha SS, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983; 1:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/25\">",
"      Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987; 5:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/26\">",
"      Harris JR, Hellman S. Observations on survival curve analysis with particular reference to breast cancer treatment. Cancer 1986; 57:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/27\">",
"      Robertson JF, Dixon AR, Nicholson RI, et al. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 1992; 22:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/28\">",
"      Barrios CH, Sampaio C, Vinholes J, Caponero R. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann Oncol 2009; 20:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/29\">",
"      Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross HA. The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors. Breast 2009; 18:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/30\">",
"      Emi Y, Kitamura K, Shikada Y, et al. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery 2002; 131:S217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/31\">",
"      Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010; 17:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/32\">",
"      Yamamoto N, Watanabe T, Katsumata N, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998; 16:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/33\">",
"      Leivonen MK, Kalima TV. Prognostic factors associated with survival after breast cancer recurrence. Acta Oncol 1991; 30:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/34\">",
"      Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984; 2:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/35\">",
"      Rubens RD, Hayward JL. Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 1980; 46:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/36\">",
"      Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/37\">",
"      Bloom ND, Tobin EH, Schreibman B, Degenshein GA. The role of progesterone receptors in the management of advanced breast cancer. Cancer 1980; 45:2992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/38\">",
"      Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990; 11:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/39\">",
"      Epstein RJ. The clinical biology of hormone-responsive breast cancer. Cancer Treat Rev 1988; 15:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/40\">",
"      Levine RM, Lippman ME. Relationship between estrogen-receptor proteins and response to chemotherapy in breast cancer. Cancer Treat Rep 1984; 68:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/41\">",
"      Lippman ME, Allegra JC, Thompson EB, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978; 298:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/42\">",
"      Kiang DT, Frenning DH, Goldman AI, et al. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 1978; 299:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/43\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/44\">",
"      De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11:4741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/45\">",
"      Ahmann DL, Schaid DJ, Ingle JN, et al. A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. Am J Clin Oncol 1991; 14:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/46\">",
"      Valagussa P, Tancini G, Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986; 58:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/47\">",
"      Perez JE, Machiavelli M, Leone BA, et al. Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncol&oacute;gico Cooperativo del Sur. Am J Clin Oncol 1990; 13:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/48\">",
"      Falkson G, Gelman R, Falkson CI, et al. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 1991; 9:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/49\">",
"      Rabinovich M, Vallejo C, Bianco A, et al. Development and validation of prognostic models in metastatic breast cancer: a GOCS study. Oncology 1992; 49:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/50\">",
"      Pronzato P, Bertelli G, Gardin G, et al. Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients. Oncology 1993; 50:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/51\">",
"      Aisner J, Cirrincione C, Perloff M, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol 1995; 13:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/52\">",
"      Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/53\">",
"      Rozan S, Vincent-Salomon A, Zafrani B, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/54\">",
"      Hatschek T, Carstensen J, Fagerberg G, et al. Influence of S-phase fraction on metastatic pattern and post-recurrence survival in a randomized mammography screening trial. Breast Cancer Res Treat 1989; 14:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/55\">",
"      Amadori D, Volpi A, Maltoni R, et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 1997; 43:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/56\">",
"      Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998; 4:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/57\">",
"      Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/58\">",
"      Clahsen PC, van de Velde CJ, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998; 16:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/59\">",
"      Formenti SC, Dunnington G, Uzieli B, et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 1997; 39:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/60\">",
"      Weisenthal LM, Kern DH. Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays. Oncology (Williston Park) 1991; 5:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/61\">",
"      Tavassoli FA, Cook CB, Pestaner JP. A comparison of two commercially available in vitro chemosensitivity assays. Oncology 1995; 52:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/62\">",
"      Elledge RM, Clark GM, Hon J, et al. Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1995; 13:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/63\">",
"      Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004; 22:3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/64\">",
"      Schrag D, Garewal HS, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004; 22:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/65\">",
"      Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003; :CD002747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/66\">",
"      Taylor SG 4th, Gelman RS, Falkson G, Cummings FJ. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 1986; 104:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/67\">",
"      A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 1986; 4:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/68\">",
"      Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005; :CD003372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/69\">",
"      Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/70\">",
"      O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/71\">",
"      Mart&iacute;n M, Ruiz A, Mu&ntilde;oz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/72\">",
"      Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/73\">",
"      Alba E, Mart&iacute;n M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004; 22:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/74\">",
"      Conte PF, Guarneri V, Bruzzi P, et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 2004; 101:704.",
"     </a>",
"    </li>",
"    <li>",
"     Soto C, Torrecillas L, Reyes S, et al. Capecitabine (X) and taxanes in patients with anthracycline-pretreated metastatic breast cancer: sequential vs. combined therapy results from a MOSG randomized phase III trial (abstract). J Clin Oncol 2006; 24:20s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/76\">",
"      Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/77\">",
"      Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998; 16:3720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/78\">",
"      Heidemann E, Stoeger H, Souchon R, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 2002; 13:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/79\">",
"      Jones D, Ghersi D, Wilcken N. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 2006; :CD003368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/80\">",
"      Wilcken N, Dear R. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. Eur J Cancer 2008; 44:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/81\">",
"      Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/82\">",
"      Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/83\">",
"      Muss HB, Case LD, Richards F 2nd, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991; 325:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/84\">",
"      Cheung KL, Evans AJ, Robertson JF. The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat 2001; 67:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/85\">",
"      Robertson JF, Whynes DK, Dixon A, Blamey RW. Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 1995; 72:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/86\">",
"      Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/87\">",
"      Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/88\">",
"      Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D, et al. Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology 2004; 67:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/89\">",
"      Symeonidis A, Kouraklis-Symeonidis A, Constantinidou I, et al. Increased CA-15.3 levels in the serum of patients with homozygous beta-thalassaemia and sickle cell/beta-thalassaemia. Br J Haematol 2006; 133:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/90\">",
"      Boga C, Ozdogu H, Sezgin N, et al. Serum cancer antigen 15-3 concentrations in patients with sickle cell disease. Br J Haematol 2006; 134:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/91\">",
"      Janicek MJ, Hayes DF, Kaplan WD. Healing flare in skeletal metastases from breast cancer. Radiology 1994; 192:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/92\">",
"      Vogel CL, Schoenfelder J, Shemano I, et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995; 13:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/93\">",
"      Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009; 39:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/94\">",
"      Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/95\">",
"      Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007; 27 Suppl 1:S215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/96\">",
"      Stafford SE, Gralow JR, Schubert EK, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002; 9:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/97\">",
"      Tateishi U, Gamez C, Dawood S, et al. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008; 247:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/98\">",
"      Specht JM, Tam SL, Kurland BF, et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007; 105:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/99\">",
"      Weigelt B, Bosma AJ, Hart AA, et al. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003; 88:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/100\">",
"      Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/101\">",
"      Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/102\">",
"      Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12:4218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/103\">",
"      Wong NS, Kahn HJ, Zhang L, et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 2006; 99:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/104\">",
"      Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 2008; 113:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/105\">",
"      Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12:6403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/11/7354/abstract/106\">",
"      Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009; 27:5153.",
"     </a>",
"    </li>",
"    <li>",
"     Information on SWOG trial 0500 available online at file://clinicaltrials.gov/ct2/show/NCT00382018 (Accessed on April 28, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 767 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7354=[""].join("\n");
var outline_f7_11_7354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H459263114\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130595\">",
"      THERAPEUTIC GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H134297\">",
"      TUMOR BIOLOGY AND RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361865859\">",
"      Disease assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H131955\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133804\">",
"      Prediction of response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H133812\">",
"      - Hormone receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H133819\">",
"      - HER2-overexpression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H133826\">",
"      - Chemotherapy response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H131585\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endocrine therapy versus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H129020\">",
"      Sequential single agents versus combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361862540\">",
"      Combining treatment modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626742034\">",
"      Biologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691733994\">",
"      Osteoclast inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H361864730\">",
"      TREATMENT ALGORITHMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361864767\">",
"      Hormone receptor-positive HER2-negative patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459262353\">",
"      Hormone receptor-positive HER2-positive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361864774\">",
"      Hormone receptor-negative HER2-negative patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361864781\">",
"      Hormone receptor-negative HER2-positive patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MONITORING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Circulating tumor cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459263114\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/767\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/767|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/29/3549\" title=\"table 1\">",
"      Performance status measure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=related_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41302?source=related_link\">",
"      Molecular intrinsic subtypes of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=related_link\">",
"      Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=related_link\">",
"      Treatment of metastatic breast cancer in older women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_11_7355="Causes malignancy ascites";
var content_f7_11_7355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of malignancy-related ascites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Cause",
"      </td>",
"      <td class=\"subtitle1\">",
"       Frequency among patients with malignancy-related ascites",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peritoneal carcinomatosis",
"      </td>",
"      <td>",
"       53 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Massive liver metastases causing portal hypertension",
"      </td>",
"      <td>",
"       13 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peritoneal carcinomatosis plus massive liver metastases",
"      </td>",
"      <td>",
"       13 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatocellular carcinoma plus cirrhosis",
"      </td>",
"      <td>",
"       13 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chylous ascites due to malignancy, usually lymphoma",
"      </td>",
"      <td>",
"       7 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Budd-Chiari syndrome due to malignancy occluding the hepatic veins",
"      </td>",
"      <td>",
"       Rare",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Runyon, BA, Hoefs, JC, Morgan, TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1998; 8:1104.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7355=[""].join("\n");
var outline_f7_11_7355=null;
var title_f7_11_7356="Food-borne diseases VII";
var content_f7_11_7356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-VII",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis A",
"       </td>",
"       <td>",
"        15-50 days, median: 28 days",
"       </td>",
"       <td>",
"        Jaundice, dark urine, fatigue, anorexia, nausea",
"       </td>",
"       <td>",
"        Detection of IgM anti-hepatitis A virus in serum from two or more persons who consumed epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Norwalk family of viruses, small round-structured viruses (SRSV)",
"       </td>",
"       <td rowspan=\"3\">",
"        15-77 hrs, usually 24-48 hrs",
"       </td>",
"       <td rowspan=\"3\">",
"        Vomiting, cramps, diarrhea, headache",
"       </td>",
"       <td>",
"        More than fourfold rise in antibody titer to Norwalk virus or Norwalk-like virus in acute and convalescent sera in most serum pairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visualization of small, round-structured viruses that react with patient's convalescent sera but not acute sera - by immune electron microscopy. Assays based on molecular diagnostic (eg, polymerase chain reaction [PCR], probes, or assays for antigen and antibodies from expressed antigen) are available in reference laboratories.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Astrovirus, calicivirus, others",
"       </td>",
"       <td>",
"        15-77 hrs, usually 24-48 hrs",
"       </td>",
"       <td>",
"        Vomiting, cramps, diarrhea, headache",
"       </td>",
"       <td>",
"        Visualization of small, round-structured viruses that react with patient's convalescent sera but not acute sera - by immune electron microscopy. Assays based on molecular diagnostics (eg, PCR, probes, or assays for antigen and antibodies from expressed antigen) are available in reference laboratories.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7356=[""].join("\n");
var outline_f7_11_7356=null;
var title_f7_11_7357="Classification diabetic neuropathy";
var content_f7_11_7357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification and staging of diabetic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I Subclinical Neuropathy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Abnormal electrodiagnostic tests (EDX)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decreased nerve conduction velocity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Decreased amplitude of evoked muscle or nerve action potential",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Abnormal quantitative sensory testing (QST)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibratory/tactile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thermal warming/cooling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Abnormal autonomic function tests (AFT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diminished sinus arrhythmia (beat-to-beat heart rate variation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diminished sudomotor function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Increased pupillary latency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class II Clinical Neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Diffuse neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Distal symmetric sensorimotor polyneuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Primarily small fiber neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Primarily large fiber neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mixed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Autonomic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Abnormal pupillary function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sudomotor dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Genitourinary autonomic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Bladder dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Sexual dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gastrointestinal autonomic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Gastric atony",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Gall bladder atony",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Diabetic diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"1\">",
"        Hypoglycemic unawareness (adrenal medullary neuropathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cardiovascular autonomic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypoglycemic unawareness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Focal neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mononeuropathy (upper or lower extremity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mononeuropathy multiplex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plexopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polyradiculopathy (can occur with diffuse neuropathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cranial mononeuropathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Neurological function tests are abnormal, but no neurological symptoms or clinically detectable neurological deficits indicative of a diffuse or focal neuropathy are present. Class I \"Subclinical neuropathy\" is further subdivided into Class Ia if an AFT or QST abnormality is present, Class Ib if EDX or AFT and QST abnormalities are present, and Class Ic if an EDX and either AFT or QST abnormalities or both are present.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Consensus Panel: Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 1988; 37:1000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7357=[""].join("\n");
var outline_f7_11_7357=null;
var title_f7_11_7358="Insulin response IV glucose";
var content_f7_11_7358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute insulin responses to IV glucose and isoproterenol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 594px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robertson RP, Porte D, Jr. The glucose receptor: A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor. J Clin Invest 1973; 52:870. Copyright &copy; 1973 American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7358=[""].join("\n");
var outline_f7_11_7358=null;
var title_f7_11_7359="Normal retina";
var content_f7_11_7359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal retina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jeffrey W Berger Retina Teaching Set. Copyrighted by the Scheie Eye Institute and the University of Pennsylvania.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_11_7359=[""].join("\n");
var outline_f7_11_7359=null;
